**CURRICULUM VITAE**

**Date Prepared**: 26 September 2023

**NAME:** Lorelei A. Mucci

**ACADEMIC TITLE:** Professor of Epidemiology

**WORK ADDRESS:** Harvard T.H. Chan School of Public Health

 Department of Epidemiology

 677 Huntington Avenue, 9th floor

 Boston, MA 02115 United States

**PHONE:** (617) 432-1732

**EMAIL:** lmucci@hsph.harvard.edu

**TWITTER**: @loreleimucci

**EDUCATION:**

1988 Certificate (Italian language and culture), American Institute for Foreign Studies, Florence, Italy

1989 BS (Biology), Tufts University, Medford, MA

1997 MPH (Epidemiology and Biostatistics), Boston University School of Public Health, Boston, MA

2003 ScD (Epidemiology), Harvard School of Public Health, Boston, MA

**POSTDOCTORAL TRAINING:**

2002-2003 Research Fellow in Epidemiology, Karolinska Institutet, Stockholm, Sweden

2003-2005 Research Fellow in Cancer Epidemiology, Harvard School of Public Health, Boston, MA

**ACADEMIC APPOINTMENTS:**

1998-2002 Graduate Research Assistant in Epidemiology, Harvard School of Public Health, Boston, MA

1998-2002 Graduate Research Assistant in Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Boston, MA

2000-2002 Graduate Research Assistant in Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden

2002-2003 Research Fellow in Epidemiology, Karolinska Institutet, Stockholm, Sweden

2003-2005 Research Fellow in Cancer Epidemiology, Harvard School of Public Health, Boston, MA

2003-2006 Instructor of Medicine, Harvard Medical School, Boston, MA

2006-2010 Assistant Professor in the Department of Epidemiology, Harvard School of Public Health, Boston, MA

2006-2016 Assistant Professor of Medicine, Harvard Medical School, Boston, MA

2010-2019 Associate Professor of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA

2019- Professor of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA

**HOSPITAL OR AFFILIATED INSTITUTION APPOINTMENTS:**

2003-2018 Associate Epidemiologist, Brigham and Women's Hospital, Boston, MA

2006- Member, Cancer Epidemiology and Prostate Cancer Programs, Dana-Farber/Harvard Cancer Center, Boston, MA

2012- Member, Center Scientific Council, Dana-Farber/Harvard Cancer Center

**OTHER ACADEMIC APPOINTMENTS:**

2004 Instructor, Boston University School of Public Health, Boston, MA

2007-2018 Visiting Professor of Public Health, University of Iceland, Reykjavik, Iceland

2012-2015 Foreign Visiting Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden

**OTHER PROFESSIONAL APPOINTMENTS:**

2012-2015 Co-Leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center

2015-2022 Leader, Cancer Epidemiology Program

2022- Deputy Associate Director of Population Science

2012- Head, Cancer Epidemiology and Cancer Prevention Area of Concentration, Harvard T.H. Chan School of Public Health

2019- Faculty Director, Master’s in Epidemiology Program, Harvard T.H Chan School of Public Health

2023- Director of Strategic Research Partnerships, American Cancer Society

**MAJOR ADMINISTRATIVE RESPONSIBILITIES:**

2005-2007 Organizer, Channing Seminar Series, Chronic Disease Epidemiology Group, Channing Laboratory, Brigham and Women’s Hospital

2005-2011 Co-Director, Channing Peer-Mentoring Program for Post-Doctoral Fellows and Instructors, Channing Laboratory, Brigham and Women’s Hospital

2006 Harvard Medical School Leadership Development for Physicians and Scientists, Harvard Medical School

2006- Member, Dana-Farber/Harvard Cancer Center Cancer Epidemiology Program and Prostate Cancer Program

2007-2008 Organizer, Epidemiology Department Seminar Series, Harvard School of Public Health

2008 Organizer, Dana-Farber/Harvard Cancer Center Interdisciplinary Workshop: Incorporating novel tumor tissue analysis into population-based studies of human cancer, Harvard Medical School

2009 Science Fair Judge, New England Science Symposium, Harvard Medical School, sponsored by the Harvard Medical School Minority Faculty Development Program of the Office of Diversity and Community Partnership

2009-2014 Advisory Board Member, Nurses’ Health Study Tissue Laboratory, Channing Laboratory, Brigham and Women’s Hospital

2010- Scientific Advisory Board, Prostate Cancer Foundation

 2015-23 Founding Organizer, Prostate Cancer Foundation Women in Science Forum

2011- Movember Global Action Plan Team Member, Prostate Cancer Foundation and Movember Foundation

2011-22 Executive Committee, Transdisciplinary Prostate Cancer Partnership (ToPCaP)

2012 Workshop Organizer, mRNA profiling pilot studies in the Harvard Cohorts, Dana-Farber/Harvard Cancer Center

2012-2017 Leader, Prostate Cancer Foundation “School of Public Health”

2012-21 Executive Committee, Nordic Twin Studies of Cancer (NorTwinCan)

2013 Evaluation Panel, Movember Revolutionary Team Award, Australia

2013, 2016, Expert Review Panel, Movember Translation Acceleration Grant, Prostate Cancer Canada

2018

2013- Organizer, Annual Celebration of Young Investigators in Cancer Research, Dana-Farber/Harvard Cancer Center

2013- Organizer, Annual Brief Update Series in Population Sciences, Dana-Farber/Harvard Cancer Center

2014 Faculty Associate, Fulbright US Scholar Program

2014 Participant, National Cancer Institute Provocative Question Workshop, Boston MA

2014 Organizer, Second Annual Celebration of Young Investigators in Cancer Research, Dana-Farber/Harvard Cancer Center

2014 Organizer, First Annual Prostate Cancer Teach-In, Harvard School of Public Health and Massachusetts Prostate Cancer Coalition

2014-2016 Co-leader, Tissue Working Group, National Cancer Institute’s Cohort Consortium

2016- Co-Leader, Prostate Tissue Biomarkers Working Group, NCI Cohort Consortium

2014-23 Scientific Advisory Board, Movember Global Action Plan 4 (GAP4), Prostate Cancer Exercise and Metabolic Health

2014- External Advisory Board, Pacific Northwest SPORE in Prostate Cancer

2015 Program Committee, American Association for Cancer Research Annual Meeting

2015 International Advisory Group, Pacific Rim Breast and Prostate Cancer Group

2015-2018 Research Advisory Council, Prostate Cancer UK

2015- Integration Panel Member, Congressionally Directed Medical Research Programs’ Prostate Cancer Research Program

 2016-2018 Executive Committee, Member at Large

 2018-2019 Chair

 2020-2024 Executive Committee

2015- Co-Principal Investigator and Executive Committee Member, International Registry of Men with Advanced Prostate Cancer (IRONMAN)

 2017- Chair, Diversity Working Group, IRONMAN registry

2016- Co-Director, Integrative Molecular Epidemiology Workshop, American Association for Cancer Research

2016- Co-Principal Investigator, Health Professionals Follow-up Study

2016-2022 External Advisory Board, The Sidney Kimmel Cancer Center at Thomas Jefferson University

2019- Faculty Director, Master’s in Epidemiology, Harvard TH Chan School of Public Health

2020-2023 External Advisory Board, Cedars Sinai Cancer Center

2021-2022 Chair Elect, Molecular Epidemiology Group, American Association for Cancer Research

2022-2024 Chair, Population Science Working Group, American Association for Cancer Research

2021- Founding Organizer, Women in Genitourinary Cancers, Dana-Farber/Harvard Cancer Center

2021- External Advisory Board, Boston Lung Cancer Study

2022- Scientific Advisory Board, Convergent Therapeutics

2022 Site Visit Review Committee, Metabolic Epidemiology Branch, National Cancer Institute

2023 2023 Cancer Progress Report Steering Committee, American Association for Cancer Research

2023- Scientific Advisory Committee, ACS BrightEdge

**COMMITTEE SERVICE:**

DEPARTMENTAL/SCHOOL AND UNIVERSITY SERVICE:

2006- Admissions Committee, Epidemiology Department, Harvard T.H. Chan School of Public Health

2006- Member and Project Leader, Dana-Farber/Harvard Cancer Center Prostate Cancer SPORE

2007-2010 Gender Equality Committee, Epidemiology Department, Harvard School of Public Health

2009-2014 Scientific Advisory Board, Pathology Cores, Dana-Farber/Harvard Cancer Center

2010-2014 Scientific Advisory Board, Tissue Studies, Nurses’ Health Study

2010-2015 Faculty Mentor, R25 Nutrition and Cancer Training Grant, Harvard School of Public Health

2010- Review Committee, Harvard School of Public Health Post-Doctoral Travel Scholarship Awards

2011-2013 Organizer, Epidemiology Department Seminar Series, Harvard School of Public Health

2011-2015 Grant Review Committee, David Mazzone, Dana-Farber/Harvard Cancer Center Prostate SPORE

2011-2016 Post-doctoral Fellow Advisory Committee, Harvard T.H. Chan School of Public Health

2011- Head of Cancer Epidemiology and Prevention Concentration, Harvard T.H. Chan School of Public Health

2012-8 Grant Review Committee, Dana-Farber/Harvard Cancer Center U54 Pilot Applications

2012- Member, Admissions and Financial Aid Committee, Department of Epidemiology, Harvard T.H. Chan School of Public Health

2012- Co-Leader, Cancer Epidemiology, Dana-Farber/Harvard Cancer Center

 2015-2022 Leader, Cancer Epidemiology

 2022- Deputy Associate Director of Population Science

2013- Faculty Member, Harvard T.H. Chan School of Public Health Disciplinary Board

 (now Code of Conduct Council)

2014-2018 Faculty Mentor, Harvard T.H. Chan School of Public Health MIRT Program

2014- Faculty Steering Committee, John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health

2015-2016 Independent Blue Ribbon Expert Panel, Massachusetts Prostate Cancer Action Council and Campaign for Prostate Cancer Research, Education and Awareness for High-Risk Men

2015-2019 Faculty Mentor, T32 Training Grant on Cancer Biostatistics, Harvard T.H. Chan School of Public Health

2015- Methods and Substantive Exam Committee, Department of Epidemiology, Harvard T.H. Chan School of Public Health

2016 Chair, *Ad Hoc* Disciplinary Board, Harvard T.H. Chan School of Public Health

2016-2019 Faculty Council Member, Harvard T.H. Chan School of Public Health

 2018-2019 Co-Chair of the Council

2016-2021 Harvard University Milton Fund Review Panel

2017 Member, Task Force on Improving Educational Quality, Harvard T.H. Chan School of Public Health

2017-2018 Member, Faculty Search Committee in Radiation Epidemiology, Harvard T.H. Chan School of Public Health

2017-2018 Advisory Committee, Sexual Assault & Harassment Prevention, Harvard T.H. Chan School of Public Health

2017-2018 Chair,Interdisciplinary Research Task Force, Harvard T.H. Chan School of Public Health

2019- Faculty Director, SM2 in Epidemiology Program, Harvard T.H. Chan School of Public Health

2019-2020 Research Platforms Advisory Committee, Harvard T.H. Chan School of Public Health

2020-2021 Promotion Committee, Caroline Buckee, Harvard TH Chan School of Public Health

2020 Targeted Search Committee, Department of Nutrition, Harvard T.H Chan School of Public Health

2020- Education Committee, Department of Epidemiology, Harvard T.H. Chan School of Public Health

2020-23 Dean’s Diversity Recruitment/Retention Group, Harvard TH Chan School of Public Health

2021-23 Diversity, Inclusion, and Belonging Group, Department of Epidemiology, Harvard TH Chan School of Public Health

2020-2021 Appointment Committee, Heather Eliassen, Harvard TH Chan School of Public Health

2020-2021 Promotion Committee, Tamarra James-Todd, Harvard TH Chan School of Public Health

2021 Reappointment Committee, Stephanie Smith-Warner, Harvard TH Chan School of Public Health

2021- Committee on the Advancement of Women Faculty, Harvard TH Chan School of Public Health

2022-2023 Committee Co-Chair

2022 Promotion Committee, Zachary Nagel, Associate Professor Harvard TH Chan School of Public Health

2022 Chair, Promotion Committee, Mingyang Song, Associate Professor of Clinical Epidemiology and Nutrition Harvard TH Chan School of Public Health

2023 Ad hoc Committee, Kenneth Mukamal, Promotion to Professor of Medicine, Harvard Medical School

2023-2024 Standing Committee, Degree of Doctor of Philosophy in Population Health Sciences, Harvard University

**PROFESSIONAL SOCIETIES:**

2001-2005 Society for Epidemiological Research, Member

2003- American Association for Cancer Research, Associate Member

2014- American Society for Preventive Oncology

**GRANT REVIEW ACTIVITIES:**

2010 Grant Review Panel, World Cancer Research Fund

2011-2016 Grant Review Committee, Prostate Cancer Foundation of Australia

2011-2018 Grant Review Committee, Prostate Cancer Charity UK Research Awards

2012 Ad Hoc Member, Special Study Section: Provocative Questions, National Institutes of Health/National Cancer Institute

2012-2015 Ad Hoc Member, Epidemiology of Cancer (EPIC) Study Section, National Institutes of Health/National Cancer Institute

2012- Grant Review Committee, Challenge Award Mechanism, Prostate Cancer Foundation

2013 Grant Review Committee, Health Research Board of Ireland

2013 Grant Review Committee, Irish Cancer Society Career Development Awards

2013 Grant Review Committee, Norwegian Cancer Society Team Science Award

2013 Grant Review Panel, US Army Prostate Cancer Program, Population Science Mechanism

2013-8 Grant Review Panel, National Institutes of Health/National Cancer Institute, PAR Physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival

2014 Grant Review Panel, US Army Prostate Cancer Program, Idea Development Mechanism

2014- Scientific Review Panel Member, Cancer Prevention Research Institute of Texas (CPRIT)

2015-2017 Member, Grant Review Panel, Bankhead-Coley Cancer Research Program, Florida Department of Health

2015-pres Member, Grant Review Panel, Fellowships: Risk, Prevention and Health Behavior, National Institutes of Health (ZRG1 F16-L 20)

2016 Member, Grant Review Panel, Basic Research in Cancer Health Disparities/ Diversity, National Institutes of Health (ZRG1 OBT-A (55) R)

2018- Grant Review Panel, PLCO Etiology and Early Marker Studies Panel, National Cancer Institute

2020 Grant Review Panel, Accelerator Award, Harvard TH Chan School of Public Health

2021 Grant Review Panel, Special Emphasis Panel ZRG1 EMNR-C 55 R, PAR Panel – Fertility Status as a Marker for Overall Health, National Institutes of Health

2021 Grant Review Panel, PCF-Pfizer Health Equity Challenge Awards

2021 Chair, Grant Review Panel, Special Emphasis Panel National Cancer Institute – PLCO Biospecimens ZCA1 TCRB-O O1

2022- Grant Review Panel, F18 Fellowships: Epidemiology and Population Sciences, National Cancer Institute

2022 Grant Review Panel, U24 Special Emphasis Panel Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), National Cancer Institute

**EDITORIAL ROLES:**

**Ad Hoc Reviewer**

American Journal of Epidemiology; British Journal of Cancer; British Journal of Urology International; British Medical Journal; Cancer Causes and Control; Cancer Epidemiology, Biomarkers and Prevention; Cancer Prevention Research; Cancer Research, Clinical Cancer Research; Epidemiology; European Urology; International Journal of Cancer; Journal of Clinical Oncology; Journal of Food Composition and Analysis; Journal of the American Medical Association; JAMA Oncology; Journal of the National Cancer Institute; Lancet Oncology; New England Journal of Medicine; PLOS One; PLOS Medicine; Proceedings of the National Academy of Science; Scientific Reports; The Prostate

**Other Editorial Roles**

2006-2008 Editorial Board, *Menopause*

2006-2008 Editorial Board, *The Open Epidemiology Journal*

2009-2018 Associate Editor, *Cancer Causes Control*

2011-2019 Editorial Board, *Clinical Genitourinary Cancer*

2017- Editorial Board, *The Prostate*

2019-2023 Senior Editor, *Cancer Epidemiology Biomarkers and Prevention*

2021- Editorial Board, *British Journal of Cancer*

2021- Editorial Board, *Cancer Prevention Research*

**HONORS AND DISTINCTIONS:**

2003 James M. Dunning Award for Research Excellence, Harvard School of Dental Medicine

2003-2010 NIH Loan Repayment Program Award, National Institutes of Health

2005 American Society for Clinical Oncology Merit Award

1. American Cancer Society Travel Scholarship
2. Harvard Dependent Care Travel Fund Award

2008-2011 Michael Milken Scholar, Prostate Cancer Foundation

2009 Top Performing Young Investigator, Prostate Cancer Foundation

2010 Harvard Dependent Care Travel Fund Award

2015 Harvard Dependent Care Travel Fund Award

2015 Best of Journal of Clinical Oncology: 2015 Genitourinary Cancer

2015 Teaching Citation, Harvard T.H. Chan School of Public Health

2015 Nominated, Outstanding Post-Doctoral Mentor Award, Harvard T.H. Chan School of Public Health

2015 Mo Sista Whiska Award, Prostate Cancer Foundation

2015 Fifth Annual Alice Hamilton Award Lecture, Harvard T.H. Chan School of Public Health

2016, 2019 Teaching Citation, Harvard T.H. Chan School of Public Health

2016 Frank McGovern Lectureship Series, Massachusetts General Hospital

2019 Seidman Prize for MD Research Mentorship, Harvard Medical School

2021 Chair Elect, American Association for Cancer Research Molecular Epidemiology Group

2022-2023 Chair, American Association for Cancer Research Population Science Working Group

2022 Harvard Chan School Student Mentoring Award

## **PAST FUNDED GRANTS:**

2002-2008 National Institutes of Health/National Cancer Institute, R01CA090598 (PI Stampfer)

*Growth Factors and Prostate Cancer Risk*

The goal of the study was to examine biomarkers in insulin/insulin-like growth factor in prostate cancer risk and progression. Role: Co-Investigator

Direct Costs: $340,000

2003-2006 US Army Prostate Cancer Program, PC031057, Idea Development Award (PI Adami)

*A Population-Based Study of Dietary Acrylamide and Prostate Cancer Risk*

This study aimed to examine the association between dietary intake of acrylamide and risk of prostate cancer. Role: Investigator

Direct Costs: $225,000

2004-2007 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50CA90381, Career Development Award (PI Mucci)

*A Composite Biomarker for Prostate Cancer Death*

The aim of this project was to develop a molecular signature in tumors that accurately predicted prostate cancer mortality. Role: Principal Investigator

Direct Costs: $50,000

2005-2008 US Army Prostate Cancer Program, PC040715, Idea Development Award (PI Rubin)

 *Identification of Aggressive Prostate Cancer using SNP Analysis*

The goal of this study was to identify inherited genetic risk loci associated with more aggressive prostate cancer. Role: Investigator

Direct Costs: $125,000

2005-2008 US Army Prostate Cancer Program, PC050696, New Investigator Award (PI Mucci)

*Molecular and Clinical Predictors of Aggressive Prostate Cancer*

The objective of this study was to integrate tumor biomarkers with detailed clinical and histological data in prostate cancer patients to predict risk of prostate cancer death during follow-up. Role: Principal Investigator

Direct Costs: $225,000

2006-2007 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50CA90381, Development Award (PI Mucci)

 *Biomarkers of Angiogenesis and Development of Lethal Prostate Cancer*

This project sought to characterize morphologic features of angiogenesis associated with tumors, including microvessel density and shape, and examine their relationship with prostate cancer mortality. Role: Principal Investigator

Direct Costs: $50,000

2007-2009 Harvard William F. Milton Fund (PI Mucci)

*Infectious origins of prostate cancer*

 This study aimed to investigate the association between serologic evidence of *Trichomonas vaginalis*, measured in pre-diagnostic bloods, and future risk of prostate cancer, particularly advanced disease. Role: Principal Investigator

Direct Costs: $50,000

2007-2009 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50CA90381, Developmental Project Award (PI Mucci)

*Genetic variation and the TMPRSS2:ETS fusion in prostate pathogenesis*

This study examined the association between genetic variants in the androgen receptor and risk of prostate cancer defined by the common molecular subtype, *TMPRSS2:ERG* nested within two cohorts of men. Role: Principal Investigator

Direct Costs: $50,000

2007-2010 US Army Prostate Cancer Program, Idea Development Award (PI Adami)

*The Infectious Pathogenesis of Prostate Cancer*

 This study aimed to investigate the association between histologic markers of inflammation and atrophy, as well as presence of a novel retrovirus (XMRV) in prostate tissue as predictors of prostate cancer mortality in a Swedish cohort. Role: Investigator

Direct Costs: $225,000

2008-2009 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50CA90381, Developmental Project Award (PI Stampfer)

*Dietary phytoestrogens in relation to prostate cancer risk and progression*

This study sought to examine the association between dietary intake of phytoestrogens and prostate cancer risk and mortality in a cohort of Swedish men. Role: Co-Investigator

Direct Costs: $50,000

2008-2009 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50 CA90381, Career Development Award (PI Stark)

*Proliferative inflammatory atrophy in prostate cancer: a patho-epidemiology study*

 This study investigated a common histologic lesion in prostate cancer, proliferative inflammatory atrophy, in prostate cancer progression as well as associations with lifestyle factors. Role: Co-Mentor

Direct Costs: $50,000

2008-2011 Prostate Cancer Foundation, Young Investigators Award (PI Mucci)

*Do dietary and lifestyle factors interact with the TMPRSS2:ERG fusion to predict progression*

 This patho-epidemiology study sought to examine the association between the *TMPRSS2:ERG* gene fusion and prostate cancer progression, as well as how lifestyle factors and genetic risk loci interact with the gene fusion to affect outcomes in men with prostate cancer. Role: Principal Investigator

Direct Costs: $225,000

2008-2013 National Institutes of Health/National Cancer Institute, R01CA131945 (PI Loda)

*Metabolic syndrome, fatty acid synthase, and prostate cancer*

This project integrated human and experimental studies to examine the role of metabolic syndrome in prostate cancer risk and progression, and to investigate the role of the de novo lipogenesis enzyme, fatty acid synthesis, in the interplay. Role: Co-Investigator

Direct Costs: $90,000

2008-2013 Harvard School of Public Health, Ellison Foundation (PI Mucci and Adami)

*Genetic and environmental contributions to cancer etiology and progression among 150,000 Nordic Twins*

 This project allowed the creation of the Nordic Twin Study of Cancer (NorTwinCan), which included almost 300,000 twins from Denmark, Finland, Norway, and Sweden. The goal of the study was to investigate the familial risk and heritability of cancers. Role: Co-Principal Investigator

Direct Costs: $400,000

2009-2012 Dana-Farber/Harvard Cancer Center Prostate SPORE, P50 CA90381, Full Project Award

*TMPRSS2:ERG and SPINK1 in Lethal Prostate Cancer*

This population-science project in the Dana-Farber SPORE in Prostate Cancer sought to determine clinical and etiological significance of two molecular events in prostate cancer, *TMPRSS2:ERG* and *SPINK1*. Role: Principal Investigator

Direct Costs: $125,000

2009-2014 National Institutes of Health/National Cancer Institute, RO1 CA136578 (PI Mucci)

*Sex hormones and the TMPRSS2:ERG fusion in prostate cancer progression*

This study investigated the role of sex steroid hormones, including circulating biomarkers, genetic variants, and tissue markers on prostate cancer mortality as a function of the common gene fusion event in prostate cancer, *TMPRSS2:ERG*. Role: Principal Investigator

Direct Costs: $250,000

2010-2011 Harvard Catalyst Pilot Award (PI Mucci)

 *Melatonin and Prostate Cancer: A biomarker study among men in the Reykjavik Cohort*

The goal of this study was to examine biomarkers of circadian rhythm, including urinary melatonin levels and genetic variants in circadian clock genes, and the risk of prostate cancer in an Icelandic Cohort. Role: Principal Investigator

Direct Costs: $50,000

2010-2012 Dana-Farber/Harvard Cancer Center Prostate SPORE, Full Project Award, NIH/NCI P50 CA90381 (PI Bubley)

*Biguanides for the treatment of prostate cancer*

This SPORE project used experimental models and epidemiological data to examine the potential of metformin for treatment of advanced prostate cancer, and assess the role of AMPK signaling as a targetable pathway. Role: Co-investigator and PI Subcontract

Direct Costs: $25,000

2010-2013 US Army Prostate Cancer Program, W81XWH-10-1-0552, Idea Development Award (PI Mucci)

*BRCA1 and Lethal Prostate Cancer*

The goal of this study was to examine the role of tumor protein expression of BRCA1(breast cancer 1)and risk of lethal prostate cancer, and assess its role in DNA repair and cell cycle regulation.Role: Principal Investigator

Direct Costs: $225,000

2010-2013 Icelandic RANNIS Foundation (PI Sigurdardottir)

*Melatonin and Prostate Cancer*

 This career development award supported a doctoral student at the University of Iceland to examine melatonin levels measured in prediagnostic urine and risk of prostate cancer. Role: Mentor

Direct Costs: $10,000

2010-2015 National Institutes of Health/National Cancer Institute R01 CA141298 (PI Stampfer)

*Growth factors and lethal prostate cancer signature*

This study sought to develop a molecular signature of lethal prostate cancer using whole genome mRNA profiling data, and to assess associations of circulating levels and genetic variants in the growth factor axis and risk of lethal cancer.

Role: Co-Investigator and PI Subcontract

Direct Costs: $228,000

2011-2012 Rose International Traveling Fellowship, Harvard TH Chan School of Public Health (PI Sarah Coseo Markt)

*Sleep, melatonin and prostate cancer in Iceland*

This travel award supported Sarah Markt to spend time with colleagues at the University of Iceland as part of her thesis project on sleep, circadian rhythm and prostate cancer. Role: Mentor

Direct Costs: $5,000

2011-2013 Dana-Farber/Harvard Cancer Center SPORE in Prostate Cancer, Mazzone Career Development Award (PI Wilson)

*Phosphorus and calcium intake, tumor microenvironment and prostate cancer progression*

The aim of this project was to investigate the association between pre- and post-diagnostic intake of phosphorus and calcium in prostate cancer progression, and assess associations of the dietary factors on tumor biomarkers. Role: Mentor

Direct Costs: $50,000

2011-2014 US Army Prostate Cancer Impact Award, PC101749 (PI Sweeney, Dana-Farber Cancer Institute)

*A Systems Biology Approach to Link Nuclear Factor Kappa B Activation with Lethal Prostate Cancer*

This study comprehensively examined biomarkers of nuclear factor kappa B (NFkappaB) and lethal prostate cancer in prostate cancer patient cohorts. The study integrated data on circulating biomarkers, tumor tissue expression, and genetic variants in genes and pathway defining NFkappaB activation. Role: Investigator and PI Subcontract

Direct Costs: $750,000

2012-2013 US Army Prostate Cancer Research Program, Post-doctoral Fellowship (PI Julie Kasperzyk)

*Prostate Cancer Tumor Heterogeneity*

The objective of this post-doctoral fellowship award was to support the training and research of the PI to investigate variability and heterogeneity of tumor tissue biomarkers in prostate cancer. Role: Mentor

Direct Costs: $90,000

2012-2013 Dana-Farber/Harvard Cancer Center, Mazzone Awards Program, Disparities Research Mechanism (PI Mucci)

*Estimating the Prostate Cancer Burden attributed to Lifestyle and Genetic Factors among African-American and White Men*

The goal of this proposal was to quantify the extent to which differences in the prevalence of lifestyle factors and genetic variants could explain the population attributable fraction associated with prostate cancer disparities. Role: Principal Investigator

Direct Costs: $100,000

2012-2013 Rose International Traveling Fellowship, Harvard TH Chan School of Public Health (PI Irene Shui)

*Prostate cancer in Ireland*

This travel award supported this post-doctoral fellow to spend time with colleagues at Trinity College, Dublin to undertake epidemiological studies of prostate cancer and to develop a short course on the patho-epidemiology of prostate cancer. Role: Mentor

Direct Costs: $5,000

2012-2014 Prostate Cancer Foundation, Challenge Award (PIs: Loda and Mucci)

*Shedding light on stromal-epithelial interactions in prostate cancer carcinogenesis and mortality*

This international and multidisciplinary project sought to identify and validate gene expression patterns in epithelial and stromal tissue associated with aggressive prostate cancer, and to develop bioinformatics tools for defining the cross-talk between the two compartments. Role: Co-Principal Investigator

Direct Costs: $1,000,000

2012-2014 Urology Care Foundation, Research Scholar Program (PI: Mark Preston)

 *Association between Finasteride and High-grade or Lethal Prostate Cancer*

The goal of this career development award was to support Dr. Preston, a urologic oncology fellow at MGH, too examine the association between finasteride and risk of high-grade or lethal prostate cancer in the Health Professionals Follow-up Study. Role: Mentor

Direct Costs: $50,000

2012-2015 Prostate Cancer Foundation, Young Investigator Award (PI: Stephen Finn, Trinity College, Ireland)

 *Identifying non-coding RNA repertoires of aggressive prostate cancer*

This career development award supported Dr. Stephen Finn at Trinity College, Dublin, to explore the expression of non-coding RNAs in tumor tissue and risk of lethal prostate cancer. Role: Co-Mentor

Direct Costs: $225,000

2012-2016 US Army Prostate Cancer Program Impact Award, PC112061 (PI: Platz, Johns Hopkins)­­­

*Telomere length and lethal prostate cancer*

This study sought to develop an automated algorithm for measuring tumor and stroma-associated telomere length in prostate tissue specimens using fluorescent in situ hybridization, and to apply this platform to prostate cancer patient cohorts to assess the prognostic significance of telomere length in lethal prostate cancer. Role: Investigator and PI Subcontract

Direct Costs: $180,000

2013-2015 Dana-Farber/Harvard Cancer Center, Mazzone Career Development Award (PI Jennifer Sinnott),

*Impact on Prognosis of Inter- and Intratumor Heterogeneity In Prostate Cancer*

This career development award supported this post-doctoral fellow to investigate the role of tissue biomarker heterogeneity, both within and across individuals, as prognostic biomarkers. Role: Mentor

Direct Costs: $50,000

2013-2016 Prostate Cancer Foundation, Young Investigator Award (PI Jennifer Rider)

*The Immunomodulatory and Androgen-Associated Actions of Vitamin D in Prostate Cancer*

 The aim of this career development award was to support the training and research of Dr. Rider focused on understanding two distinct pathways – immunomodulation and androgen signaling – as underlying the link between vitamin D and prostate cancer. Role: Mentor

Direct Costs: $225,000

2013-2019 Dana-Farber/Harvard Cancer Center SPORE in Prostate Cancer, National Cancer Institute/National Institutes of Health, P50 CA090381 (PI: Loda)

*Tumor and circulating markers as links between obesity and lethal prostate cancer*

This population science project within the DFHCC SPORE in Prostate Cancer aims to understand the mechanism underlying the link between obesity and lethal prostate cancer. The proposal integrates systemic and tissue-based biomarkers of metabolism and inflammation, and also integrates data on molecular subtypes of prostate cancer. Role: Project Leader

Direct Costs: $603,772

2014-2016US Army Prostate Cancer Program, Post-doctoral Fellowship (PI: Ericka Noonan Ebot)

*Molecular Epidemiology Investigation of Obesity and Lethal Prostate Cancer*

This post-doctoral award supported the training and research of the candidate to investigate tissue-specific biomarkers associated with obesity, and examine their role in lethal prostate cancer. Role: Mentor

Direct Costs: $90,000

2014-2016 American Cancer Society, Post-doctoral Fellowship (PI: Thomas Ahearn)

*TMPRSS2:ERG, insulin/IGF1 signaling axis and prostate cancer progression*

The goal of this post-doctoral fellowship award was to support the training and research of the candidate to investigate whether insulin and IGF1 signaling contribute to lethal prostate cancer among men whose tumors contain the common gene fusion event. Role: Mentor

Direct Costs: $100,000

2014-2016 National Institutes of Health/National Cancer Institute, R21 CA185787 (PI: Svitlana Tyekucheva)

*Statistical methods for tumor expression data from archival tissues in clinical and epidemiologic research*

The goal of this proposal is to develop new biostatistical methods to analyze transcriptome profiling data from archival tumor materials, and to develop a publically available software tool. Finally, the aim is to test these tools in a prostate cancer patient cohort with whole genome expression profiling data. Role: Co-Investigator and PI Subcontract

Direct Costs: $225,000

2014-2016 Dana-Farber/Harvard Cancer Center, Mazzone Awards Disparities Research Program

*Do Baseline Prostate Specific Antigen (PSA) Levels Predict Advanced Prostate Cancer in African-American Men?* (PI: Mark Preston)

The goal of this study was to examine whether pre-diagnostic levels of PSA accurately predict future risk of prostate cancer, particularly aggressive disease, in the Southern Community Cohort Study. Role: Co-Investigator

Direct Costs: $100,000

2014-2017 Prostate Cancer Foundation, Young Investigator Award (PI: Kathryn Wilson)

*Bone metabolism and bone metastases in prostate cancer*

This career development award was focused on investigating whether prostate tumors exhibit bone like features that facilitate the development of metastatic prostate cancer. Moreover, the goal was to assess whether obesity altered the tumor environment to influence the bone homing that is common in prostate cancer metastases. Role: Mentor

 Direct Costs: $225,000

2015-2016 Dana-Farber Cancer Institute Sponsored Research (PI: Mucci)

*International Registry to Improve Outcomes in Men with Advanced Prostate Cancer, IRONMAN*

This pilot funding supported the design and protocol development of an international registry of 5,000 men with advanced prostate cancer. Role: Principal Investigator

Direct Costs: $50,000

2016-2018 Harvard TH Chan School of Public Health, Career Incubator Award (PI: Mucci)

*Obesity, histone modifications and lethal prostate cancer*

 This pilot project seeks to test the hypothesis that excess body weight is associated with specific histone alterations that contribute to the transcriptional dysregulation of genes involved in tumor progression. Role: PI

Direct Costs: $50,000

2017-2018 DF/HCC SPORE in Prostate Cancer Mentored Award (PI: Sarah Markt)

*Circadian rhythm disruption and advanced prostate cancer*

This mentored career development award seeks to further investigate the hypothesis that disruption of the circadian system is a risk factor for advanced prostate cancer. The project leverages data across five unique cohorts and uses integrative molecular epidemiology approaches to investigate progression across the continuum of disease. Role: Mentor

Direct Costs: $85,935

2013-2019 National Institutes of Health/National Cancer Institute, R01 CA174206 (PI: Giovanni Parmigiani)

*Bioinformatics Tools for Genomic Analysis of Tumor and Stromal Pathways in Cancer*

The focus of this project is to develop new computational methods to identify unique signals of gene expression from tumor epithelium and stroma from admixture samples, and to develop methods to identify the cross-talk of transcriptional programs of the two compartments. Finally, the aim is to apply these tools to study the role of obesity on alterations in stromal gene expression. Role: PI Subcontract and Co-Investigator

Direct Costs: $100,645

2013-2019 National Cancer Institute/National Institutes of Public Health R01 CA179129 (PI: Kathryn Wilson)

*Bone metabolism and bone metastases in prostate cancer*

This proposal seeks to investigate tissue biomarkers and circulating markers associated with bone metabolism as predictors of lethal prostate cancer, and to study the association between lifestyle and dietary factors in relation to the biomarkers. Role: Co-Investigator

Direct Costs: $861,426

2016-2021 National Cancer Institute/National Institutes of Health, U01CA113913 (PI: Sanda)

*Harvard and University of Washington Prostate Cancer Biomarker Center*

This clinical validation center seeks to advance innovative assays to facilitate the detection of prostate cancer through meaningful application. Role: Co-Investigator and PI subcontract

Direct Costs: $124,526

2017-2020 Prostate Cancer Foundation Young Investigator Award (PI: Mark Preston)

*Improving risk prediction of aggressive prostate cancer using baseline PSA during midlife and inherited genetic variants in African-American and Caucasian men*

The goal of this mentored project is to devise smarter PSA screening strategies by comprehensively investigating the ability of baseline PSA along at midlife with inherited genetic variants to predict future risk of aggressive prostate cancer, with a focus on African-Americans populations. Role: Mentor

Direct Costs: $225,000

2017-2020 Prostate Cancer Foundation Young Investigator Award (PI: Konrad Stopsack)

*Cholesterol metabolism, statins and lethal prostate cancer*

The goal of this mentored project is to investigate the role of a key gene in cholesterol metabolism, SQLE in lethal prostate cancer. Moreover, to examine the interaction between SQLE, statins and risk of lethal disease. Role: Co-Mentor

Direct Costs: $225,000

2016-2020 National Cancer Institute/National Institutes of Health, R01 R01CA202690 (PI: Mucci)

*Circadian disruption and risk of prostate cancer in a multiethnic cohort*

The study aims to investigate circadian disruption as a risk factor for prostate cancer in a multiethnic cohort. The study integrates a molecular epidemiology approach to evaluate common variation in circadian related genes, urinary levels of melatonin and sleep data. Role: PI

Direct Costs: $670,961

2018-2022 Stand Up 2 Cancer (SU2C)/American Association for Cancer Research (PI: Irene Ghobrial)

*Predicting progression of developing Myeloma in a High-Risk screened population (PROMISE)*

Multiple Myeloma is a fatal plasma cell cancer characterized by bone marrow infiltration and lytic bone lesions. Multiple myeloma almost always progresses from precursor states of monoclonal gammopathy of undetermined significance (MGUS)/smoldering multiple myeloma (SMM) to overt cancer. We propose to establish is a prospective cohort of patients with MGUS/SMM identified by screening a high-risk population (defined as those of African-Americans descent or individuals with first-degree relatives). The collection and integrated analysis of matched biological samples (bone marrow and blood), longitudinal clinical data (progression to myeloma, pre-existing clinical characteristics and comorbidities), and questionnaire data is designed to assess biological and clinical risk factors for progression. The aims are to determine clinical/genomic alterations present in individuals with monoclonal gammopathies who are diagnosed through screening of a high-risk population, and to determine clinical/genomic/epigenetic and immune environmental predictors of progression to myeloma in patients with monoclonal gammopathies. Role: PI Subcontract.

Direct Costs: $904,690

2020-2022 National Cancer Institute Administrative Supplement (PI: Mucci)

 *Cancer Epidemiology Cohort in Male Health Professionals*

 This administrative supplement to the Health Professionals Follow-up Study U01 grant brings together six NCI-funded cancer epidemiology cohorts to look at the association between geocoded measures of exposure to light at night and circadian rhythm in relation to risk of prostate cancer.

Direct Costs: $150,000

2021-2022 Janssen Pharmaceuticals (PI: Mucci)

 *HRR HOPE Study*

This is a pilot project to assess feasibility to examine men with metastatic prostate cancer in the Health Professionals Follow-up Study. The goal is to examine the quality of epidemiologic, clinical, and quality of life data for men diagnosed or who progress to metastatic disease. In addition, we will assess DNA repair pathway mutations leveraged from whole exome sequencing data from prostate tumors.

**CURRENT FUNDED GRANTS:**

2013-2023 National Institutes of Health/National Cancer Institute, R25 CA174664 Institutional Training and Education Grant (PI: Lorelei Mucci)

*Integrative Molecular Epidemiology Workshop*

The goal of this training and education grant is to support an annual one-week educational workshop to train the next generation of cancer researchers with skill sets integrating biology and epidemiology. Role: Co-Director and Faculty Mentor

Direct Costs: $180,000

2015-2027 National Institutes of Health/National Cancer Institute, P30 CA006516 (PI: Laurie Glimcher)

*Dana-Farber/Harvard Cancer Center Support Grant*

The aim of the Cancer Epidemiology Program is to support program members to undertake studies of cancer etiology and facilitate the translation of this research into prevention strategies. Role: PI Subcontract and Cancer Epidemiology Program Leader

* On P30 Renewal, Cancer Epidemiology received a score of “Exceptional Merit”

Direct Costs: $373,985

2015-2027 National Institutes of Health/National Cancer Institute, U01 CA167552 (PIs: Willett and Mucci)

 *Cancer Epidemiology Cohort of Male Health Professionals*

 The aim of this cohort infrastructure grant is to support the continued follow-up of the Health Professionals Follow-up Study, including biorepositories, follow-up forincidence and mortality, questionnaires, and participation in consortia. Role: co-PI

Direct Costs: $1,242,965

2022-2024 Prostate Cancer Clinical Trials Consortium (PI: Mucci)

*IRONMAN: International registry to improve outcomes in men with advanced prostate cancer*

IRONMAN is a global registry of 5,000 men with advanced prostate cancer being recruited from 8 countries. The overarching goals are to understand the optimal patterns of drug therapies in advanced prostate cancer, to gain understanding of the quality of life detriments among these men, and to identify novel biomarkers that are associated with response to therapy and overall survival. Role: PI

Direct Costs: $959,317

2018-2023 The Bridge Project of MIT and Dana-Farber/Harvard Cancer Center (PI: Mucci and Amon)

  *Credentialing aneuploidy as a prognostic biomarker in prostate cancer*

In preliminary studies, we developed a computational algorithm that defined aneuploidy using transcriptomic profiling data within the Cancer Genome Atlas. In applying the algorithm to 400 prostate cancer patients, we found that extent of prostate tumor aneuploidy was a strong predictor of lethal prostate cancer beyond clinical factors. This Bridge Project brings together researchers across MIT and DFHCC to expand these findings in both population and experimental science projects. In aim 1, we will validate the tumor aneuploidy findings in a cohort of men with access to prostate biopsy specimens. In aim 2, we will undertake experiments within 2-D and 3-D systems to investigate the molecular consequences of aneuploidy in prostate cancer. Role: co-PI

 Direct Costs: $800,000

2018-2023 Prostate Cancer Foundation Challenge DNA Repair (PI: Kantoff, Mucci, Pomerantz)

*The Impact of DNA Damage Repair Abnormalities in Prostate Cancer*

It is increasingly apparent that pathogenic variants in DNA damage repair (DDR) pathways are associated with aggressive forms of PC5. In this project, we will determine the association between inherited DDR variation and clinical outcome in localized high-risk PC patients. By identifying DDR variants that confer a more aggressive phenotype within the high-risk PC population, our findings could substantially change clinical practice. Genetic screening of all high-risk patients for deleterious variants (Aim 1) would help determine prognosis and identify men who could benefit from a more aggressive and tailored approach to treatment, especially in light of emerging data regarding DDR variants and sensitivity to poly ADP ribose polymerase (PARP) inhibition and platinum chemotherapy. Finally, we will model how clinical and cost/benefit implications of this proposal would translate into clinical practice (Aim 2). Role: PI Subcontract and co-investigator.

Direct Costs: $199,885 (no cost extension)

2018-2024 National Cancer Institute/National Institutes of Health (PI: Kathryn Penney)

*Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer*

The pressing need to distinguish potentially lethal from indolent prostate cancer is usually approached by attempting to identify genomic predictors in the malignant epithelial tissue. However, from extensive cell biology research, it is known that the microenvironment plays a critical role in cancer progression, though a deeper understanding of the mechanism is needed. In this proposal, we will study gene expression of the prostate microenvironment to improve the understanding of its impact on the biology of the tumor and to augment previously proposed genomic predictors of lethal prostate cancer by developing a gene expression signature from the stromal tissue. Role: PI Subcontract

Direct Costs: $162,675

2019-2023 Prostate Cancer Foundation Challenge Clonal Hematopoesis (PI: Kantoff, Mucci, Berger)

*Clonal Hematopoiesis in Prostate Cancer*

Clonal hematopoiesis (CH) is a biological state of blood cells that was initially recognized as a strong risk factor for myeloid malignancies and more recently, for cardiovascular disease. In our proposed study, we break new ground by defining the impact of CH on patients with prostate cancer. The proposed aims will be first-in-field research on the impact of CH on adverse outcomes among patients with both localized and advanced prostate cancer. This risk factor will be directly actionable, as CH is likely driven by treatment choices that patients and physicians make. No study to date has investigated whether the presence of CH increases risks of cancer-specific or cardiovascular outcomes among men with prostate cancer, nor whether specific treatments accelerate progression of CH in men with prostate cancer. As such, while grounded in solid preliminary data from Memorial Sloan Kettering Cancer Center (MSK), our hypothesis is completely novel and has never been tested before Role: co-PI and PI Subcontract.

Direct Costs: $249,261 (No cost extension)

2019-2025 P01 DNA Repair (PI: Kantoff)

*The Impact of DNA Damage Repair Abnormalities in Prostate Cancer*

The scientific premise of this proposal is that germline and somatic variations in the DDR pathways identify a more aggressive form of disease within the high-risk PC population, suggesting that men with high-risk PC require genetic screening at the time of diagnosis and that carriers require treatment regimens distinct from patients who similarly presenting with high-risk disease, but are non-carriers. Further, we hypothesize that these molecular pathways similarly affect risk of aggressive PC in men of African ancestry, possibly with genetic profiles distinct from men of European ancestry. We have access to several unique and complementary cohorts which will enable us to rigorously address these questions: a large hospital-based case cohort at the Dana-Farber Cancer Institute (DFCI) with deep clinical annotation (the DFCI Gelb cohort), well-characterized population based cohorts at the Harvard T. H. Chan School of Public Health [Physicians’ Health Study (PHS) and Health Professionals Follow-up Study (HPFS), and to reproduce findings with ongoing prospective clinical cohorts (at Memorial Sloan Kettering Cancer Center, MSK, DFCI and University of Cambridge), and an expansive cohort that includes biologic samples from hundreds of African American men [Multiethnic Cohort (MEC)]. Role: PI Subcontract and co-Investigator.

Direct Costs: $579,722

2020-2023 Zhu Center for Global Cancer Prevention PEER Award (PI: Mucci)

*Prediagnostic tissue biomarkers in prostate cancer*

Our scientific premise is that tissue biomarkers in negative prostate biopsies hold translational potential to improve classification of patients at low and high-risk of prostate cancer. We will develop a novel repository of negative prostate biopsies within the Health Professionals Follow-up Study to identify early-detection biomarkers. We will sample 500 men from >9,600 who have had a negative prostate biopsy, of whom 250 ultimately were diagnosed with cancer during a median 14.5-years follow-up and 250 cancer-free controls. Specifically, we will: Aim 1: Examine histologic biomarkers of inflammation and future prostate cancer risk. Aim 2: Use RNAseq to identify genes and pathways in prostate epithelial and stromal tissue associated with future cancer risk.

Direct Costs: $200,000 (No cost extension)

2018-2023 National Cancer Institute (R25 CA 174664, PI Mucci)

 *Integrative Molecular Epidemiology Workshop*

This grant supports an annual workshop in partner ship with the American Association for Cancer Research (AACR). The Integrative Molecular Epidemiology Workshop is an innovative, unique, and intensive one-week educational experience to accelerate the training of the next generation of cancer researchers who must be well-skilled in the integration of biology and epidemiology in studies of etiology and outcome.

Direct Costs: $207,685

2021-2023 Astra Zeneca (co-investigator and site PI)

 *NYBAZ Study of DNA Repair*

 This project is a partnership between Astra Zeneca, Dana-Farber Cancer Institute, Harvard Chan School, Memorial Sloan Kettering Cancer Center, and Columbia University. It involves whole exome sequencing of prostate cancer patients to identify the role of germline variation in DNA repair pathways and other rare variants on prostate cancer survival.

2022-2024 Prostate Cancer Foundation (Co-PI)

 *IRONMAN-A novel study of advanced prostate cancer survivorship*

 This study aims to understand the survivorship experience of patients with advanced prostate cancer, either metastatic, hormone sensitive prostate cancer or castration resistant disease. We will explore the patient reported outcomes of patients, both as outcomes and as predictors of survival. We will investigate potential disparities in survivorship and opportunities for intervention. Finally, we will investigate treatment decision making among patients with metastatic hormone sensitive prostate cancer.

2023-2028 National Cancer Institute P50 DF/HCC SPORE in Prostate Cancer

Role – co-Investigator Project 3, Leader Cancer Enchancement Program.

2023-2028 National Cancer Institute (U01 CA268810, PI: Kibel)

*Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer*

The premise of this proposal is that an optimal early detection strategy to identify clinically relevant prostate cancer will involve a two-tiered algorithm that leverages inherited genetic information to determine who is at risk for prostate cancer followed by MRI imaging to determine which of these high risk patients has clinically relevant disease. We propose to test this premise by implementing a polygenic risk score in men and conducting a prospective trial among 1,500 men with MRI to prove the two-tiered algorithm works.

Role: Co-Investigator and Subcontract PI

Direct costs: $540,039

**PENDING GRANTS:**

 2022 R01 NCI: IRONMAN Study of Advanced Prostate Cancer Survivors (Role – PI)

 2023 R35 NCI: Outstanding Investigator Award (Role – PI), Impact Score 13

 2022 R01 Etiologic heterogeneity between molecular subtypes of prostate cancer (Role – co-investigator) - funded

 2022 R01 Etiology and implications of tumor aneuploidy in prostate cancer (Role – co-investigator) – to be resubmitted in February 2023

 2023 Moderna

 2023 US Army Grant

**TEACHING AND TRAINING**:

TEACHING IN HARVARD CHAN SCHOOL COURSES:

1999 *EPI200: Introduction to Epidemiology*

 Teaching Assistant

 110 Students; 55 hours/year

1999-2002 *Epidemiology of Infectious Disease*

Teaching Assistant; Senior Teaching Assistant

 50 Students; 55 hours/year

2000-2001 *Epidemiological Analysis of Outbreaks and Infectious Disease*

Teaching Assistant

 50 Students; 55 hours/year

2000-2002 *EPI255 and EPI256: Epidemiology of HIV/AIDS*

Senior Teaching Assistant

 40 Graduate Students; 50 hours/year

2000-2002 *EPI 204: Analysis of Case-control and Cohort Studies*

Senior Teaching Assistant

 90 Graduate Students; 120 hours/year

2004-2005 *EPI224: Cancer Prevention*

 Guest Lecturer

 40 Graduate Students; 20 hours/year

2005 *EPI257: Advanced Topics in Cancer Epidemiology*

Course Instructor (with Jing Ma)

 10 Graduate Students; 60 hours/year

2006-2007 *EPI294: Screening*

Course Instructor

 40 Graduate Students; 160 hours/year

2006-2017 *EPI246: Applied Biomarkers in Cancer Epidemiology*

Guest Lecturer

 15 Graduate Students; 20 hours/year

2007-2013 *EPI205: Practice of Epidemiology*

 Course Instructor

20 Graduate Students, 60 hours/year

2007-pres *EPI213: Epidemiology of Cancer*

Course Instructor

35 Graduate Students, 100 hours/year

2009 *ID510: Nutritional Epidemiology of Cancer*

Guest Lecturer

15 Graduate Students, 15 hours/year

2012-2014 *EPI208: Clinical Epidemiology, Clinical Effectiveness Program*

Workshop Leader

4 Graduate Students, 5 hours/year

2014 *Summer Program in Quantitative Sciences*

T32 Funded Summer Training Program

Guest Lecturer

2014-2016 *Summer Program in Epidemiology*

 Student Mentor

 3 Undergraduate Students

2014-2017 *WGH211: Gender and Health: Introductory Perspectives*

 Guest Lecturer

 20 Graduate Students, 10 hours/year

2015 *ID 201: Core Biostatistics and Epidemiology for Public Health Practice*

 Guest Lecturer

 80 Graduate Students, 10 hours/year

2015 *EPI510: Global Epidemiology of Cancer*

 Guest Lecturer

 15 Graduate Students, 10 hours/year

2018 *EH289: Environmental Epigenetics*

 Guest Lecturer

 5 Graduate Students, 10 hours/year

2019 *EPI246: Applied Biomarkers in Cancer*

 Guest Lecturer

 15 Graduate Students, 10 hours/year

2021 *Independent Study: Cancer Prevention*

 Course Instructor

 5 Graduate Students, 20 hours/year

2021 *EPI246: Applied Biomarkers in Cancer*

 Guest Lecturer

 15 Graduate Students, 10 hours/year

2022 *EH 520: Research Design in Enviromental Health*

 Faculty Discussant

 15 Graduate Students, 3 hours/year

TEACHING IN OTHER HARVARD COURSES:

2010 *Molecular Pathology Bootcamp, Harvard Medical School*

Guest Lecturer

10 Graduate Students, 10 hours/year

2011-2013 *Molecular Pathology and Epidemiology Bootcamp, Harvard Medical School*

Co-course Leader (with Dr. Massimo Loda)

2012-2013 *PH207x. Health in Numbers: Quantitative Methods in Clinical and Public Health Research, edX of Harvard and MIT*

Guest Lecturer

2019 *Cancer Epidemiology*

Global Education High Impact Cancer Research, Harvard Medical School

Guest Lecturer

2020 The Epidemiology of Cancer

Global Education High Impact Cancer Research, Harvard Medical School

Guest Lecturer

TEACHING COURSES AT OTHER INSTITUTIONS:

2003 *Design Issues in Epidemiology, Boston University School of Public Health*

 Guest Lecturer

 8 Graduate Students; 15 hours/year

2004  *Cancer Epidemiology, Boston University School of Public Health*

Course Instructor/Director

 10 Graduate Students; 120 hours/year

2006 *Cancer Epidemiology and Biomarkers, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy*

 Course Instructor/Director

 12 Graduate students, 60 hours/year

2007-2008 *Design and Analysis of Case-control Studies, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy*

 Course Instructor/Director

 16 Graduate students, 60 hours/year

2009 *Design of Case-control Studies and Cohort, Modern Methods in Biostatistics and Epidemiology, University of Iceland, Reykjavik, Iceland*

 Course Instructor/Director

 25 Graduate Students, 60 hours/year

2011 *Translational Research using Bioinformatics and Epidemiology, Kings College, London, UK*

Course Instructor

20 Graduate Students, 20 hours/year

2012 *Study Design in Epidemiology Research: Case-control Studies, University of Iceland, Reykjavik*

 Guest Lecturer

35 Graduate Students, 20 hours/year

2013 *Integrative methods for prostate cancer research: bridging molecular and population science, Molecular Medicine Ireland, Trinity College, Dublin*

Course Instructor

50 Graduate and Medical Students, 8 hours/year

2019 *Integrative Molecular Epidemiology, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy*

 Course Instructor/Director

 16 Graduate students, 60 hours/year

TEACHING IN EXECUTIVE AND CONTINUING EDUCATION COURSES:

2011- *American Association for Cancer Research Integrative Workshop on Molecular Epidemiology*

Workshop Faculty Member

2015- Workshop Co-Director

50 Graduate Students, Post-docs, junior faculty, 40 hours/year

2016, 2018 *Bienniel Jerome P Richie Urologic Oncology Course*

2021, 2022Course Faculty Member

 180 Urologists, Medical Oncologists, Physicians, 10 hours/year

2017 *2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic*

*Oncology*

New York, NY

Course Faculty Member

200 Urologists, Medical Oncologists, Radiation Oncologists, Physicians, 10 hours/year

2019 *XXIV Workshop Urologia Oncologica – Multidisciplinary Genitourinary Course*

 Lisbon, Portugal

 Course Faculty Member

150 Urologists, Medical Oncologists, Radiation Oncologists, Physicians, 10 hours/year

2023 *Prostate Cancer Clinical Masterclass Series*

 Virtual

 Course Faculty Member

 >500 Urologists, Medical Oncologists, Radiation Oncologists, other Physicians

2023 Prostate Cancer Foundation Thought Leaders of the Future

 Los Angeles, California

 Course Faculty Member

 80 Urologists, Medical Oncologists, Radiation Oncologists, Pathologists

ADVISORY AND SUPERVISORY RESPONSIBILITIES:

*Training Name Current Position*

2004-2006 Stephanie Bakaysa, MD Attending Physician

MPH Student Newton-Wellesley Hospital, MA

2004-2007 Katja Fall, MD, PhD Professor

Post-doctoral Fellow University of Orebro, Sweden

2005-2008 Christine Jesser, ScD Director of Research Enterprise

SD Student (Primary Mentor) Ascension Texas

2005- Kathryn Wilson, ScD Senior Research Scientist

SD Student (Secondary Mentor) Harvard T.H. Chan School of Public Health

Post-doctoral fellow (Mentor)

2006-2007 Patravoot Vatanasapt, DMD Chairman of Otolaryngology,

 MPH (Advisor) Khon Kaen University

2006-2015 Jennifer (Stark) Rider, ScD Senior Director

SD Student (Secondary Mentor) Aetion

Post-doctoral Fellow (Mentor)

Junior faculty (Mentor)

2007-2008 Ioannis Rigas, MD, MPH

 MPH Student (Advisor)

2007-2008 Julia Hayes, MD, MPH Attending Medical Oncologist

 MPH Student (Advisor) Dana-Farber Cancer Institute

2007-2010 Aditi Hazra, PhD Assistant Professor

Postdoctoral Fellow (2nd Mentor) Harvard Medical School

2007-2012 Mara Meyer Epstein, ScD Associate Professor

 Doctoral Student (Advisor) University of Massachusetts

 Post-doctoral Fellow (Mentor) Medical Center

2007-2015 Irene Shui, ScD Senior Scientist

 Doctoral Student (Advisor) Merck

 Post-doctoral Fellow (2nd Mentor)

2008 Keerthana Gnanapradeepan Scientist

 Continuing Umbrella of Research CAMP4 Therapeutics

 Experience (CURE) (Mentor)

2008-2009 Shih-Wen Lin, PhD, MPH Epidemiologist

 MPH Student (Advisor) Genentech

2008-2009 Michaela Cada, MD, MPH Associate Professor of Pediatrics

 MPH Student (Advisor) University of Toronto

2008-2010 David Wheeler, PhD, MPH Associate Professor of Biostatistics

 MPH Student (Advisor) Virginia Commonwealth University

2009-2010 Danielle Margalit, MD, MPH Associate Professor of Radiation Oncology

 MPH Student (Mentor) Dana-Farber Cancer Institute

 Clinical Fellow (Mentor)

2009-2010 Annette Kaufman, PhD, MPH Program Director, Tobacco Control

 MPH Student (Advisor) National Cancer Institute

2009-2012 Wang Xiang Brilent, Inc

 Doctoral Student (Advisor) Data Analytics Fellow

2009-2014 Rebecca Graff, ScD Assistant Professor

 SD Student (Advisor) University of California, San Francisco

2009-2015 Lara Sigurdardottir, PhD Researcher

 PhD Student (University of Icelandic Cancer Society

 Iceland; Co-Mentor)

2010-2011 Piotr Zareba, MD, MPH Assistant Professor

 MPH Student (Advisor) McMaster University

2010-2011 Tryggvi Thorgeirsson, MD, MPH Attending Physician

 MPH Student (Advisor) University of Iceland

2010-2012 Andreas Pettersson, MD, PhD Associate Professor, Medical Oncology

 Post-doctoral Fellow (Mentor) Karolinska Institutet, Sweden

2010-2013 Elisabete Moller, PhD Nutritionist

 Doctoral Student Swedish Association of Professional

 (Karolinska Inst; Co-Supervisor) Scientists

2010-2016 Jennifer Sinnott, PhD Assistant Professor of Biostatistics

 PhD Student (Thesis Committee) The Ohio State University

 Post-doctoral Fellow (Mentor)

2010-2018 Sarah Coseo Markt, ScD Director-Oncology

 SD Student (Advisor) Merck

 Post-doctoral Fellow (Mentor)

2011-2012 Henry Park, MD, MPH Associate Professor, Vice Chair of Clinical

 MPH Student (Advisor) Research

 Yale University Medical School

2011-2012 Yen Chien

 MPH Student (Advisor)

2011-2012 Sun Mi Yoo, MD, MPH Medical Director, Internal Medicine

 MPH Student (Advisor) University of California, Los Angeles

2011-2013 Jonathan Schoenfeld, MD, MPH Associate Professor of Radiation Oncology

 MPH Student/Clinical Fellow Dana-Farber Cancer Institute

 (Mentor/Research advising)

2011- Mark Preston Assistant Professor and Attending

 MPH student and Clinical Fellow Physician

 at MGH (Research advising) Brigham and Women’s Hospital/HMS

2012 Gregory Judson, MD Attending Physician, Internal Medicine

 MD student, Columbia Maine Health

 (Faculty Mentor)

2012-2013 Ardalan Ebrahimi, MD, MPH Associate Professor of Surgery

 MPH Student (Advisor) Canberra

2012-2014 Travis Gerke, ScD Director of Data Science

 SD Student (Mentor) Prostate Cancer Clinical Trials Consortium

 Memorial Sloan Kettering Cancer Center

2012-2014 Alejandro Sanchez, MD Assistant Professor of Urology

 Resident in Urology, University of Utah/Huntsman Cancer

 Massachusetts General Hospital Center

 (Research Mentor)

2012-2016 Thomas Ahearn, PhD Staff Scientist

 Post-doctoral Fellow (Mentor) National Cancer Institute

2012-2019 Ericka (Noonan) Ebot, PhD, MPH Senior Scientist

 Post-doctoral Fellow (Mentor) Foundation Medicine

2013-2014 Kimberly Mak, MD, MPH Assistant Professor in Radiation Oncology

 MPH Student and Resident Boston Medical Center

 at BWH (Research advising)

2013-2014 Kazusa Ishii, MD, MPH Physician Scientist Early Investigator

 MPH student (Mentor) National Cancer Institute

2013-2014 Sigrid Carlsson, MD, PhD Associate Professor and Urologist

 MPH student (Research mentor) Memorial Sloan Kettering Cancer Center

2013-2018, Claire Hampton Pernar, MS Epidemiologist

 ScD Student (Mentor) Optum Health

2018-2019 Post-doctoral Fellow

2019-2021 Research Scientist

2014 Lorenzo Richiardi, PhD Professor of Epidemiology

 Fulbright Scholar, HSPH University of Turin, Italy

 (Faculty mentor)

2014-2015 Vicente Morales Oyarvide, MD Assistant Instructor

 MPH Student (Advisor) University of Texas Southwestern

2014-2015 Taylor Medwig Postdoctoral Fellow

 Undergraduate student Stony Brook University

 Summer Program in Epidemiology

 (Research advising)

2014-2015 Christopher Allard, MD Attending Urologist

 MPH Student and Urologic Oncology Clinical Assistant Professor

 Fellow at MGH/DFCI McMaster University

 (Research advising)

2014-2015 Alexandra Greenberg, PhD Senior Medical Writer

 MPH Student (Research mentor) Boston Scientific

2014-2016 Reginald Tucker-Seeley, PhD Assistant Professor and Schneider Chair

 Assistant Professor (K01 mentor) in Gerontology

 University of Southern California

 Chief Diversity Officer

 Zero Prostate Cancer

2014-2016 Masis Isikbay Resident in Radiology

 Harvard Medical School student University of California at San Francisco

 (Research mentor)

2014-2016 Barbara Dickerman, PhD Assistant Professor of Epidemiology

 SM2 Student (Advisor) Harvard T.H. Chan School of

2016-2018 PhD Student (Advisor) Public Health

2022-pres Assistant Professor of Epidemiology

 (Secondary Mentor)

2014-2016 Sarah Lucht, SM Post-doctoral Fellow in Epidemiology

 SM2 Student (Advisor) University of Minnesota

2014-2016 Lauren Barber, SM Postdoctoral Fellow

 SM2 Student (Research Mentor) Emory University School of Public Health

2014-2016 Sarah Legge, ALM Teacher

 ALM Student, Harvard University Massachusetts School system

 Extension School

 (Thesis Director)

2014- Konrad Stopsack, MD Assistant Professor

 MPH Student (Research Mentor) Clinical Translational Epidemiology Unit

2015-2022 Research Associate (Secondary Mentor) Massachusetts General Hospital

 Memorial Sloan Kettering Cancer Center Harvard Medical School

2015-2016 Vitor Moutinho da Coneicao Junior, MD Post-doctoral Fellow

 SM1 Student (Advisor) Dana-Farber Cancer Institute

2015-2016 Hsi Yen, MD

 MPH Student (Advisor)

2015-2016 Cendrine Robinson, PhD Chief Diversity Officer

 MPH Student (Advisor) National Institute on Deafness and other

 Communication Disorders

2015-2018 Emma Allott, PhD Assistant Professor

 Research Mentor Queen’s College, Belfast

 John Fitzpatrick Fellowship

 Boston-Irish Prostate Cancer

 Collaboration

2016-2017 Kristen Pluchino, PhD Clinical Team Leader

 MPH Student (Mentor) US Food and Drug Administration

2016-2017 Sabrina Tsang, PhD Clinical Scientist

 MPH Student (Advisor) Merck

2016-2017 Suna Park Senior Manager

 SM2 Student (Mentor) Takeda

2016-2017 Nadine Hamieh Post-doctoral Fellow

 Visiting Student, American University INSERM

 of Lebanon

 (Research Advising)

2016-2017 Dana Hashim, PhD Post-doctoral Fellow

 Research Fellow Mt Sinai Cancer Institute

 (Research Advising)

2017 Brendan Rowen Medical Student

 MD Student, University College, Dublin University College, Dublin

 Research Advising

2017-2018 Cindy Zhou, PhD Epidemiologist

 Post-doctoral Fellow (Mentor) National Cancer Institute

2017-2018 Dongzhengyan An

 SM2 Student (Advisor)

2017-2018 Christopher Sauer Physician-Data Scientist

 MPH Student (Advisor) University of Essen

2017-2018 Michael Liu

 MPH Student (Advisor)

2017-2019 Junkun Ren PhD Candidate

 SM2 Student (Advisor) Massachusetts Institute of Technology

2018 Chang Lu

 MPH Student (Research Mentor)

2018 Latifa Bazza Epidemiologist

 MPH Student, University of Michigan University of Michigan

 (Summer Research Mentor)

2018-2019, Yiwen Wang, SM2 Post-doctoral Fellow

2019-2023 SM2 Student (Research Mentor) Harvard Chan School

 PhD Student (Research Mentor)

2018-2019 Charlie Zhou, MD Consultant

 MPH Student (Advisor) MacKenzie

2018-2019, Emily Rencsok

2019-pres MD/PhD Student, Harvard Medical School

 (Research Advisor)

 PhD Student, Harvard University

 (Primary Mentor)

2018-pres Mingyang Song, MD, ScD

 Assistant Professor of Epidemiology

 Harvard Chan School of Public Health

 (Secondary Mentor)

2018-2023 Kathryn Barry, PhD, MPH Assistant Professor

 University of Maryland (K07 Co-Mentor) University of Maryland

2018-2021 Benjamin Fu, PhD Staff Scientist

 Post-doctoral Fellow Bristol Meyers Squib

 (Primary Mentor)

2018-pres Ilkania Chowdhury-Paulino, MS

 PhD Student, Harvard Chan School

 (Primary Mentor)

2018-2020 Christian Fankhauser, MD Urologist

 Clinical Effectiveness Program University of Manchester

 (Research Mentor)

2019 Victor Nhilziyo Resident

 Visiting Scholar Walter Reed Medical Center

 (Research Mentor)

2019-2020 Xiaoshuang Feng Post-doctoral fellow

 Visiting Scholar International Agency for Research

 Research Mentor on Cancer

2019-2020 Carl Ceraolo Resident in Urology

 MPH in QM Student Rochester University School of Medicine

 Harvard Chan School

 (Primary Mentor)

2019-2020 Lu Zhu Research Associate

 SM2 Student, Harvard Chan School Harvard Chan School

 (Research Mentor)

2019-2020 Mirzya Haider Senior Research Analyst

 MPH in Epidemiology Center for Health Information and

 (Research Advisor) Analysis

2020-2023 Rachel Nethery, PhD

 Assistant Professor of Biostatistics

 Harvard Chan School of Public Health

 (Advisory Committee, K Award)

2019-2021 Eleni Rettig, MD

 Assistant Professor of Surgery

 Brigham and Women’s Hospital

 (Research Mentor)

2020-pres Naiyu Chen

 PhD in Population Science (Epidemiology)

 Harvard Chan School

 (Advisor and Primary Mentor)

2020-2022 Colleen McGrath

 SM2 Student, Harvard Chan School

2022-pres PhD Student, Harvard Chan School

 (Advisor and Thesis Mentor)

2021-2022 Tiffany Dang College Student

 Dana-Farber/Harvard Cancer Center CURE study Mass College of Pharmacy

 (Research Mentor) and Health Sciences

2021 Kevin Tesorero

 Dana-Farber/Harvard Cancer Center CURE study Student

 (Research Mentor) Revere High School

2021-2023 Catherine Allende

 SM2 Student, Harvard Chan School

 (Advisor)

2021-2023 Aiza Malik

 SM2 Student, Harvard Chan School

 (Advisor)

2021-2023 Yuchen Zhao PhD Student

 SM2 Student, Harvard Chan School Harvard Chan School

 (Advisor)

2021-2022 Tanawin Noposin Research Associate

 MPH Student, Harvard Chan School Mass General Hospital

 (Research Advising)

2021-2022 Alaina Shreves PhD Student

 SM2 Student, Harvard Chan School NCI-Oxford University

 (Research Advising)

2021-pres Michelle Sodipo

 PhD in Population Science (Epidemiology)

 Harvard Chan School

 (Advisor and Primary Mentor)

2022 Mireya Dorado

 Summer Program in Epidemiology Undergraduate Student

 Harvard Chan School Northeastern University

 (Research Advisor)

2022 Osase Idahor

 Harvard University

 Undergraduate Researcher

 (Research Advisor)

2022-2023 Liang Qi

 MPH-Epidemiology Program

 Harvard Chan School

 (Research Advisor)

2022-2023 Jay Santos Cabrera

 SM2 in Epidemiology Program

 Harvard Chan School

 (Academic Advisor)

2022-2024 Megan Shanahan

 SM2 in Epidemiology Program

 Harvard Chan School

 (Academic Advisor)

2023-2024 Qi Dong

 MPH-Epidemiology Program

 Harvard Chan School

 (Research Advisor)

2022-pres Sinead Flanagan

 Research Associate

 Harvard Chan School

 (Mentor)

2022-pres Yanguang Wei

 Postdoctoral Fellow in Environmental Health

 Harvard Chan School

 (Mentor on K99/R00 Application)

2022-pres Claire Kim

 Research Fellow

 Harvard Chan School

 (Mentor)

2023-pres Anqi Wang

 Research Fellow

 Harvard Chan School

 (Mentor)

2023-pres Sarah Robertson

 Postdoctoral Fellow in Epidemiology

 Harvard Chan School

 (Mentor on K99/R00 Application)

2023-pres Yuan Ma

 Assistant Professor of Epidemiology

 Harvard Chan School

 (Secondary Mentor)

2023-pres Chaoran Ma

 Assistant Professor of Epidemiology

 UMass Amherst School of Public Health

 (Primary Mentor on Young Investigator Award)

2022-2023 Lindsay Page Cancer Prevention Fellow

 MPH in Quantitative Methods National Cancer Institute

 Harvard Chan School

 (Research Advisor)

2022-2023 Isani Singh

 MD Student

 Harvard Medical School

 (Research Mentor)

2023-2024 LeeAnn Lucas

 SM2 in Epidemiology Student

 Harvard TH Chan School of Public Health

 (Research Advisor)

2023 Alice Dalsass

 Visiting MD Student

 University of Bologna

 (Research Mentor)

2023-pres Aimee Huang, PhD

 Post-doctoral Fellow

 Harvard Chan School of Public Health

 (Secondary Mentor)

**Doctoral dissertation committee membership**

2005 – 2008 2005-2008 Jennifer (Stark) Rider, Epidemiology

2005 – 2008 2005-2008 Kathryn Wilson, Epidemiology

2006 – 2009 2006-2009 Julie Kasperzyk, Epidemiology

2006 – 2009 2006-2009 Kathryn Penney, Epidemiology

2007 – 2008 2007-2008 Justin Manjourides, Biostatistics

2008 – 2010 2008-2010 Matthew Austin, Biostatistics

2009 – 2014 2009-2014 Rebecca Graff, Epidemiology

2010 – 2012 2010-2012 Jennifer Sinnott, Biostatistics

2010 – 2012 2010-2012 Johanna Torfadottir (University of Iceland), Epidemiology

2010 – 201 2010-2013 Ke Zu, Nutrition and Epidemiology

2011-2015 Lara Sigurdardottir (University of Iceland), Epidemiology

2012 Ran Zhang, Nutrition and Epidemiology (Oral Exam)

2012-2016 Christina McInstosh, Biostatistics

2014-2015 2014-2015 Kevin Kensler, Epidemiology (Oral Exam)

2014-6 2014-2016 Natalie DuPre, Epidemiology (Oral Exam)

2016- 2016-2017 Elizabeth Loehler, Environmental Health (Oral Exam)

2017-2018 Mary Kathryn Downer, Epidemiology

2018 Omar Soliman, Harvard Medical School, MMSI Program (External Examiner)

2018-2019 Hector Maldonado Perez, Population Health Sciences (PQE Committee Examiner)

2018-2020 Zhihui Wang, Environmental Health (PQE Committee Examiner; Thesis Committee)

2019-2020 David Cote, Epidemiology (PQE Committee Chair)

2019-2021 Kristen Brantley, Epidemiology (PQE Committee Examiner)

2019-2021 Xinan Wang, Environmental Health (PQE Committee Examiner)

2020-2022 Rui Song, Epidemiology and Nutrition (PQE Committee Examiner)

2022 Ziwei Zhang, Computational Biology and Quantitative Genetics (Masters Thesis

 Committee)

2021-2023 Yiwen Zhang, Epidemiology (PQE Committee Examiner; Thesis Committee)

**Other Mentoring**

2009 Thesis Examiner for PhD candidate (Janneke Hogervorst), *Dietary acrylamide and human cancer risk,* Maastricht University, Maastricht The Netherlands

2010 Thesis Examiner for PhD candidate (Elizabeth Tindall), *Genetic contributions to inflammatory mediated prostate cancer*, University of New South Wales, Australia

**INVITED PRESENTATIONS:**

Local

2004 *Molecular Signatures of Prostate Cancer Survival*

Harvard School of Public Health

2004 *Plasma Levels of Free IGF-1, Acid-labile Subunit and Prostate*

*Cancer Risk: A Prospective Study*

Channing Laboratory/Brigham and Women's Hospital Seminar Series

2004 Invited Speaker, *Acid-labile Subunit and Prostate Cancer Risk: A Prospective Study*, Slone Epidemiology Seminar, Boston University School of Public Health, Boston, MA

2005 Invited Speaker, *Identifying Molecular Markers of Indolent and Aggressive*

*Prostate Cancer,* Boston University Medical Grand Rounds, Boston Medical Center, Boston MA

2006 *Microvessel Density and architecture: biomarkers of lethal prostate cancer*

Harvard Prostate Cancer Working Group

2006 *Molecular signatures to predict lethal and indolent prostate cancer*

BWH-BRI Inaugural Cancer Research Center Retreat

2007 *Biomarkers of tumor angiogenesis and lethal prostate cancer*

Dana-Farber/Harvard Cancer Center Prostate SPORE Meeting

2007 *Incorporating tumor biomarkers into cancer epidemiology studies: the prostate cancer story* Department of Epidemiology Seminar Series, Harvard School of Public Health

2008 Invited Speaker, *Metabolism and Prostate Cancer in the PHS and HPFS cohorts*, Cancer Genome Program, Broad Institute, Cambridge, MA

2008 *Genetic susceptibility and the TMPRSS2:ERG fusion*

Dana-Farber/Harvard Cancer Center SPORE Meeting

2008 *Dietary and biochemical predictors of prostate cancer risk and progression* Harvard Urology and Prostate Cancer Seminar Series, Harvard Institute of Medicine

2008 Invited Panelist, *Work and Family Balance Panel*

Office for Women’s Careers, Brigham and Women’s Hospital

2008 Invited Panelist, *Women in Academe: Balancing Family and Careers*

 Harvard School of Public Health

2008 *Prostate Tumor Biomarker Studies in the Health Professionals Follow-up Study*

Health Professionals Follow-up Study External Advisory Board Meeting, Harvard School of Public Health

2008 *The TMPRSS2:ERG fusion and the sex hormone milieu*

Dana-Farber/Harvard Cancer Center SPORE in Prostate Cancer Meeting, DFCI

2009 *The TMPRSS2:ERG fusion in prostate cancer*

Molecular Epidemiology Working Group Seminar, Harvard School of Public Health

2009 Invited Speaker, *Prostate Cancer Epidemiology and the TMPRSS2:ERG fusion*

Dana-Farber/Harvard Cancer Center Conference on Cancer

2009 Invited Speaker, *Translocations and Aberrations: a patho-epidemiology study of prostate cancer risk and progression*

Department of Epidemiology Seminar, Harvard School of Public Health

2010 *TMPRSS2:ERG and SPINK1 in Lethal Prostate Cancer*

Dana-Farber/ Harvard Cancer Center SPORE in Prostate, External Advisory Board Meeting

2011 *TMPRSS2:ERG, SPINK1 and Lethal Prostate Cancer*

Dana-Farber/Harvard Cancer Center Prostate SPORE Meeting

2011 *The Burden of Cancer from an Epidemiologist’s Perspective*

Summer Program in Quantitative Methods, Harvard School of Public Health

### 2011 *Future Directions for Translation of Archival Tissue Studies* (Panel Discussion). **Emerging Technologies for Translation Bioinformatics: A symposium on gene expression profiling for archival tissues, Harvard School of Public Health**

2011 *Shedding Light on the Heritability of Cancer: a study of 200,000 Nordic Twins*

Department of Epidemiology Seminar Series, Harvard School of Public Health

2011 Keynote Address, *Prevention of Lethal Prostate Cancer: opportunities and novel hypotheses*, Massachusetts Prostate Cancer Coalition, Newton MA

2011 Invited Speaker, *The burden of cancer from an epidemiologist’s perspective*, Massachusetts College of Pharmacy CAPSTONE course, Boston, MA

2012 *Cancer: what have we learned and where do we go from here?*

Harvard School of Public Health Leadership Council Meeting

2012 *Unveiling the potential of patho-epidemiology to understand prostate cancer*

Quantitative Issues in Cancer Research Working Seminar, Department of Biostatistics, Harvard School of Public Health

2012 *The burden of cancer from an epidemiologist’s perspective*, Massachusetts College of Pharmacy CAPSTONE course, Boston, MA

2012 Invited Speaker, *MicroRNA in tumor tissue: overview of design and pilots for prostate cancer*, Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston MA

2013 *Exploring Mechanisms Underlying the Link between Obesity, Physical Activity and Lethal Prostate Cancer*

Harvard Transdisciplinary Research in Energetics and Cancer (TREC) Annual Meeting

2013 *Tumor/Patient Genotyping Efforts within DF/HCC*

Dana-Farber/Harvard Cancer Center Scientific Council Meeting

2013 *What’s hot, what’s not: ongoing controversies in PSA screening for prostate cancer*

Hot Topics in Public Health, Harvard School of Public Health

2013 *Unveiling the enigma of prostate cancer epidemiology*

Genitourinary Oncology Seminar, Dana-Farber Cancer Institute

2013 Organizer, *Celebration of Young Investigators in Cancer Research*, Dana-Farber/Harvard Cancer Center

2013 Organizer and Speaker, *What’s Up in Cancer Epidemiology*, Dana-Farber/Harvard Cancer Center Population Science Group

2013 Moderator*, “History and Future of Epidemiology” panel session*

Cutter Lecture Symposium, Harvard School of Public Health

2013 *Tumor/Patient Genotyping Efforts within DF/HCC*

Dana-Farber/Harvard Cancer Center Scientific Council Meeting

2014 Invited Speaker, *Gene expression profiling studies in the HSPH cohorts: tantalizing preliminary results*

Dana-Farber/Harvard Cancer Center SPORE in Prostate Cancer meeting

2014 Invited Speaker, *Metabolic consequences of obesity on cancer risk and mortality,*

Using basic and epidemiological studies to identify metabolic vulnerabilities in cancer, Dana-Farber/Harvard Cancer Center Symposium on Metabolism and Cancer

2014 Invited Speaker, *Integrating Tissue Biomarkers into Prostate Cancer Epidemiology Research,* 2nd International Molecular Pathological Epidemiology Meeting, Dana-Farber Cancer Institute

2014 *Estimating the prostate cancer burden attributed to lifestyle and genetic factors among African-American and White men,* Dana-Farber/Harvard Cancer Center – Prostate Cancer Foundation A. David Mazzone Awards Program Scientific Retreat

2014 *Assessment of the DF/HCC Catchment Area: Massachusetts,* Dana-Farber/Harvard Cancer Center Executive Committee

2014 Invited Speaker, *Estimating the prostate cancer burden attributed to lifestyle and genetic factors among African-American and White men*, A. David Mazzone Awards Program Retreat, Dana Farber/Harvard Cancer Center

2014 Panelist, *Development and Safety Management of Cancer Drugs Workshop.* Harvard School of Public Health and Takeda Pharmaceuticals

2014 Invited Speaker, *Integrating tissue biomarkers into cancer epidemiology studies: examples from prostate cancer,* Harvard University Transdisciplinary Research on Energetics and Cancer Scientific Retreat

2014 Invited Speaker, *The prevention of lethal prostate cancer*, Boston Prostate Cancer Support Group, Beth Israel Deaconess Medical Center, Boston

2014 Invited Panelist, *Prostate Cancer Awareness Day*, Massachusetts State House

2015 Invited Speaker, *Prevention of lethal prostate cancer,* Prostate Health Education Network (PHEN) Support Group Meeting, Dana-Farber Cancer Institute

2015 Invited Speaker, *Assessment of the DF/HCC Catchment Area: Massachusetts*, 2015 Liver Cancer Incubator, Dana-Farber/Harvard Cancer Center

2015 Invited Speaker, *The prevention of lethal prostate cancers,* Boston Prostate Cancer Support Group, Beth Israel Deaconess Medical Center, Boston MA

2016 Invited Speaker, *Prevention of lethal prostate cancer*

Massachusetts General Hospital Urology Grand Rounds

2016 Invited Speaker, *Obesity and lethal prostate cancer*

DF/HCC SPORE in Prostate Cancer Monthly Meetings

2016 Invited Speaker, *Novel advances in prostate cancer prevention*, Massachusetts Prostate Cancer Coalition, Newton MA

2016 Invited Speaker, *Opportunities for research in GU Cancers in the Harvard Cohorts*, Genitourinary Oncology Research Seminar, Dana-Farber Cancer Institute

2018 Host and panel discussion, *Do statins increase the survival of cancer patients*? Inaugural Kolokotrones Symposium, Harvard T.H. Chan School of Public Health

2018 Seminar Speaker, *Examples of interdisciplinary strategies in cancer epidemiology*. Department of Epidemiology Seminar Series, Harvard T.H. Chan School of Public Health

2019 Invited Speaker, *Optimizing screening strategies in prostate cancer*. Dana-Farber/Harvard Cancer Center Prostate Cancer Program

2019 Invited Speaker, A David Mazzone Awards Symposium, *Prostate cancer epidemiology studies of disparities*. Dana-Farber/Harvard Cancer Center

2020 Invited Speaker and Panel Member, Massachusetts Prostate Cancer Coalition Annual Symposium, *State of Evidence of Diet and Lifestyle for Prostate Cancer*

2020 Invited Speaker, Boston Prostate Cancer Support Group, *State of Evidence of Diet and Lifestyle for Prostate Cancer*

2021 Invited Speaker, Department of Epidemiology Seminar Series, Harvard TH Chan School of Public Health, *Building a global cohort of advanced prostate cancer survivors*

2021 Invited Speaker, Boston Area Prostate Cancer Support Group, *State of Evidence on Diet and Prostate Cancer and IRONMAN global cohort of prostate cancer survivors*

2022 Invited Speaker, *Inherited susceptibility to prostate cancer: opportunities for prevention and early detection,* Harvard Cancer Working Group

2022 Invited Speaker, *Inherited genetics and prostate cancer epidemiology*, MPH-Epidemiology Program, Harvard TH Chan School of Public Health

2022 Invited Speaker, *Epidemiology and lessons learned along the journey,* Summer Program in Epidemiology, Harvard TH Chan School of Public Health

2022 Organizer, *Obesity, Metabolism, and Cancer, Brief Update Series,* Dana-Farber/Harvard Cancer Center

2023 Organizer, *10th Annual* *Celebration of* *Early career Investigators in Cancer Research*, Dana-Farber/Harvard Cancer Center

National

2004 Invited Speaker, *Dietary acrylamide and risk of cancer*, American Chemical Society, 227th National Meeting in Anaheim, CA

2005 Invited Speaker, *Dietary Acrylamide and risk of human cancer: the role of*

*epidemiology*, Society of Toxicology, 44th Annual Meeting, New Orleans, LA

2006 Invited Speaker, *Identifying molecular signatures of indolent and lethal prostate cancer.* Prostate Cancer InterSPORE Meeting, National Cancer Institute, Houston, TX

2007 Invited Speaker, *Multigene signatures of indolent and lethal prostate cancer*, Active Surveillance for Early Stage Prostate Cancer, San Francisco, CA

2007 Panelist, *The role of acrylamide in diet and risk of cancer*, American Chemical Society, 229th National Meeting, Boston, MA

2008 Invited Speaker, *Obesity and the TMPRSS2:ERG Fusion*, Prostate Cancer Foundation Annual Retreat, Lake Tahoe, CA

2008 Invited Speaker, *Obesity and Prostate Cancer Progression in the Physicians’ Health Study*, National Cancer Institute Translational Meeting, Washington DC.

 2008 Invited Speaker, *Central adiposity and prostate cancer survival in relation to tumor tissue expression of sex steroid hormone receptors*, Tri-institutional Prostate Cancer Program Retreat, Newport, RI

2009 Invited Speaker, *Tomatoes, lycopene and prostate cancer: is the association with disease progression mediated through angiogenesis?* Tri-institutional Prostate Cancer Program Retreat, Baltimore, MD

2009 Invited Speaker, *Do antioxidants prevent risk of TMPRSS2:ERG fusion prostate cancer?* Prostate Cancer Foundation Annual Scientific Retreat, Lake Tahoe CA

2009 Invited Speaker, *TMPRSS2:ERG fusion and SPINK1 in prostate cancer etiology and progression,* National Cancer Institute Translational Meeting, Tyson’s Corner, VA

2010 Invited Speaker, *Genetic and lifestyle factors impact prostate cancer survival through angiogenesis.* 7th Annual International M. Judah Folkman Conference Antiangiogenesis: New Frontiers in Therapeutic Development, Boston, MA

2010 Invited Speaker, *The patho-epidemiology of prostate cancer.* Multi-institutional Prostate Cancer Program Retreat, Ft Lauderdale, FL

2012 Invited Speaker, *Genetic variation in antioxidant pathway and prostate cancer progression*, SELECT Trial Symposium, Southwest Oncology Group, Dallas, TX

2012 Invited Speaker, *Promenadgruppen: a pilot walking intervention among men with prostate cancer.* Fourth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

2012 Session Chair, Prostate Cancer: Risk, Fifth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

2012 Organizer and Co-Leader, Sixth Annual International Prostate Cancer Patho-

Epidemiology Retreat, Martha’s Vineyard

2012 Invited Speaker, *Tumor Tissue Collection: The Experience of the Harvard Cohorts.* 2011 Annual Meeting of the National Cancer Institute Cohort Consortium, Boston MA

2012 Panelist, Celebration of Science, FasterCures and the Milken Institute, Washington DC

2012 Poster Discussant, American Society for Clinical Oncology Annual Meeting, Genitourinary (Prostate) Cancer, Chicago, Illinois

2013 Session Chair, Prostate Cancer: Risk Session, Sixth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

2013 Panelist, *Living to 1000: Impossible or in reach?* Milken Institute Global Conference, Beverly Hills, CA

2013 Invited Panelist, *Prouts Neck 2.0 Meeting on Prostate Cancer.* Beyond AR: New Approaches to Treating Metastatic Prostate Cancer, San Diego, CA

2013 Invited Speaker, *Unveiling the potential to prevent lethal prostate cancer: Integrative molecular epidemiology approaches to public health*, Northwestern SPORE in Prostate Cancer, Fred Hutchinson Cancer Institute, Seattle, WA

2013 Session chair and speaker, *The patho-epidemiology of prostate cancer: translating population science to prevention and treatment of advanced prostate cancer*, 20th Annual Prostate Cancer Foundation Annual Scientific Retreat, Washington DC

2014 Invited Speaker, *Chronic Diseases associated with prostate cancer*, Bienniel Prostate Cancer Forum, Prostate Cancer UK, Baltimore, MD

2014 Invited Speaker, *Where are we and where are we going: risk*, Seventh annual Multi-Institutional Prostate Cancer Program Retreat, Ft Lauderdale, FL

2014 Invited Speaker, Educational Session, *Integrative Molecular Epidemiology*, American Association for Cancer Research, San Diego, CA

2014 Invited Speaker, *Tumor Drivers of the Link between Obesity and Lethal Prostate Cancer*, Prostate Cancer Foundation Coffey-Holden Prostate Cancer Academy, Carlsbad, CA

2014 Program Committee and Moderator, 21st Annual Prostate Cancer Foundation Scientific Retreat, Carlsbad, CA

2014 Invited Speaker, *Integrative tissue biomarkers into cancer epidemiology studies: examples from prostate cancer*. Transdisciplinary Research on Energetics and Cancer (TREC) Annual Scientific Meeting, Boston, MA

2014 Invited Speaker, *Integrative molecular epidemiology of prostate cancer*, Vermont Cancer Center's Clinical & Translational Research Symposium, Burlington, VT

2015 Invited Speaker, *Precision prevention in prostate cancer: the case for TMPRSS2:ERG*, 6th International PACRIM Breast and Prostate Cancer Meeting, Stevenson, WA

2015 Session chair and speaker, *Integrating Tissue Biomarkers into Cancer Epidemiology Studies*, National Cancer Institute’s Cohort Consortium, Gaithersberg, MD

2015 Invited Speaker, *PCF5000: A Novel Disease Registry among Men with Advanced Prostate Cancer,* Eighth Annual Multi-Institutional Prostate Cancer Program Retreat, Ft Lauderdale, FL

2015 Invited Speaker, *Unraveling the mystery of prostate cancer’s etiology*, Department of Epidemiology Seminar Series, University of Florida, Gainesville, FL

2015 Featured Invited Speaker, *Epidemiology of Prostate Cancer Risk and Progression,* Prostate Cancer Evidence Academy, University of Pennsylvania

2016 Presenter, *Cancer Epidemiology Cohort in Male Health Professionals*, National Cancer Institute Tissue Supplement Webinar

2016 Invited Speaker, *Diet, lifestyle and Lethal Prostate Cancer*, Centennial Meeting of the Endocrine Society (ENDO 2016), Boston, MA

2016 Invited Speaker, *Unraveling the enigma of prostate cancer epidemiology*, H. Lee Moffitt Cancer Center, Tampa, FL

2016 Organizer and Moderator, First Annual Prostate Cancer Foundation Women’s Networking Forum, Carlsbad, CA

2017 Invited Speaker, *Genomic tests in active surveillance and the role of hereditary testing,* 2017 Genitourinary Cancers Symposium, ASCO, Orlando, FL

2017 Chair, Molecular and Genetic Epidemiology Mini-symposium, 2017 American Association for Cancer Research Meeting, Washington DC

2017 Invited Speaker, *Prostate Cancer Survivorship: IRONMAN Registry*,7th Annual Prostate Cancer Symposium, Karmanos Cancer Institute, Detroit, Michigan

2017 Invited Speaker and Panelist, *Screening and Low risk disease: Prostate Cancer Epidemiology*, 2017 International Prostate Cancer Symposium, Icahn School of Medicine at Mt Sinai, New York

2017 Session Chair, *Do we need better biomarkers to identify higher-risk, locally advanced disease?* Prostate Cancer: Advances in Basic, Translational, and Clinical Research, American Association for Cancer Research, Orlando, Florida

2018 Invited Speaker and Session Chair, *Exploring mechanisms underlying the link between obesity and lethal prostate* cancer, Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes, American Association for Cancer Research, Austin, Texas

2018 Invited Speaker, *Integrative Molecular Epidemiology Workshop*, NCIs Continued Support of Cancer Education through the R25 Mechanism, International Cancer Education Conference, Atlanta, GA

2018 Organizer and Moderator, Third Annual Prostate Cancer Foundation Women in Science Networking Forum, Carlsbad, CA

2019 Moderator, *Population Science*, 12th Annual Multi-Institutional Prostate Cancer Retreat, Fort Lauderdale, FL

2019 Invited Speaker, *Examples of Interdisciplinary Strategies in Cancer Epidemiology,* Fox Chase Cancer Center Grand Rounds, Philadelphia, PA

2019 Invited Speaker, *Interdisciplinary Studies of Prostate Cancer Epidemiology,* Karmanos Cancer

Center Grand Rounds, Detroit Michigan

2019 Invited Speaker, *Molecular Epidemiology of Prostate Cancer*, National Cancer Institute, Genitourinary Malignancies Center of Excellence Seminar, MD

2019 Organizer and Moderator, Fourth Annual Prostate Cancer Foundation Women in Science Networking Forum, Carlsbad, CA

2019 Invited Speaker, *The Ups and Downs of an Academic Career*, Young Investigator Day, Prostate Cancer Foundation Annual Retreat, Carlsbad CA

2019 Panel Moderator, *Are there racial disparities in prostate cancer?,* Prostate Cancer Foundation Annual Retreat, Carlsbad CA

2020 Conference Organizer, 13th Annual Multi-Institutional Prostate Cancer Retreat, Fort Lauderdale, FL

2020 Invited Speaker, *IRONMAN: Findings and Future Directions of a global registry of men with advanced prostate cancer*, Cancer Prevention and Control Program Grand Rounds, MD Anderson Cancer Center, Houston, TX (remote)

2020 Invited Speaker, *IRONMAN: Findings and Future Directions of a global registry of men with advanced prostate cancer*, Cancer Prevention, Control, and Population Science Program, Case Western Cancer Center, Houston, TX (remote)

2021 Invited Speaker, *Epidemiology Studies of prostate cancer: from early detection to survivorship*,University of Chicago Comprehensive Cancer Center, Seminar Series, Chicago, IL (remote)

2021 Panel Member, *Epidemiologic and Surveillance Research,* Survivorship Needs for Individuals Living with Advanced and Metastatic Cancers, National Cancer Institute Conference, National Cancer Institute (remote)

2021 Invited Speaker, *COVID-19 Vaccines*, The KJLH Women’s Health Expo, California (remote)

2021 Invited Speaker, *Healthy lifestyle among men at high genetic susceptibility,* Prostate Cancer Foundation Board, California (remote)

2021 Invited Speaker, *Biomarker studies within the Harvard Prostate Cancer Tumor Cohorts*, Early Detection Research Network, Atlanta GA (remote)

2021 Invited Speaker and Panelist, *Dietary Patterns and Prostate Cancer*, Prostate Cancer Foundation Webinar, Santa Monica CA (remote)

2021 Invited Speaker and Panelist, *Epidemiologic aspects of prostate cancer in Black men and men of African ancestry*, Prostate Cancer Foundation Annual Scientific Retreat (remote)

2022 Invited Panelist, *What Cancer Research Teaches us about a Healthy Body and Brain,* Milken Institute South Florida Dialogue, Palm Beach, FL

2022 Invited Speaker, *Integrative Molecular Epidemiology Studies of Prostate Cancer*, Cancer Epidemiology Seminar Series, USC Norris Comprehensive Cancer Center (remote)

2022 Invited Speaker, *Unraveling the enigma of prostate cancer epidemiology,* Distinguished Seminar Series, Herbert Irving Comprehensive Cancer Center (remote)

2022 Invited Speaker, *Unraveling the enigma of prostate cancer epidemiology,* Population Sciences Seminar Series, Vanderbilt-Ingram Cancer Center (remote)

2022 Keynote Speaker, *Prostate Cancer Heritability: Etiology, early detection, and prevention*, UCLA Prostate Cancer SPORE

2022 Plenary Session, *Cancer the inherited susceptibility to prostate cancer be modified?* 2022 American Institute for Cancer Research Annual Meeting, Leesburg, Virginia

2022 Panel member and organizer, *State of Evidence on Diet and Lifestyle in Prostate Cancer*, Prostate Cancer Foundation, Carlsbad, CA

2022 Invited Speaker, *Experiences and lessons learned using real world data in oncology
Early results from IRONMAN: International Registry of Man with Advanced Prostate Cancer*, Bayer Real World Evidence Seminar Series (remote)

2023 Invited Speaker, *Opportunities to Reduce Disparities in Prostate Cancer,* CONDUC 2023 Scientific Symposium (remote)

2023 Panel Member and Organizer,

International

2004 Invited Speaker, *Tissue Microarrays in Cancer Epidemiology*, 2004 Hydra

Cancer Meeting, Hydra, Greece

2006 Invited Speaker, *Epidemiological studies on the relationship between acrylamide in the diet and cancer risk, Multidisciplinary approaches to reducing the levels of acrylamide in food*, Association of Applied Biologists, Hertfordshire, UK

2007 Panelist, *Icelandic Meeting on Prostate Cancer* (*Progress*), University of Iceland, Reykjavik, Iceland

2008 Invited Speaker, *Tumor angiogenesis and prostate cancer mortality*, Department of Urology, University of Orebro, Orebro, Sweden

2008 Invited Speaker, *Concepts and Principles of Cancer Screening*, University of Iceland, Reykjavik, Iceland

2008 Panelist, *Bladder Cancer-from Pathogenesis to Prevention-International Consultation*, World Health Organization International Consultation, Stockholm, Sweden

2008 Educational Review Panel for MPH and doctoral students at the Division of Public Health Sciences, University of Iceland, Reykjavik

2009 Panelist, *Prostate Cancer Retreat*, University of Orebro, Orebro, Sweden

2009 Invited Speaker, *The state of affairs of epidemiological research on acrylamide and human cancer risk*, Maastricht University, The Netherlands

2010 Invited Speaker, *Promenade Gruppen: Background and Hypothesis for the randomized trial*, Prostate Cancer at Solstice Meeting, University of Iceland, Reykjavik, Iceland

2010 Invited Speaker, *The Patho-Epidemiology of Prostate Cancer: An epidemiologist’s perspective*, Società Italiana di Urologia Oncologica (SIURO), Rome, Italy

2010 Symposium Panelist and Speaker, *Bologna Patho-epidemiology Prostate Cancer Retreat*, University of Bologna, Italy

2010 Invited Speaker, *Nutrigenetics: Antioxidants and SNPs in antioxidant genes in relation to prostate cancer*, Neon Annual Meeting, Nobel Forum, Karolinska Institutet, Stockholm, Sweden

2011 Invited Speaker, *Patho-epidemiology studies of molecular signatures in the SPCG-4 trial*, Scandinavian Prostate Cancer Group Annual Meeting, Stockholm, Sweden

2011 Invited Speaker, *Molecular Markers of Lethal Prostate Cancer*, 9th Annual World Congress of Urological Research, Innsbruck Austria

2011 Invited Speaker, *Shedding Light on the Heritability of Prostate Cancer: a study of 100,000 Nordic Twins*, Invited Lecture, Trinity College, Dublin Ireland

2011 Invited Speaker, *Tumor Drivers of the Link Between Obesity and Lethal Prostate Cancer*, Research Oncology Seminar, Kings College, London UK

2012 Invited Speaker, *Tumor markers of Lethal Prostate Cancer: Links with Obesity*, Faculty Meeting Seminar, Karolinska Institutet, Stockholm, Sweden

2012 Invited Speaker, *Unveiling the heritability in cancer: an updated analysis from the Nordic twin registry of cancer*, 14th Congress of the International Society Twin Studies, Florence, Italy

2012 Invited Speaker, *Integrating mRNA profiling in prostate cancer risk prediction*, Prostate Cancer UK Action Forum, Rotterdam, the Netherlands

2013 Invited Speaker, *Obesity and TMPRSS2:ERG fusion: an example of precision patho-epidemiology*, Australian – Canadian Prostate Cancer Research Alliance, Port Douglas, Queensland, Australia

2013 Invited Speaker, *Circadian disruption: a biomarker of aggressive prostate cancer?* Australian – Canadian Prostate Cancer Research Alliance, Port Douglas, Queensland, Australia

2014 Invited Speaker, *Tumor drivers of the link between obesity and lethal prostate cancer,* Oslo Prostate Cancer Symposium 2014, Oslo, Norway

2015 Invited Speaker, *Obesity, Metabolism and Prostate Cancer Survival*, Sixth International Congress of Uro-Oncology, Sao Paolo, Brazil

2015 Invited Speaker, *PCF 500: A novel registry of men with advanced prostate cancer*, Sixth International Congress of Uro-Oncology, Sao Paolo, Brazil

2015 Invited Speaker, *The role of the circadian rhythm in prostate cancer*, Sixth International Congress of Uro-Oncology, Sao Paolo, Brazil

2015 Invited Speaker, *A Female Researcher Exploring the Male Prostate*, Medical Oncology Departmental Seminar, Kings College, London

2016 Invited Speaker, *International Registry to Improve Outcomes in Men with Advanced Prostate Cancer*, Movember Executive Board, Melbourne, Australia

2017 Invited Speaker, *Epidemiology and Genetics of Prostate Cancer,* American Association for Cancer Research International Meeting, New Frontiers in Cancer Research, Cape Town, South Africa

2017 Invited Speaker, *IRONMAN: International Registry to Improve Outcomes in Men with Advanced Prostate Cancer*, St Gallen Advanced Prostate Cancer Consensus Meeting, St. Gallen, Switzerland

2017 Invited Speaker, *Obesity, altered metabolism, and advanced prostate cancer*, Forum of Public Health and Social Medicine Webinar, University of Athens, Greece

2017 Invited Speaker, *The Integrative Molecular Epidemiology of Prostate Cancer,* 2017 John Fitzpatrick Irish Genitourinary Cancer Meeting, Dublin, Ireland

2017 Invited Speaker, *Prostate Cancer Outcomes: IRONMAN Registry*, TrueNth International Meeting, Vancouver, BC

2018 Invited Speaker, *Biomarkers of Lethal Prostate Cancer: Example of baseline PSA level in midlife,* IX International Congress of Uro-Oncology, Sao Paolo Brazil

2018 Invited Speaker, *Diet, lifestyle and risk of lethal prostate cancer,* IX International Congress of Uro-Oncology, Sao Paolo Brazil

2018 Invited Speaker, *Familial risk and inherited genetics in prostate cancer,* IX International Congress of Uro-Oncology, Sao Paolo Brazil

2018 Invited Speaker, *IRONMAN: An International Registry for Men with Advanced Prostate Cancer,* IX International Congress of Uro-Oncology, Sao Paolo Brazil

2020 Invited Speaker and Panel, *IRONMAN Study: Improving Outcomes in Men with Advanced Prostate Cancer,* Biennial Science of Global Prostate Cancer Disparities in Black Men Conference (Virtual)

Podcasts

1. **Mucci LA**, Stampfer MJ. Risks of suicide and cardiovascular disease after a prostate cancer death. J National Cancer Institute 2010. <http://www.oxfordjournals.org/podcasts/jnci_102.05.interview.mp3>
2. **Mucci LA.** Prostate Cancer Podcast: Is prostate cancer inherited. Malecare 2016. <https://www.iheart.com/podcast/256-prostate-cancer-podcast-30943785/episode/prostate-cancer-and-family-history-40545979/>
3. **Mucci LA**. Is the evidence sufficient to recommend statins for all men with prostate cancer? UroToday 2017. <https://www.urotoday.com/video-lectures/prostate-cancer/video/833-embedded-media2017-09-19-22-59-30.html>
4. **Mucci LA**. IRONMAN: An international registry to improve outcomes in men with advanced prostate cancer. UroToday 2017. <https://www.urotoday.com/video-lectures/advanced-prostate-cancer/video/777-embedded-media2017-05-31-18-58-51.html>
5. **Mucci LA**, Kantoff P. Outcomes Research and the IRONMAN project. UroToday 2017 <https://www.urotoday.com/video-lectures/advanced-prostate-cancer-consensus-conference-apccc/video/712-embedded-media2017-03-14-02-51-21.html>
6. **Mucci LA.** The State of Evidence Behind Lifestyle and Diet for Prostate Cancer Patients 2020 <https://masspcc.org/page/podcast>
7. **Mucci LA**, Kantoff P. *TMPRSS2* and COVID-19: Serendipity or Opportunity for Intervention? UroToday 2020 <https://www.urotoday.com/video-lectures/covid-19-and-genitourinary-cancers/video/1755-tmprss2-and-covid-19-serendipity-or-opportunity-for-intervention-philip-kantoff-lorelei-mucci.html>
8. **Mucci LA.** Impact of Molecular and Genomic Factors on Prostate Cancer Disease Etiology and Health Disparities. UroToday, 2023 <https://www.urotoday.com/video-lectures/pcf-2022/video/2968-the-impact-of-molecular-and-genomic-factors-on-prostate-cancer-disease-etiology-and-health-disparities-and-the-state-of-science-on-diet-and-lifestyle-lorelei-mucci.html>
9. **Mucci LA, George D.** Insights into Global treatment patterns for Advanced prostate cancer patients: the IRONMAN registry. UroToday, 2023 <https://www.urotoday.com/video-lectures/asco-gu-2023/video/3249-insights-into-global-treatment-patterns-for-advanced-prostate-cancer-the-ironman-registry-lorelei-mucci-daniel-george.html>

**BIBLIOGRAPHY**

**Peer-reviewed Research Articles**

1. Kuper H, Tzonou A, Lagiou P, **Mucci LA**, Trichopoulos D, Stuver SO and Trichopoulou A. Diet and hepatocellular carcinoma: a case-control study in Greece. Nutr Cancer 2000;38(1):6-12.
2. Signorello LB, Kuper H, Lagiou P, Wuu J, **Mucci LA**, Trichopoulos D and Adami HO. Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 2000;9(3):173-8.
3. Hathaway JE, **Mucci LA**, Silverman JG, Brooks DR, Mathews R and Pavlos CA. Health status and health care use of Massachusetts women reporting partner abuse. Am J Prev Med 2000;19(4):302-7.
4. Kuper H, Hsieh C, Stuver SO, **Mucci LA**, Tzonou A, Zavitsanos X, Lagiou P and Trichopoulos D. Birth order, as a proxy for age at infection, in the etiology of hepatocellular carcinoma. Epidemiology 2000;11(6):680-3.
5. Petridou E, Giokas G, Kuper H, **Mucci LA** and Trichopoulos D. Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer 2000;83(9):1234-7. PMCID: PMC2363586.
6. Kuper H, Lagiou P, **Mucci LA**, Tamimi R, Benetou V and Trichopoulos D. Risk factors for cholangiocarcinoma in a low risk Caucasian population. Soz Praventivmed 2001;46(3):182-5.
7. Kuper H, Mantzoros C, Lagiou P, Tzonou A, Tamimi R, **Mucci L**, Benetou V, Spanos E, Stuver SO and Trichopoulos D. Estrogens, testosterone and sex hormone binding globulin in relation to liver cancer in men. Oncology 2001;60(4):355-60.
8. Lagiou A, Trichopoulos D, Tzonou A, Lagiou P and **Mucci L**. Are there age-dependent effects of diet on prostate cancer risk? Soz Praventivmed 2001;46(5):329-34.
9. Orner MB, Meehan T, Brooks DR, **Mucci LA** and McGuire JF. Support for condom availability and needle exchange programs among Massachusetts adults, 1997. AIDS Educ Prev 2001;13(4):365-76.
10. Silverman JG, Raj A, **Mucci LA** and Hathaway JE. Dating violence against adolescent girls and associated substance use, unhealthy weight control, sexual risk behavior, pregnancy, and suicidality. JAMA. 2001 Aug 1;286(5):572-9.
11. Brooks DR and **Mucci LA**. Support for smoke-free restaurants among Massachusetts adults, 1992-1999. Am J Public Health 2001;91(2):300-3. PMCID: PMC1446536.
12. Weiderpass E, Ye W, **Mucci LA**, Nyren O, Trichopoulos D, Vainio H and Adami HO. Alcoholism and risk for endometrial cancer. Int J Cancer 2001;93(2):299-301.
13. **Mucci LA** and Brooks DR. Lower use of dental services among long term cigarette smokers. J Epidemiol Community Health 2001;55(6):389-93. PMCID: PMC1731911.
14. **Mucci LA**, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E and Trichopoulos D. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87(9):814-20.
15. Tamimi R, **Mucci LA**, Spanos E, Lagiou A, Benetou V and Trichopoulos D. Testosterone and oestradiol in relation to tobacco smoking, body mass index, energy consumption and nutrient intake among adult men. Eur J Cancer Prev 2001;10(3):275-80.
16. **Mucci LA**, Kuper HE, Tamimi R, Lagiou P, Spanos E and Trichopoulos D. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 2001;108(3):291-4.
17. Demissie S, Green RC, **Mucci L**, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Sharrow N, Lautenschlager N, Friedland R, Cupples LA and Farrer LA. Reliability of information collected by proxy in family studies of Alzheimer's disease. Neuroepidemiology 2001;20(2):105-11.
18. Kuper H, Ye W, Broome U, Romelsjo A, **Mucci LA**, Ekbom A, Adami HO, Trichopoulos D and Nyren O. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001;34(4 Pt 1):714-8.
19. Boffetta P, Ye W, Adami HO, **Mucci LA** and Nyren O. Risk of cancers of the lung, head and neck in patients hospitalized for alcoholism in Sweden. Br J Cancer 2001;85(5):678-82. PMCID: PMC2364115.
20. Lagiou P, Tamimi R, Lagiou A, **Mucci L** and Trichopoulos D. Is epidemiology implicating extremely low frequency electric and magnetic fields in childhood leukemia? Environ Health Prev Med 2002;7(2):33-9. PMCID: PMC2723397.
21. Lagiou P, Hsieh CC, Trichopoulos D, Xu B, Wuu J, **Mucci L**, Tamimi R, Adami HO and Cnattingius S. Birthweight differences between USA and China and their relevance to breast cancer aetiology. Int J Epidemiol 2003;32(2):193-8.
22. Lagiou P, Tamimi R, **Mucci LA**, Trichopoulos D, Adami HO and Hsieh CC. Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. Obstet Gynecol 2003;101(4):639-44.
23. **Mucci LA**, Dickman PW, Steineck G, Adami HO and Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br J Cancer 2003;88(1):84-9. PMCID: PMC2376776.
24. Tamimi R, Lagiou P, Vatten LJ, **Mucci L**, Trichopoulos D, Hellerstein S, Ekbom A, Adami HO and Hsieh CC. Pregnancy hormones, pre-eclampsia, and implications for breast cancer risk in the offspring. Cancer Epidemiol Biomarkers Prev 2003;12(7):647-50.
25. Brawarsky P, Brooks DR and **Mucci LA**. Correlates of colorectal cancer testing in Massachusetts men and women. Prev Med 2003;36(6):659-68.
26. Tamimi RM, Lagiou P, **Mucci LA**, Hsieh CC, Adami HO and Trichopoulos D. Average energy intake among pregnant women carrying a boy compared with a girl. BMJ 2003;326(7401):1245-6. PMCID: PMC161555.
27. **Mucci LA**, Lagiou P, Tamimi RM, Hsieh CC, Adami HO and Trichopoulos D. Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Causes Control 2003;14(4):311-8.
28. Brawarsky P, Brooks DR, **Mucci LA** and Wood PA. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev 2004;28(4):260-8.
29. Brooks DR, **Mucci LA**, Hatch EE and Cnattingius S. Maternal smoking during pregnancy and risk of brain tumors in the offspring. A prospective study of 1.4 million Swedish births. Cancer Causes Control 2004;15(10):997-1005.
30. Lagiou P, Tamimi RM, **Mucci LA**, Adami HO, Hsieh CC and Trichopoulos D. Diet during pregnancy in relation to maternal weight gain and birth size. Eur J Clin Nutr 2004;58(2):231-7.
31. **Mucci LA**, Hsieh CC, Williams PL, Dickman PW, Bjorkman L and Pedersen NL. Birth order, sibship size, and housing density in relation to tooth loss and periodontal disease: a cohort study among Swedish twins. Am J Epidemiol 2004;159(5):499-506.
32. **Mucci LA**, Lindblad P, Steineck G and Adami HO. Dietary acrylamide and risk of renal cell cancer. Int J Cancer 2004;109(5):774-6.
33. **Mucci LA**, Granath F and Cnattingius S. Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 Swedish children. Cancer Epidemiol Biomarkers Prev 2004;13(9):1528-33.
34. **Mucci LA**, Lagiou P, Hsieh CC, Tamimi R, Hellerstein S, Vatten L, Adami HO, Cnattingius S and Trichopoulos D. A prospective study of pregravid oral contraceptive use in relation to fetal growth. BJOG 2004;111(9):989-95.
35. Badovinac RL, Morgan KE, Lefevre J, Wadhawan S, **Mucci L**, Schoeff L and Douglass CW. Risk assessment criteria applied to a screening exam: implications for improving the efficiency of a sealant program. J Public Health Dent 2005;65(4):203-8.
36. Lagiou P, **Mucci L**, Tamimi R, Kuper H, Lagiou A, Hsieh CC and Trichopoulos D. Micronutrient intake during pregnancy in relation to birth size. Eur J Nutr 2005;44(1):52-9.
37. Margolis KL, **Mucci L**, Braaten T, Kumle M, Trolle Lagerros Y, Adami HO, Lund E and Weiderpass E. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev 2005;14(1):27-32.
38. Bradbury BD, Brooks DR, Brawarsky P and **Mucci LA**. Test-retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS). Prev Med 2005;41(1):303-11.
39. Rubin MA, Bismar TA, Andren O, **Mucci L**, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW and Johansson JE. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14(6):1424-32.
40. **Mucci LA**, Sandin S, Balter K, Adami HO, Magnusson C and Weiderpass E. Acrylamide intake and breast cancer risk in Swedish women. JAMA 2005;293(11):1326-7.
41. Trolle-Lagerros Y, **Mucci LA**, Kumle M, Braaten T, Weiderpass E, Hsieh CC, Sandin S, Lagiu P, Trichopoulos D, Lund E and Adami HO. Physical activity as a determinant of mortality in women. Epidemiology 2005;16(6):780-5.
42. **Mucci LA**, Bjorkman L, Douglass CW and Pedersen NL. Environmental and heritable factors in the etiology of oral diseases--a population-based study of Swedish twins. J Dent Res 2005;84(9):800-5.
43. Lagerros YT, **Mucci LA**, Bellocco R, Nyren O, Balter O and Balter KA. Validity and reliability of self-reported total energy expenditure using a novel instrument. Eur J Epidemiol 2006;21(3):227-36.
44. Lagiou P, Trichopoulos D, Sandin S, Lagiou A, **Mucci L**, Wolk A, Weiderpass E and Adami HO. Mediterranean dietary pattern and mortality among young women: a cohort study in Sweden. Br J Nutr 2006;96(2):384-92.
45. **Mucci LA**, Adami HO and Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int J Cancer 2006;118(1):169-73.
46. Clements KM, Cohen BB, Brawarsky P, Brooks DR, **Mucci LA** and Wood PA. Identifying Health Maintenance Organization membership through self-report of health plan name: ascertainment and reliability. J Public Health Manag Pract 2006;12(3):278-87.
47. **Mucci LA**, Wood PA, Cohen B, Clements KM, Brawarsky P and Brooks DR. Validity of self-reported health plan information in a population-based health survey. J Public Health Manag Pract 2006;12(6):570-7.
48. Hunt H, Valdimarsdottir U, **Mucci L**, Kreicbergs U and Steineck G. When death appears best for the child with severe malignancy: a nationwide parental follow-up. Palliat Med 2006;20(6):567-77.
49. Lagiou P, Sandin S, Weiderpass E, Lagiou A, **Mucci L**, Trichopoulos D and Adami HO. Low carbohydrate-high protein diet and mortality in a cohort of Swedish women. J Intern Med 2007;261(4):366-74.
50. Bakaysa SL, **Mucci LA**, Slagboom PE, Boomsma DI, McClearn GE, Johansson B and Pedersen NL. Telomere length predicts survival independent of genetic influences. Aging Cell 2007;6(6):769-74.
51. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, **Mucci LA**, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE and Rubin MA. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26(31):4596-9.
52. Li H, Stampfer MJ, Hollis JB, **Mucci LA**, Gaziano JM, Hunter D, Giovannucci EL and Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4(3):e103. PMCID: PMC1831738.
53. Baik I, Lambe M, Liu Q, Cnattingius S, **Mucci LA**, Riman T, Ekbom A, Adami HO and Hsieh CC. Gender of offspring and maternal risk of invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16(11):2314-20.
54. McIntyre MH, Kantoff PW, Stampfer MJ, **Mucci LA**, Parslow D, Li H, Gaziano JM, Abe M and Ma J. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 2007;16(11):2233-6.
55. **Mucci LA**, Dickman PW, Lambe M, Adami HO, Trichopoulos D, Riman T, Hsieh CC and Cnattingius S. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiol Biomarkers Prev 2007;16(9):1828-32. PMCID: PMC2646123.
56. Andren O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE and **Mucci LA**. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97(6):730-4. PMCID: PMC2360377.
57. **Mucci LA** and Wilson KM. Acrylamide intake through diet and human cancer risk. J Agric Food Chem 2008;56(15):6013-9.
58. Baik I, Lambe M, Liu Q, Chie L, Cnattingius S, **Mucci LA**, Riman T, Ekbom A, Adami HO and Hsieh CC. Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort. Cancer Causes Control 2008;19(10):1131-7. PMCID: PMC3221393.
59. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, **Mucci L**, Giovannucci E, Finn S and Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 2008;88(12):1340-8. PMCID: PMC3223737.
60. Sarzani R, Marcucci P, Salvi F, Bordicchia M, Espinosa E, **Mucci L**, Lorenzetti B, Minardi D, Muzzonigro G, Dessi-Fulgheri P and Rappelli A. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond) 2008;32(2):259-67.
61. **Mucci LA**, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE and Rubin MA. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev 2008;17(1):249-51.
62. **Mucci LA**, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE and Rubin MA. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008;17(7):1682-8. PMCID: PMC2536630.
63. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, **Mucci LA**, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR and Rubin MA. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100(11):815-25. PMCID: PMC3073404.
64. Ma J, Li H, Giovannucci E, **Mucci L**, Qiu W, Nguyen PL, Gaziano JM, Pollak M and Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9(11):1039-47. PMCID: PMC2651222.
65. Jesser C, **Mucci L**, Farmer D, Moon C, Li H, Gaziano JM, Stampfer M, Ma J and Kantoff P. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer 2008;99(10):1743-7. PMCID: PMC2584945.
66. Cnattingius S, Eloranta S, Adami HO, Axelsson O, Dickman PW, Hsieh CC, **Mucci LA**, Trichopoulos D, Lambe M and Johansson AL. Placental weight and risk of invasive epithelial ovarian cancer with an early age of onset. Cancer Epidemiol Biomarkers Prev 2008;17(9):2344-9. PMCID: PMC2643070.
67. Fall K, Stark JR, **Mucci LA**, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P and Ma J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate 2008;68(13):1416-20. PMCID: PMC2958090.
68. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, **Mucci L**, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S and Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101(7):519-32. PMCID: PMC2664091.
69. Wilson KM, **Mucci LA**, Cho E, Hunter DJ, Chen WY and Willett WC. Dietary acrylamide intake and risk of premenopausal breast cancer. Am J Epidemiol 2009;169(8):954-61. PMCID: PMC2727226.
70. Fall K, Fang F, **Mucci LA**, Ye W, Andren O, Johansson JE, Andersson SO, Sparen P, Klein G, Stampfer M, Adami HO and Valdimarsdottir U. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med 2009;6(12):e1000197. PMCID: PMC2784954.
71. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA and **Mucci LA**. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18(2):595-600. PMCID: PMC2692093.
72. Andren O, Garmo H, **Mucci L**, Andersson SO, Johansson JE and Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009;100(1):170-3. PMCID: PMC2634678.
73. Holmberg L, Adolfsson J, **Mucci L**, Garmo H, Adami HO, Moller H, Johansson JE and Stampfer M. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 2009;20(5):663-70. *No Federal Funding.*
74. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, **Mucci L**, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S and Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009;69(13):5568-74. PMCID: PMC2884104.
75. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA and **Mucci LA**. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009;27(21):3459-64. PMCID: PMC2717753.
76. Stark JR, Wiklund F, Gronberg H, Schumacher F, Sinnott JA, Stampfer MJ, **Mucci LA** and Kraft P. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18(6):1859-63. PMCID: PMC2833418.
77. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J and **Mucci LA**. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124(11):2683-9. PMCID: PMC2667697.
78. Liu C, Wang XD, **Mucci L**, Gaziano JM and Zhang SM. Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study. Cancer 2009;115(5):1049-58. PMCID: PMC2649969.
79. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, **Mucci L**, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ and Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009;15(9):3223-30. PMCID: PMC2878092.
80. Wilson KM, Balter K, Adami HO, Gronberg H, Vikstrom AC, Paulsson B, Tornqvist M and **Mucci LA**. Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study. Int J Cancer 2009;124(10):2384-90. PMCID: PMC2905318.
81. **Mucci LA**, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ and Clinton SK. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009;27(33):5627-33. PMCID: PMC2792955.
82. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ and **Mucci LA**. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst 2009;101(20):1406-11. PMCID: PMC2765259.
83. Kasperzyk JL, Fall K, **Mucci LA**, Hakansson N, Wolk A, Johansson JE, Andersson SO and Andren O. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr 2009;90(3):561-9. PMCID: PMC2728642.
84. **Mucci LA**, Hsieh CC, Williams PL, Arora M, Adami HO, de Faire U, Douglass CW and Pedersen NL. Do genetic factors explain the association between poor oral health and cardiovascular disease? A prospective study among Swedish twins. Am J Epidemiol 2009;170(5):615-21. PMCID: PMC2732988.
85. **Mucci LA**, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J and Kantoff PW. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer 2009;125(5):1143-6. PMCID: PMC2838373.
86. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, **Mucci LA**, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA and Andren O. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8. PMCID: PMC2855514.
87. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M and **Mucci L**. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010;70(8):3136-9. PMCID: PMC3049266.
88. Schumacher FR, Cheng I, Freedman ML, **Mucci L**, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ and Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010;19(15):3089-101. PMCID: PMC2901143.
89. **Mucci LA**, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ and Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2010;19(2):484-91. PMCID: PMC2820127.
90. Li H, Stampfer MJ, **Mucci L**, Rifai N, Qiu W, Kurth T and Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56(1):34-43. PMCID: PMC2858593.
91. Arora M, Weuve J, Fall K, Pedersen NL and **Mucci LA**. An exploration of shared genetic risk factors between periodontal disease and cancers: a prospective co-twin study. Am J Epidemiol 2010 Jan 15;171(2):253-9. PMCID: PMC2878098.
92. Vikstrom AC, Wilson KM, Paulsson B, Athanassiadis I, Gronberg H, Adami HO, Adolfsson J, **Mucci LA**, Balter K and Tornqvist M. Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data. Food Chem Toxicol 2010;48(3):820-4. *No Federal Funding.*
93. Fang F, Keating NL, **Mucci LA**, Adami HO, Stampfer MJ, Valdimarsdottir U and Fall K. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010;102(5):307-14. *No Federal Funding.*PMC Journal – In Process.
94. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, **Mucci LA**, Hunter DJ, Kantoff PW, Stampfer MJ and Ma J. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 2010;3(5):604-10. PMCID: PMC2865569.
95. Penney KL, Pyne S, Schumacher FR, Sinnott JA, **Mucci LA**, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ and Freedman ML. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010;19(11):2869-76. PMCID: PMC3197738.
96. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, **Mucci LA**, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC and Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010;6(11):e1001204. PMCID: PMC2978684.
97. Fang F, Valdimarsdottir U, **Mucci L**, Sparen P, Ye W and Fall K. Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. Cancer Epidemiol 2010;34(5):644-7. *No Federal Funding.*
98. Wilson KM, **Mucci LA**, Rosner BA and Willett WC. A prospective study on dietary acrylamide intake and the risk for breast, endometrial, and ovarian cancers. Cancer Epidemiol Biomarkers Prev 2010;19(10):2503-15. PMCID: PMC2952046.
99. Meyer MS, **Mucci LA**, Andersson SO, Andren O, Johansson JE, Tretli S and Adami HO. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol 2010;58(3):427-32. PMCID: PMC2936655.
100. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J and **Mucci LA**. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010;31(9):1597-603. PMCID: PMC2930803.
101. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, **Mucci LA**, Stampfer MJ, Giovannucci E and Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol 2010;28(25):3958-64. PMCID: PMC2940394.
102. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, **Mucci LA** and Giovannucci E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One 2011;6(4):e18625. PMCID: PMC3071841.
103. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, **Mucci LA**, Giovannucci E, Stampfer MJ and Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2618-27. PMCID: PMC3700351.
104. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, **Mucci L**, Chin L and DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470(7333):269-73. PMCID: PMC3753179.
105. Penney KL, Schumacher FR, Kraft P, **Mucci LA**, Sesso HD, Ma J, Niu Y, Cheong JK, Hunter DJ, Stampfer MJ and Hsu SI. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis 2011;32(6):853-9. PMCID: PMC3106437.
106. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E and **Mucci LA**. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 2011;103(11):876-84. PMCID: PMC3110172.
107. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, **Mucci LA** and Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 2011;29(17):2378-85. PMCID: PMC3107752.
108. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andren O, Stampfer MJ and **Mucci LA**. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011;29(17):2391-6. PMCID: PMC3107753.
109. Epstein MM, Kasperzyk JL, Andren O, Giovannucci EL, Wolk A, Hakansson N, Andersson SO, Johansson JE, Fall K and **Mucci LA**. Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr 2011;93(3):586-93. PMCID: PMC3041600.
110. Kasperzyk JL, Shappley WV, 3rd, Kenfield SA, **Mucci LA**, Kurth T, Ma J, Stampfer MJ and Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol 2011;186(5):1862-7. PMCID: PMC3491639.
111. Davidsson S, Fiorentino M, Andren O, Fang F, **Mucci LA**, Varenhorst E, Fall K and Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(10):2280-7. PMCID: PMC3671592.
112. Epstein MM, Andren O, Kasperzyk JL, Shui IM, Penney KL, Fall K, Rider JR, Stampfer MJ, Andersson SO, Giovannucci E and **Mucci LA**. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control 2012;23(8):1359-66. PMCID: PMC3589913.
113. Epstein MM, Kasperzyk JL, **Mucci LA**, Giovannucci E, Price A, Wolk A, Hakansson N, Fall K, Andersson SO and Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol 2012;176(3):240-52. PMCID: PMC3491963.
114. Etzioni R, **Mucci L**, Chen S, Johansson JE, Fall K and Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012;18(24):6742-7. PMCID: PMC3711175.
115. Barry M, Dhillon PK, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, **Mucci LA** and Rubin MA. alpha-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate 2012;72(3):301-6. PMCID: PMC3267640.
116. Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, **Mucci LA**, Sinnott JA, Loda MF, Sui G, Berquin IM and Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 2012;33(2):404-12. PMCID: PMC3271270.
117. Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E and **Mucci LA**. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate 2012;72(2):209-16. PMCID: PMC3175021.
118. Torfadottir JE, Steingrimsdottir L, **Mucci L**, Aspelund T, Kasperzyk JL, Olafsson O, Fall K, Tryggvadottir L, Harris TB, Launer L, Jonsson E, Tulinius H, Stampfer M, Adami HO, Gudnason V and Valdimarsdottir UA. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol 2012;175(2):144-53. PMCID: PMC3249408.
119. Wilson KM, Giovannucci E, Stampfer MJ and **Mucci LA**. Dietary acrylamide and risk of prostate cancer. Int J Cancer 2012;131(2):479-87. PMCID: PMC3320687.
120. Torfadottir JE, Valdimarsdottir UA, **Mucci L**, Stampfer M, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Adami HO, Gudnason V and Steingrimsdottir L. Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes Control 2012;23(6):941-50. PMCID: PMC3568695.
121. Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, Willett WC, Stampfer MJ, **Mucci LA** and Giovannucci EL. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev 2012;21(3):428-36. PMCID: PMC3297731.
122. Margalit DN, Kasperzyk JL, Martin NE, Sesso HD, Gaziano JM, Ma J, Stampfer MJ and **Mucci LA**. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study. Int J Radiat Oncol Biol Phys 2012;83(1):28-32. PMCID: PMC3386602.
123. Shui IM, **Mucci LA**, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ and Giovannucci E. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012;104(9):690-9. PMCID: PMC3341310.
124. Moller E, Galeone C, Adami HO, Adolfsson J, Andersson TM, Bellocco R, Gronberg H, **Mucci LA** and Balter K. The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study. Public Health Nutr 2012;15(10):1897-908. *No Federal Funding.*
125. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M and **Mucci LA**. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21(9):1497-509. PMCID: PMC3671609.
126. Epstein MM, Edgren G, Rider JR, **Mucci LA** and Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104(17):1335-42. PMCID: PMC3529593.
127. Song Y, Chavarro JE, Cao Y, Qiu W, **Mucci L**, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S and Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 2013;143(2):189-96. PMCID: PMC3542910.
128. Shui IM, **Mucci LA**, Wilson KM, Kraft P, Penney KL, Stampfer MJ and Giovannucci E. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22(1):118-26. PMCID: PMC3538912.
129. Moller E, Galeone C, Andersson TM, Bellocco R, Adami HO, Anden O, Gronberg H, La Vecchia C, **Mucci LA** and Balter K. Mediterranean Diet Score and prostate cancer risk in a Swedish population-based case-control study. Journal of Nutritional Science 2013;2:e15. PMCID: PMC4153088.
130. Preston MA, Harisinghani MG, **Mucci L**, Witiuk K and Breau RH. Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer. BJU Int 2013;111(3):514-7. *No Federal Funding*.
131. Cai C, Wang H, He HH, Chen S, He L, Ma F, **Mucci L**, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP and Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013;123(3):1109-22. PMCID: PMC3582143.
132. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, **Mucci LA**, Loda M, Yuan GC, Orkin SH and Li Z. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013;27(6):683-98. PMCID: PMC3613614.
133. Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ and **Mucci LA**. A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clin Cancer Res 2013;19(6):1612-9. PMCID: PMC3602407.
134. Sigurdardottir LG, Valdimarsdottir UA, **Mucci LA**, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW. Sleep disruption among older men and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22(5):872-9. PMCID: PMC3652595.
135. Torfadottir JE, Valdimarsdottir UA, **Mucci LA**, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Gudnason V, Adami HO, Stampfer M, Steingrimsdottir L. Consumption of Fish Products across the Lifespan and Prostate Cancer Risk. PLoS One. 2013 Apr 17;8(4):e59799. PMCID: PMC3629172.
136. Penney KL, Li H, **Mucci LA**, Loda M, Sesso HD, Stampfer MJ and Ma J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate 2013 May;73(7):700-5. PMCID: PMC3640488.
137. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R and **Mucci LA**. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 2013 Jun;24(6):1427-34. PMCID: PMC3660083.
138. Robinson D, Garmo H, Bill-Axelson A, **Mucci L**, Holmberg L, Stattin P. Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. Nation-wide, population-based case-control study. British Medical Journal 2013; BMJ. 2013 Jun 18;346:f3406.  PMCID: PMC3685512.
139. Wilson KM, Bälter K, Möller E, Adami HO, Andrén O, Andersson SO, Grönberg H, **Mucci LA**. Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study. Cancer Causes Control. 2013 Aug;24(8):1575-81. *No Federal Funding.*
140. Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, **Mucci LA**, Fiorentino M. Gleason Grade Progression Is Uncommon. Cancer Res. 2013 Aug 15;73(16):5163-5168. PMCID: PMC3775342.
141. Flynn-Evans EE, **Mucci L**, Stevens RG, Lockley SW. Shiftwork and Prostate-Specific Antigen in the National Health and Nutrition Examination Survey. J Natl Cancer Inst. 2013 Sep 4;105(17):1292-7. PMCID: PMC3859215
142. Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, **Mucci LA**, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. Cancer Discov. 2013 Oct;3(10):1130-41. PMCID: PMC3797255.
143. Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, **Mucci L**, Kantoff PW, Sweeney CJ. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2013 Oct 16. *No Federal Funding.*
144. Hogervorst JG, Fortner RT, **Mucci LA**, Tworoger SS, Eliassen AH, Hankinson SE, Wilson KM. Associations between dietary acrylamide intake and plasma sex hormone levels. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2024-36. PMCID: PMC3827947.
145. Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn SP, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, **Mucci LA\*\***, Giovannucci EL\*\*. Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. \*\* Shared last authorship. PMCID: PMC3818474.
146. Kasperzyk JL, Finn SP, Flavin RJ, Fiorentino M, Lis RT, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, **Mucci LA**. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63. PMCID: PMC3893763.
147. Möller E, Adami HO, **Mucci** **LA**, Lundholm C, Bellocco R, Johansson JE, Grönberg H, Bälter K. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control. 2013 Dec;24(12):2143-55. *No Federal Funding.*
148. Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, **Mucci LA**. Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90. PMCID: PMC3866157.
149. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, **Mucci** **L**, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G; The Breast and Prostate Cancer Cohort Consortium (BPC3); The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; The COGS (Collaborative Oncological Gene-environment Study) Consortium; The GAME-ON/ELLIPSE Consortium, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics. 2014;46(10):1103-9. PMC ID: PMC4383163.
150. Zu K, **Mucci L**, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Institute 2014; 2014 Feb 1;106(2). PMCID: PMC3952200.
151. Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu S, Dolph M, **Mucci LA**, Alhajj R. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. BJU Int. 2014 Feb;113(2):309-19. No Federal Funding.
152. Russnes KM, Wilson KM, Epstein MM, Kasperzyk JL, Stampfer MJ, Kenfield SA, Smeland S, Blomhoff R, Giovannucci EL, Willett WC, **Mucci LA**. Total antioxidant intake in relation to prostate cancer incidence in the health professionals follow up study. Int J Cancer. 2014 Mar 1;134(5):1156-65. PMCID: PMC4274735.
153. Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, Dupre N, Giovannucci E and **Mucci LA**. Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. Eur Urol 2014 Apr;65(4):683-9. PMCID: PMC3664134.
154. Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, **Mucci L**, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014 Jun;74(8):820-8. PMID: 24668612. *No Federal Funding.*
155. Shui IM, Lindstrom S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Marchand LL, Ma J, Navarro C, Overvad K, Schumacher F, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, **Mucci LA**, Yeager , Giovannucci E, Kraft P. Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 2014 Jun;65(6):1069-75. PMCID: PMC4006298.
156. Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, **Mucci** **LA**. Genetic variation across C-reactive protein and risk of prostate cancer. Prostate. 2014 Jul;74(10):1034-42. PMCID: PMC4063346.
157. Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, **Mucci LA**, Olumi AF. 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA Intern Med. 2014 Aug;174(8):1301-7. PMCID: PMC4122627.
158. Flavin RJ, Pettersson A, Hendrickson WK, Fiorentino M, Finn SP, Kunz L, Judson G, Lis RT, Bailey D, Fiore C, Nuttall EJ, Martin NE, Stack EC, Penney KL, Rider JR, Sinnott JA, Sweeney CS, Sesso HD, Fall K, Giovannucci EL, Kantoff PW, Stampfer MJ, Loda M, **Mucci LA**. SPINK1 Protein Expression and Prostate Cancer Progression. Clin Cancer Res. 2014 Sep 15;20(18):4904-11. PMCID: PMC4167171.
159. Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, **Mucci LA**. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncology 2014 Sep 20;32(27):3033-8. PMCID: PMC4162499. \*\* ***This article was listed as the #1 paper in the Best of Journal of Clinical Oncology 2015.***
160. Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, **Mucci LA**. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2027-31. PMCID: PMC4184923.
161. Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E, Christensen K, Adami HO, Holm NV, Nuttall E, Hansen S, Hartman M, Czene K, Harris JR, Kaprio J, **Mucci LA**. The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2303-10. PMCID: PMC4221420.
162. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, **Mucci** LA, Adami HO, Sørensen HT. Metformin Use and Prostate Cancer Risk. Eur Urol. 2014 Dec;66(6):1012-20. *No Federal Funding.*
163. Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, Harris T, Smith AV, Gudnason V, Lindstrom S, Kraft P, **Mucci LA**. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015; 26(1):25-33. PMCID: PMC4282953.
164. Hoffmann TJ, Van Den Eeden SK, Sakoda LC, Jorgenson E, Habel LA, Graff RE, Passarelli MN, Cario CL, Emami NC, Chao CR, Ghai NR, Shan J, Ranatunga DK, Quesenberry CP, Aaronson D, Presti J, Zhaoming W, Berndt SI, Chanock SJ, McDonnell SK, French AJ, Schaid DJ, Thibodeau SN, Li Q, Freedman ML, Penney KL, **Mucci LA**, Haiman CA, Henderson BE, Seminara D, Kvale MN, Kwok PY, Schaefer C, Risch N, Witte JS. [A large multi-ethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences.](http://www.ncbi.nlm.nih.gov/pubmed/26034056) Cancer Discov. 2015;5(8):878-91. PMCID: PMC4527942.
165. Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, **Mucci LA**, Stampfer MJ. Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-60. PMCID: PMC4294966.
166. Wilson KM, Shui IM, **Mucci LA**, Giovannucci E. Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. Am J Clin Nutr. 2015 Jan;101(1):173-83. PMCID: PMC4266887.
167. Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, **Mucci** **LA**. Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. Eur Urol. 2015 Feb;67(2):191-4. PMCID: PMC4318783.
168. Alemozaffar M, Sanda M, Yecies D, **Mucci LA**, Stampfer MJ, Kenfield SA. Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study. Eur Urol. 2015 Mar;67(3):432-8. PMCID: PMC4128909.
169. Gerdtsson A, Poon JB, Thorek DL, **Mucci LA**, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. [Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.](http://www.ncbi.nlm.nih.gov/pubmed/25794458) Eur Urol. 2015 Mar 17. pii: S0302-2838(15)00226-2. PMCID: PMC4573834.
170. Shui IM, Mondul AM, Lindström S, Tsilidis KK, Travis RC, Gerke T, Albanes D, **Mucci LA**, Giovannucci E, Kraft P; for the Breast and Prostate Cancer Cohort Consortium Group. [Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.](http://www.ncbi.nlm.nih.gov/pubmed/25731953) Cancer. 2015 June 15;121(12):1949-56. PMCID: PMC4457645.
171. Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, **Mucci LA**; on behalf of the Transdisciplinary Prostate Cancer Partnership ToPCaP. [The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/25728532) Prostate. 2015 June 15;75(9):897-906. PMCID: PMC4424159.
172. Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, **Mucci LA**, Pawitan Y, Andersson SO, Andrén O. [Molecular Differences in Transition Zone and Peripheral Zone Prostate Tumors.](http://www.ncbi.nlm.nih.gov/pubmed/25870172) Carcinogenesis. 2015 Jun;36(6):632-8. PMCID: PMC4572920.
173. Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci E, Loda M, **Mucci LA**, Finn S. [Tumor expression of Adiponectin Receptor 2 and lethal prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/25863129) Carcinogenesis. 2015 Jun;36(6):639-47. PMCID: PMC4481603.
174. Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, **Mucci LA**\*\*, Birrer M\*\*. [Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.](http://www.ncbi.nlm.nih.gov/pubmed/25937617) J Mol Diagn. 2015 Jul;17(4):374-81. \*\* Shared senior authorship. PMCID: PMC4483460.
175. Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, **Mucci LA**, Pomerantz M, Lee GS, Kantoff PW. [Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26181260) JAMA Oncol. 2015 Jul;1(4):495-504. PMCID: [PMC5554437](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5554437/).
176. Margalit DN, Jordahl KM, Werner L, Wang X, Gwo-Shu Lee M, Penney KL, Batista JL, Martin NE, Chan JM, Kantoff PW, Stampfer MJ, Nguyen PL, **Mucci LA**. Germline variation in superoxide dismutase-2 (SOD2) and survival outcomes after radiation therapy: results of a test and validation set. Clin Genitourin Cancer 2015 Aug;13(4):370-377.e1. PMCID: PMC5038132.
177. Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, **Mucci LA**, Giovannucci EL, Stampfer MJ, Yun G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. [Pre-diagnostic obesity and physical inactivity are associated with shorter telomere length in prostate stromal cells.](http://www.ncbi.nlm.nih.gov/pubmed/25990087) Cancer Prev Res (Phila). 2015 Aug;8(8):737-42. PMCID: PMC4526348.
178. Platz EA, Drake CG, Wilson KM, Sutcliffe S, Kenfield SA, **Mucci LA**, Stampfer MJ, Willett WC, Camargo CA, Giovannucci E. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-up Study. Int J Cancer. 2015 Aug 15;137(4):949-58. PMCID: PMC4478199.
179. Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, **Mucci LA**, Signorello LB. [Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study.](http://www.ncbi.nlm.nih.gov/pubmed/26012482) Prostate. 2015 Sep;75(13):1384-93. PMCID: PMC4536142.
180. Hrafnkelsdottir SM, Torfadottir JE, Aspelund T, Magnusson K, Tryggvadottir L Clinical Professor, Gudnason V, **Mucci LA**, Stampfer M, Valdimarsdottir UA. [Physical activity from early adulthood and risk of prostate cancer: a 24 year follow-up study among Icelandic men.](http://www.ncbi.nlm.nih.gov/pubmed/26152935) Cancer Prev Res (Phila). 2015 Oct;8(10):905-11. PMID: 26152935.
181. Martin NE, Gerke T, Sinnott JA, Stack EC, Andren O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, **Mucci LA**, Loda M. [Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26124442) Mol Cancer Res. 2015 Oct;13(10):1431-40. PMCID: PMC4618038.
182. Liu H, Shui IM, Platz EA, **Mucci LA**, Giovannucci EL. [No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study.](http://www.ncbi.nlm.nih.gov/pubmed/26189769) Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1632-4. PMCID: PMC4743244.
183. Sutcliffe S, Alderete JF, Neace C, Joyce PA, Gaydos CA, Huth JI, **Mucci LA**, Signorello LB. Persistence of Trichomonas vaginalis serostatus in men over time. Cancer Causes Control. 2015 Oct;26(10):1461-6. PMCID: PMC4567958.
184. Ahrenfeldt LJ, Skytthe A, Möller S, Czene K, Adami HO, **Mucci LA**, Kaprio J, Petersen I, Christensen K, Lindahl-Jacobsen R. [Risk of sex-specific cancers in opposite-sex and same-sex twins in Denmark and Sweden.](http://www.ncbi.nlm.nih.gov/pubmed/26282631) Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1622-8. PMCID: PMC4782008.
185. Van Blarigan EL, Gerstenberger JP, Kenfield SA, Giovannucci EL, Stampfer MJ, Jones LW, Clinton SK, Chan JM, **Mucci LA**. [Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study.](http://www.ncbi.nlm.nih.gov/pubmed/26276753) Cancer Prev Res (Phila). 2015 Oct;8(10):962-7. PMCID: PMC4596787.
186. Markt SC, Shui IM, Unger RH, Urun Y, Berg CD, Black A, Brennan P, Bueno-de-Mesquita HB, Gapstur SM, Giovannucci E, Haiman C, Henderson B, Hoover RN, Hunter DJ, Key TJ, Khaw KT, Canzian F, Larranga N, Le Marchand L, Ma J, Naccarati A, Siddiq A, Stampfer MJ, Stattin P, Stevens VL, Stram DO, Tjønneland A, Travis RC, Trichopoulos D, Ziegler RG, Lindstrom S, Kraft P, **Mucci LA**, Choueiri TK, Wilson KM. [ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).](http://www.ncbi.nlm.nih.gov/pubmed/26268879) Prostate. 2015 Nov;75(15):1677-81. PMCID: PMC4578997.
187. Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, **Mucci LA\*\*,** Lotan TL\*\*. [A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.](http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/26615022) J Natl Cancer Inst. 2015 Nov 27;108(2). PMCID: PMC4862436. \*\*Shared last authorship
188. Binder M, Shui IM, Wilson KM, Penney KL; PRACTICAL/ELLIPSE Consortium, **Mucci LA**, Kibel AS. [Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26407952) Cancer Causes Control. 2015 Dec;26(12):1751-9. PMCID: PMC4633306.
189. Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, **Mucci LA**. [Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.](http://www.ncbi.nlm.nih.gov/pubmed/26469352) Prostate. 2015 Dec; 75(16):1926-33. PMCID: PMC4831584.
190. Wilson KM, **Mucci LA**, Drake BF, Preston MA, Stampfer MJ, Giovannucci EL, Kibel AS. [Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression.](https://www.ncbi.nlm.nih.gov/pubmed/27651069) Cancer Prev Res (Phila). 2016; 9(12):933-941. PMID: 27651069.
191. Gerke T, Tyekucheva S, Mucci L, Parmigiani G. Logistic push: a regression framework for partial AUC optimization. 2016 arXiv: 1606.06562. <https://arxiv.org/pdf/1606.06562v1.pdf>
192. Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, **Mucci LA**. [Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/27298404) J Clin Oncol. 2016; 34: 2705-11. PMCID: PMC5019757.
193. Sigurdardottir LG, Markt SC, Sigurdsson S, Aspelund T, Fall K, Schernhammer E, Rider JR, Launer L, Harris T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, **Mucci LA**. [Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men.](http://www.ncbi.nlm.nih.gov/pubmed/27449477) J Biol Rhythms. 2016;31(5):461-9. PMCID: [PMC5393913](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5393913/).
194. Russnes KM, Möller E, Wilson KM, Carlsen M, Blomhoff R, Smeland S, Adami HO, Grönberg H, **Mucci LA**, Bälter K. [Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study.](http://www.ncbi.nlm.nih.gov/pubmed/27400803) BMC Cancer. 2016; 16:438. PMCID: [PMC4939657](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4939657/).
195. Yang M, Zu K, **Mucci LA**, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. [Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.](http://www.ncbi.nlm.nih.gov/pubmed/27379990) Cancer Causes Control. 2016; 27:1043-7. PMCID: PMC4958547.
196. Dickerman BA, Markt SC, Koskenvuo M, Pukkala E, **Mucci LA**, Kaprio J. [Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins.](http://www.ncbi.nlm.nih.gov/pubmed/27351919) Cancer Causes Control. 2016; 27:1049-58. PMCID: PMC5278639.
197. Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, Adami HO, Stattin P, Nyrén O, **Mucci LA**. [Snus use, smoking and survival among prostate cancer patients.](https://www.ncbi.nlm.nih.gov/pubmed/27582277) Int J Cancer 2016; 139: 2735-2739. PMCID: PMC5061636.
198. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, **Mucci LA**, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. [Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26446945) Clin Cancer Res. 2016 Jan 15;22(2):448-58. PMCID: PMC4715968.
199. Möller S, **Mucci LA**, Harris JR, Scheike T, Holst K, Halekoh U, Adami HO, Czene K, Christensen K, Holm NV, Pukkala E, Skytthe A, Kaprio J, Hjelmborg JB. [The Heritability of Breast Cancer among women in the Nordic Twin Study of Cancer.](http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/26554920) Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):145-50. PMID: 26554920.
200. **Mucci LA**, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkilä K, Pukkala E, Skytthe A, Adami HO, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) Collaboration. [Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.](http://www.ncbi.nlm.nih.gov/pubmed/26746459) JAMA. 2016 Jan 5;315(1):68-76. PMCID: [PMC5498110](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5498110/).
201. Möller E, Wilson KM, Batista JL, **Mucci LA**, Bälter K, Giovannucci E. [Body size across the life course and prostate cancer in the Health Professionals Follow-up Study.](http://www.ncbi.nlm.nih.gov/pubmed/26355806) Int J Cancer. 2016 Feb 15;138(4):853-65. PMCID: PMC5042346.
202. Lu D, Sinnott JA, Valdimarsdottir UA, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, **Mucci LA**\*\*, Fall K\*\*. [Stress-Related Signaling Pathways in Lethal and Non-Lethal Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26490316) Clin Cancer Res. 2016 Feb 1;22(3):765-72. PMCID: PMC4738177. \*\*Shared Last Authorship
203. Markt SC, Flynn-Evans EE, Valdimarsdottir U, Sigurdardottir LG, Tamimi RM, Batista JL, Haneuse S, Lockley SW, Stampfer M, Wilson KM, Czeisler CA, Rider JR, **Mucci LA**. Sleep duration and disruption and prostate cancer risk: a 23-year prospective study. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):302-8. PMCID: PMC4767658.
204. Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, **Mucci LA**. [Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.](http://www.ncbi.nlm.nih.gov/pubmed/26817504) Am J Clin Nutr. 2016 Mar;103(3):851-60. PMCID: PMC4763492.
205. Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L\*\*, **Mucci LA\*\***; Transdisciplinary Prostate Cancer Partnership (ToPCaP). [Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.](http://www.ncbi.nlm.nih.gov/pubmed/26775038) Carcinogenesis. 2016 Mar;37(3):262-8. PMCID: [PMC6233023](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6233023/). \*\* Shared last authorship
206. Linn DE, Penney KL, Bronson RT, **Mucci LA**, Li Z. [Deletion of interstitial genes between TMPRSS2 and ERG promotes prostate cancer progression.](http://www.ncbi.nlm.nih.gov/pubmed/26880803) Cancer Res. 2016 Apr 1;76(7):1869-81. PMCID: PMC4873435.
207. Börnigen D, Tyekucheva S, Wang X, Rider JR, Lee GS, **Mucci LA**, Sweeney C, Huttenhower C. [Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/27078000) PLoS Comput Biol. 2016 Apr 14;12(4):e1004820. PMCID: PMC4831844.
208. Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, **Mucci LA**, Pettersson A. [Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.](http://www.ncbi.nlm.nih.gov/pubmed/26986253) Br J Cancer. 2016 Apr 12;114(8):939-44. PMCID: PMC4984801.
209. Xie W, Yang M, Chan J, Sun T, **Mucci LA**, Penney KL, Lee GM, Kantoff PW. [Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.](http://www.ncbi.nlm.nih.gov/pubmed/26847995) Prostate. 2016 May;76(7):691-9. PMCID: [PMC5510241](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5510241/).
210. [Penney KL, Pettersson A, Shui IM, Graff RE, Kraft P, Lis RT, Sesso HD, Loda M, **Mucci LA**. Association of prostate cancer risk variants with TMPRSS2:ERG status: evidence for distinct molecular subtypes.](http://www.ncbi.nlm.nih.gov/pubmed/26941365) Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):745-9. PMCID: PMC4873420.
211. Sanchez A, Schoenfeld JD, Nguyen PL, Fiorentino M, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, **Mucci LA**, Shui IM. [Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.](http://www.ncbi.nlm.nih.gov/pubmed/26926928) Prostate Cancer Prostatic Dis. 2016 Jun;19(2):197-201. PMCID: PMC486540.
212. Ahearn TU, Tchrakian N, Wilson KM, Lis R, Nuttall E, Sesso HD, Loda M, Giovannucci E, **Mucci LA**, Finn S, Shui IM. Calcium sensing receptor tumor expression and lethal prostate cancer progression. J Clin Endocrinol Metab. 2016 Jun;101(6):2520-7. PMCID: PMC4891799.
213. Chan JM, Darke AK, Penney KL, Tangen CM, Goodman PJ, Lee GM, Sun T, Peisch S, Tinianow AM, Rae JM, Klein EA, Thompson IM Jr, Kantoff PW, **Mucci LA**. [Selenium- or Vitamin E-related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.](http://www.ncbi.nlm.nih.gov/pubmed/27197287) Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1050-8. PMCID: PMC5086806.
214. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, **Mucci LA**, Rider JR. [Cholesterol metabolism and prostate cancer lethality.](http://www.ncbi.nlm.nih.gov/pubmed/27325648) Cancer Res. 2016 Aug 15;76(16):4785-90. PMCID: PMC4987257.
215. Yang M, Zu K, **Mucci LA**, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. [Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.](http://www.ncbi.nlm.nih.gov/pubmed/27379990) Cancer Causes Control. 2016 Aug;27(8):1043-7. PMCID: PMC4958547.
216. Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, **Mucci LA**\*\*, Chinnaiyan AM\*\*. [Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/26724257) Eur Urol. 2016 Oct;70(4):549-552. PMCID: PMC4919276.
217. Dickerman BA, Markt SC, Koskenvuo M, Hublin C, Pukkala E, **Mucci LA**, Kaprio J. [Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins.](https://www.ncbi.nlm.nih.gov/pubmed/27734240) Cancer Causes Control. 2016 Nov;27(11):1361-1370. PMCID: PMC5278774.
218. Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG, Loda M, **Mucci LA**, Sweeney CJ. [Risk of prostate cancer specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/26805930) BJU Int. 2016 2016 Dec;118(6):919-926. PMCID: PMC4960002.
219. Rider JR, Wilson KM, Sinnott JA, Kelly RS, **Mucci LA**, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urology 2016 Dec;70(6):974-982. PMCID: PMC5040619.
220. Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, **Mucci LA**. [The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.](https://www.ncbi.nlm.nih.gov/pubmed/?term=The+role+of+tumor+metabolism+as+a+driver+of+prostate+cancer+progression+and+lethal+disease%3A+results+from+a+nested+case-control+study.) Cancer Metab. 2016 Dec 7;4:22. PMCID: PMC5142400.
221. Markt SC, Nuttall E, Turman C, Sinnott J, Rimm EB, Ecsedy E, Unger RH, Fall K, Finn S, Jensen MK, Rider JR, Kraft P, **Mucci LA**. [Sniffing out significant "Pee values": genome wide association study of asparagus anosmia.](https://www.ncbi.nlm.nih.gov/pubmed/27965198) BMJ. 2016 Dec 13;355:i6071. PMCID: PMC5154975.
222. Downer MK, Batista JL, **Mucci LA**, Stampfer MJ, Epstein MM, Håkansson N, Wolk A, Johansson JE, Andrén O, Fall K, Andersson SO. [Dairy intake in relation to prostate cancer survival.](https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/28187509) Int J Cancer. 2017; 140(9):2060-2069. PMID: 28187509
223. Tsianakas V, Harris J, Ream E, Van Hemelrijck M, Purushotham A, **Mucci L**, Green JS, Fewster J, Armes J. [CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer.](https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/28202500) BMJ Open. 2017;7(2):e013719. PMCID: PMC5318561.
224. Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, **Mucci LA\*\***, Loda M\*\*. [Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28871082) Nat Commun. 2017;8(1):42. PMCID: PMC5583238.
225. Sud A, Thomsen H, Law PJ, Försti A, Filho MIDS, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N; **PRACTICAL consortium**, Hoffmann P, Nöthen MM, Jöckel KH, Strandmann EPV, Lightfoot T, Kane E, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun. 2017;8(1):1892. PMCID: [PMC5711884](http://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pmc/articles/pmc5711884/).
226. Pernar CH, Fall K, Rider JR, Markt SC, Adami HO, Andersson SO, Valdimarsdottir U, Andrén O, **Mucci LA**. [A Walking Intervention Among Men With Prostate Cancer: A Pilot Study.](https://www.ncbi.nlm.nih.gov/pubmed/28668276) Clin Genitourin Cancer. 2017; 15:e1021-1028. PMCID: PMC5705588.
227. Sinnott JA, Peisch S, Tyekucheva S, Gerke TA, Lis RT, Rider JR, Fiorentino M, Stampfer MJ, **Mucci LA**, Loda M, Penney KL. [Prognostic Utility of a New mRNA Expression Signature of Gleason Score.](https://www.ncbi.nlm.nih.gov/pubmed/27663590) Clin Cancer Res. 2017 Jan 1;23(1):81-87. PMCID: PMC521564.
228. Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, **Mucci LA**, Pettersson A. [Circulating antioxidant levels and risk of prostate cancer by *TMPRSS2:ERG.*](https://www.ncbi.nlm.nih.gov/pubmed/28102015) Prostate. 2017 Jan 19. 2017 May;77(6):647-653. PMCID: PMC5354965.
229. Pettersson A, Gerke T, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami HO, Rider JR, **Mucci LA**; Transdisciplinary Prostate Cancer Partnership (ToPCaP).[The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.](https://www.ncbi.nlm.nih.gov/pubmed/28152172) Cancer. 2017 Feb 2. PMCID: PMC5716345.
230. Haraldsdottir A, Steingrimsdottir L, Valdimarsdottir U, Aspelund T, Tryggvadottir L, Harris TB, Launer L, **Mucci LA**, Giovannucci EL, Adami HO, Gudnason V, Torfadottir JE. [Early life residence, fish consumption and risk of breast cancer.](https://www.ncbi.nlm.nih.gov/pubmed/27765796) Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):346-354. PMCID: PMC5336533.
231. Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, **Mucci LA**. [Perineural invasion and risk of lethal prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28062398) Cancer Epidemiol Biomarkers Prev. 2017 May;77(6):647-653. PMCID: PMC5413395
232. Graff RE, Möller S, Passarelli MN, Witte JS, Skytthe A, Christensen K, Tan Q, Adami HO, Czene K, Harris JR, Pukkala E, Kaprio J, Giovannucci E, **Mucci LA**, Hjelmborg JB. [Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28130150) Clin Gastroenterol Hepatol. 2017 Aug;15(8):1256-1264. PMCID: PMC5522647
233. Dickerman BA, Ahearn TU, Giovannucci E, Stampfer MJ, Nguyen PL, **Mucci LA**, Wilson KM. [Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28543830) Int J Cancer. 2017 Sep 1;141(5):933-944. PMCID: PMC5518616
234. Lu D, Carlsson J, Penney KL, Davidsson S, Andersson SO, **Mucci LA**, Valdimarsdóttir U, Andrén O, Fang F, Fall K. [Expression and Genetic Variation in Neuroendocrine Signaling Pathways in Lethal and Nonlethal Prostate Cancer among Men Diagnosed with Localized Disease.](https://www.ncbi.nlm.nih.gov/pubmed/28939587) Cancer Epidemiol Biomarkers Prev. 2017 Sep 22. PMID: 28939587.
235. Downer MK, Allard CB, Preston MA, Gaziano JM, Stampfer MJ, **Mucci LA**, Batista JL. [Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.](https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pubmed/28189429) 2017 Nov;72(5):821-827. PMID: 28189429.
236. Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, **Mucci LA**. [Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/28700821) Cancer. 2017 Nov 1;123(21):4130-4138. PMCID: PMC5802874.
237. Gu F, Zhang H, Hyland PL, Berndt S, Gapstur SM, Wheeler W; ELLIPSE consortium, Amos CI, Bezieau S, Bickeböller H, Brenner H, Brennan P, Chang-Claude J, Conti DV, Ann Doherty J, Gruber SB, Harrison TA, Hayes RB, Hoffmeister M, Houlston RS, Hung RJ, Jenkins MA, Kraft P, Lawrenson K, McKay J, Markt S, **Mucci L**, Phelan CM, Qu C, Risch A, Rossing MA, Wichmann HE, Shi J, Schernhammer E, Yu K, Landi MT, Caporaso NE. [Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.](https://www.ncbi.nlm.nih.gov/pubmed/28699174) Int J Cancer. 2017 Nov 1;141(9):1794-1802. PMCID: PMC5907928.
238. Pergolini I, Sahora K, Ferrone CR, Morales-Oyarvide V, Wolpin BM, **Mucci LA**, Brugge WR, Mino-Kenudson M, Patino M, Sahani DV, Warshaw AL, Lillemoe KD, Fernández-Del Castillo C. [Long-Term Risk of Pancreatic Malignancy in Patients with Branch Duct Intraductal Papillary Mucinous Neoplasm in A Referral Center.](https://www.ncbi.nlm.nih.gov/pubmed/28739282) Gastroenterology. 2017 Nov;153(5):1284-1294.e1. PMID: 28739282.
239. Hjelmborg J, Korhonen T, Holst K, Skytthe A, Pukkala E, Kutschke J, Harris JR, **Mucci LA**, Christensen K, Czene K, Adami HO, Scheike T, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) collaboration. [Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29054888) Thorax. 2017 Nov;72(11):1021-1027. PMID: 29054888.
240. Sheill G, Brady L, Guinan E, Hayes B, Casey O, Greene J, Vlajnic T, Cahill F, Van Hemelrijck M, Peat N, Rudman S, Hussey J, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, **Mucci L**, Sheils O, O'Leary J, O'Donnell DM, McDermott R, Finn S. [The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/28978344) Trials. 2017;18(1):456. PMCID: PMC5628461
241. Kurushima Y, Silventoinen K, Dokkedal U, Skytthe A, **Mucci LA**, Christensen K, Hjelmborg JVB. [Heritability of the Number of Teeth in Middle-Aged and Older Danish Twins.](https://www.ncbi.nlm.nih.gov/pubmed/28787219) J Dent Res. 2017 Dec;96(13):1513-1517. PMID: 28787219.
242. Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, **Mucci LA**, Loda M. [MYC overexpression at the protein and mRNA level and cancer outcomes among men treated with radical prostatectomy for prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29141848) Cancer Epidemiol Biomarkers Prev. 2018;27(2):201-207. PMCID: PMC5831163
243. Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS; **PRACTICAL Consortium**. [Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.](https://www.ncbi.nlm.nih.gov/pubmed/29632299) Nat Commun. 2018; 9(1):1340. PMCID: [PMC5890276](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5890276/).
244. Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, **Mucci L**, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F. [Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.](https://www.ncbi.nlm.nih.gov/pubmed/29764892) BMJ Open. 2018;8(5):e022899. PMCID: [PMC5961562](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5961562/)
245. Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, **Mucci L**, Parmigiani G, Schrag D, Syngal S, Tamimi RM, Viswanath K, Yurgelun MB, Garber JE. [Precision Prevention and Early Detection of Cancer: Fundamental Principles.](https://www.ncbi.nlm.nih.gov/pubmed/29907587) Cancer Discov. 2018;8(7):803-811. PMID: 29907587
246. Tsang SH, Peisch SF, Rowan B, Markt SC, Gonzalez-Feliciano AG, Sutcliffe S, Platz EA, **Mucci LA**, Ebot EM. [Association between Trichomonas vaginalis and prostate cancer mortality.](https://www.ncbi.nlm.nih.gov/pubmed/30242839) Int J Cancer. 2019 May 15;144(10):2377-2380. PMCID: [PMC6430694](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6430694/).
247. Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; **PRACTICAL consortium**. [Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.](https://www.ncbi.nlm.nih.gov/pubmed/30213928) Nat Commun. 2018; 9:3707. PMCID: [PMC6137048](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6137048/)
248. Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, **Mucci LA**\*\*, Wilson KM\*\*. [Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.](https://www.ncbi.nlm.nih.gov/pubmed/30237027) Eur Urol. 2019 Mar;75(3):399-407. PMCID: [PMC6390280](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6390280/). \*\* Shared last authorship.
249. Dickerman BA, Giovannucci E, Pernar CH, **Mucci LA**, Hernán MA. [Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/30496346) Am J Epidemiol. 2019 Mar 1;188(3):579-586. PMCID: [PMC6395165](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6395165/).
250. Sauer CM, Myran DT, Costentin CE, Zwisler G, Safder T, Papatheodorou S, **Mucci LA**. [Effect of long term aspirin use on the incidence of prostate cancer: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/30447928) Crit Rev Oncol Hematol. 2018; 132:66-75. PMID: 30447928.
251. Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, **Mucci LA**. [Height, obesity, and the risk of *TMPRSS2:ERG*-defined prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29167279) Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. PMCID: PMC5809280.
252. Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, **Mucci LA**, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. [Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.](https://www.ncbi.nlm.nih.gov/pubmed/29164645) Prostate. 2018 Feb;78(3):233-238. PMCID: PMC5774625.
253. Sun M, Cole AP, Hanna N, **Mucci LA**, Berry DL, Basaria S, Ahern DK, Kibel AS, Choueiri TK, Trinh QD. [Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29410294) J Urol. 2018 Feb 2. pii: S0022-5347(18)30109-5. PMID: 29410294.
254. Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T, Batista JL, Fall K, Giovannucci E, Sigurdardottir LG, Tryggvadottir L, Gudnason V, Markt SC, **Mucci LA**. [Midlife metabolic factors and prostate cancer risk in later life.](https://www.ncbi.nlm.nih.gov/pubmed/29114858) Int J Cancer. 2018 Mar 15;142(6):1166-1173. PMCID: PMC5773388.
255. Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, **Mucci LA**, Lipsitz SR, Chun FK, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Trinh QD. [Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29673944) J Urol. 2018 Sep;200(3):573-581. PMID: 29673944.
256. Allott EH, Markt SC, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Adriole GL, **Mucci LA**, Freedland SJ. [Geographic differences in baseline prostate inflammation and relationship with subsequent prostate cancer risk: results from the multinational REDUCE trial.](https://www.ncbi.nlm.nih.gov/pubmed/29669727) Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):783-789. PMCID: [PMC6035080](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6035080/).
257. Graff RE, Cho E, Preston MA, Sanchez A, **Mucci LA**, Wilson KM. [Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.](https://www.ncbi.nlm.nih.gov/pubmed/29760239) Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):979-982. PMCID: [PMC6072568](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6072568/).
258. Sinnott JA, Brumberg K, Wilson KM, Ebot EM, Giovannucci EL, **Mucci LA**, Rider JR. [Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency.](https://www.ncbi.nlm.nih.gov/pubmed/29784192) Eur Urol. 2018 Nov;74(5):545-548. PMCID: [PMC6489461](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6489461/).
259. Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, **Mucci LA**, Azuma H, Sweeney CJ, Kantoff PW. [ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.](https://www.ncbi.nlm.nih.gov/pubmed/29863497) J Clin Invest. 2018 Jul 2;128(7):2979-2995. PMCID: [PMC6025984](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6025984/).
260. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, **Mucci LA**, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA. [Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.](https://www.ncbi.nlm.nih.gov/pubmed/29892016) Nat Genet. 2018 Jul;50(7):928-936. PMCID: [PMC6568012](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6568012/).
261. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, **Mucci L**, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z. [Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.](https://www.ncbi.nlm.nih.gov/pubmed/29892050) Nat Commun. 2018 Jun 11;9(1):2256. PMCID: [PMC5995836](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5995836/).
262. Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, **Mucci LA**. [Regular aspirin use and gene expression profiles in prostate cancer patients.](https://www.ncbi.nlm.nih.gov/pubmed/29915914) Cancer Causes Control. 2018 Aug;29(8):775-784. PMCID: [PMC6298857](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6298857/).
263. DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, Fiorentino M, De Marzo AM, Rider JR, **Mucci LA**; Transdisciplinary Prostate Cancer Partnership (ToPCaP). [Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.](https://www.ncbi.nlm.nih.gov/pubmed/30009541) Prostate. 2018 Nov;78(15):1172-1180. PMCID: [PMC6501556](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6501556/).
264. Barber LE, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn TU, Giovannucci EL, Parmigiani G, **Mucci LA**. [Family history of breast or prostate cancer and prostate cancer risk.](https://www.ncbi.nlm.nih.gov/pubmed/30082473) Clin Cancer Res. 2018 Dec 1;24(23):5910-5917. PMCID: [PMC6279573](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6279573/).
265. Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, Lis RT, Graff RE, Pettersson A, Pernar CH, Loda M, Kantoff PW, Ahearn TU, **Mucci LA**; Transdisciplinary Prostate Cancer Partnership (ToPCaP). [A Prospective Study of Aspirin Use and Prostate Cancer Risk by *TMPRSS2:ERG* Status.](https://www.ncbi.nlm.nih.gov/pubmed/30108097) Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1231-1233. PMCID: [PMC6170677](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6170677/).
266. Xie W, Stopsack KH, Drouin SJ, Fu H, Pomerantz MM, **Mucci LA**, Lee GM, Kantoff PW. [Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.](https://www.ncbi.nlm.nih.gov/pubmed/30141208) Prostate. 2019 Jan;79(1):73-80. PMCID: [PMC6476182](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6476182/).
267. Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, **Mucci LA**, Freedland SJ, Allott EH. [Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.](https://www.ncbi.nlm.nih.gov/pubmed/30139875) Cancer Prev Res (Phila). 2018 Oct;11(10):621-628. PMID: 30139875.
268. Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou K, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, **Mucci LA**; Transdisciplinary Prostate Cancer Partnership (ToPCaP). [Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.](https://www.ncbi.nlm.nih.gov/pubmed/30165429) Carcinogenesis. 2018 Dec 31;39(12):1431-1437. PMCID: [PMC6314328](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6314328/).
269. Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, **Mucci LA**, Sweeney CJ. Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer. 2019 Feb;17(1):32-37. PMID: 30348512.
270. Mancuso N, Gayther S, Gusev A, Zheng W, Penney KL, Kote-Jarai Z, Eeles R, Freedman M, Haiman C, Pasaniuc B; **PRACTICAL consortium**. Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nat Commun. 2018 Oct 4;9(1):4079. PMCID: [PMC6172280](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6172280/).
271. Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, **Mucci LA**. [A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.](https://www.ncbi.nlm.nih.gov/pubmed/30301696) Eur Urol. 2019 Jul;76(1):33-40. PMCID: [PMC6451672](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6451672/).
272. Robinson CD, Gonzalez-Feliciano A, **Mucci LA**, Markt SC. Smoking cessation among men following cancer diagnosis: a matched cohort study. J Cancer Surviv. 2018 Dec;12(6):786-793. PMID: 30302603.
273. Elfandy H, Armenia J, Pederzoli F, Pullman E, Pértega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, **Mucci LA**, Barbieri C, Loda M. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019 Feb;17(2):446-456. PMCID: [PMC6359952](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6359952/).
274. Zelic R, Fiano V, Ebot EM, Coseo Markt S, Grasso C, Trevisan M, De Marco L, Delsedime L, Zugna D, **Mucci LA**, Richiardi L. [Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality.](https://www.ncbi.nlm.nih.gov/pubmed/30341411) Prostate Cancer Prostatic Dis. 2019 May;22(2):284-291. PMID: 30341411.
275. Adams C, Richmond RC, Santos Ferreira DL, Spiller W, Tan VY, Zheng J, Wurtz P, Donovan JL, Hamdy FC, Neal DE, Lane JA, Davey Smith G, Relton CL, Eeles RA, Henderson BE, Haiman CA, Kote-Jarai Z, Schumacher FR, Amin Al Olama A, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur SM, Stevens VL, Tangen CM, Batra J, Clements JA, Grönberg H, Pashayan N, Schleutker J, Albanes D, Wolk A, West CML, **Mucci LA**, Cancel-Tassin G, Koutros S, Sørensen KD, Maehle L, Travis RC, Hamilton R, Ingles SA, Rosenstein BS, Lu YJ, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, DeRuyck K, Razack A, Newcomb LF, Lessel D, Kaneva RP, Usmani N, Claessens F, Townsend P, Gago Dominguez M, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Martin RM. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):208-216. PMCID: [PMC6746173](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6746173/).
276. Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, **Mucci L**, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 Nov 5;9(1):4616. PMCID: [PMC6218483](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6218483/).
277. Yuan C, Shui IM, Wilson KM, Stampfer MJ, **Mucci LA**, Giovannucci EL. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. Int J Cancer. 2019 May 15;144(10):2401-2407. PMCID: [PMC7211036](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7211036/).
278. Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, **Mucci LA**, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. PMCID: [PMC6494092](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6494092/).
279. Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, Gao F, Li B, Lu W, Tang X, Wistuba II, Bowden M, **Mucci L**, Loda M, Parmigiani G, Holmes CC, Wang W. Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. iScience. 2018 Nov 30;9:451-460. PMCID: [PMC6249353](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6249353/).
280. Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, **Mucci LA**, Kantoff PW. [Low expression of the androgen-induced tumor suppressor gene PLZF and lethal prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/30602500) Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):707-714. PMCID: [PMC6532645](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6532645/).
281. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, **Mucci L**, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. [Shared heritability and functional enrichment across six solid cancers.](https://www.ncbi.nlm.nih.gov/pubmed/30683880) Nat Commun. 2019 Jan 25;10(1):431. PMCID: [PMC6347624](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6347624/).
282. Torfadottir JE, Aspelund T, Valdimarsdottir UA, Cotch MF, Tryggvadottir L, Harris TB, Gudnason V, Adami HO, **Mucci LA**, Giovannucci EL, Stampfer MJ, Steingrimsdottir L.[Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients.](https://www.ncbi.nlm.nih.gov/pubmed/30805814) Cancer Causes Control. 2019 Apr;30(4):333-342. PMCID: [PMC6602548](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6602548/).
283. Hang D, Kværner AS, Ma W, Hu Y, Tabung FK, Nan H, Hu Z, Shen H, **Mucci LA**, Chan AT, Giovannucci EL, Song M. [Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals.](https://www.ncbi.nlm.nih.gov/pubmed/30834441) Am J Clin Nutr. 2019 Mar 1;109(3):635-647. PMCID: [PMC6408210](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6408210/).
284. Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, **Mucci LA**, Kantoff PW. [Intratumoral Sterol-27-Hydroxylase (*CYP27A1*) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/30867220) Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1052-1058. PMCID: [PMC6548616](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6548616/).
285. Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Hercberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, **Mucci LA**, Neal DE, Neuhouser ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, Pollak M, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC. [The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.](https://www.ncbi.nlm.nih.gov/pubmed/30873591) Int J Cancer. 2019 Dec 15;145(12):3244-3256. PMCID: [PMC6745281](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6745281/).
286. Heath EI, Nanus DM, Slovin S, Strand C, Higano C, Simons VH, Johnson C, Kyriakopoulos CE, Reichert ZR, Lory S, George DJ, **Mucci LA**, Marcus JD, Trendel JA, Bock CH. [Prostate Cancer National Summit's Call to Action.](https://www.ncbi.nlm.nih.gov/pubmed/31085057) Clin Genitourin Cancer. 2019 Jun;17(3):161-168. PMID: 31085057.
287. Skytthe A, Harris JR, Czene K, **Mucci L**, Adami HO, Christensen K, Hjelmborg J, Holm NV, Nilsen TS, Kaprio J, Pukkala E. [Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers.](https://www.ncbi.nlm.nih.gov/pubmed/31020942) Twin Res Hum Genet. 2019 Apr;22(2):99-107. PMID: 31020942.
288. Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, Giovannucci EL, Rimm EB, Wang M, **Mucci LA**, Willett WC, Chan JM, Van Blarigan EL. [Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.](https://www.ncbi.nlm.nih.gov/pubmed/31026211) J Clin Oncol. 2019 Jun 10;37(17):1499-1511. PMCID: [PMC6599404](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6599404/).
289. Campbell PT, Ambrosone CB, Nishihara R, Aerts HJWL, Bondy M, Chatterjee N, Garcia-Closas M, Giannakis M, Golden JA, Heng YJ, Kip NS, Koshiol J, Liu XS, Lopes-Ramos CM, **Mucci LA**, Nowak JA, Phipps AI, Quackenbush J, Schoen RE, Sholl LM, Tamimi RM, Wang M, Weijenberg MP, Wu CJ, Wu K, Yao S, Yu KH, Zhang X, Rebbeck TR, Ogino S. [Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting.](https://www.ncbi.nlm.nih.gov/pubmed/31069578)Cancer Causes Control. 2019 Aug;30(8):799-811. PMCID: [PMC6614001](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6614001/).
290. Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, **Mucci LA**\*\*, Amon A\*\*. [Aneuploidy drives lethal progression in prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31085648) Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. PMCID: [PMC6561291](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6561291/). \*\*Shared last author
291. Malik VS, Guasch-Ferre M, Hu FB, Townsend MK, Zeleznik OA, Eliassen AH, Tworoger SS, Karlson EW, Costenbader KH, Ascherio A, Wilson KM, **Mucci LA**, Giovannucci EL, Fuchs CS, Bao Y. [Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women.](https://www.ncbi.nlm.nih.gov/pubmed/31095304) J Nutr. 2019 Jul 1;149(7):1215-1221. PMCID: [PMC6602895](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6602895/).
292. Yu B, Zanetti KA, Temprosa M, Albanes D, Appel N, Barrera CB, Ben-Shlomo Y, Boerwinkle E, Casas JP, Clish C, Dale C, Dehghan A, Derkach A, Eliassen AH, Elliott P, Fahy E, Gieger C, Gunter MJ, Harada S, Harris T, Herr DR, Herrington D, Hirschhorn JN, Hoover E, Hsing AW, Johansson M, Kelly RS, Khoo CM, Kivimäki M, Kristal BS, Langenberg C, Lasky-Su J, Lawlor DA, Lotta LA, Mangino M, Le Marchand L, Mathé E, Matthews CE, Menni C, **Mucci LA**, Murphy R, Oresic M, Orwoll E, Ose J, Pereira AC, Playdon MC, Poston L, Price J, Qi Q, Rexrode K, Risch A, Sampson J, Seow WJ, Sesso HD, Shah SH, Shu XO, Smith GCS, Sovio U, Stevens VL, Stolzenberg-Solomon R, Takebayashi T, Tillin T, Travis R, Tzoulaki I, Ulrich CM, Vasan RS, Verma M, Wang Y, Wareham NJ, Wong A, Younes N, Zhao H, Zheng W, Moore SC. [The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies.](https://www.ncbi.nlm.nih.gov/pubmed/31155658) Am J Epidemiol. 2019 Jun 1;188(6):991-1012. PMCID: [PMC6545286](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6545286/).
293. Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, Ebot EM, Isikbay M, Finn SP, Giovannucci EL, Lis RT, Loda M, Parmigiani G, Lotan T, Kantoff PW, **Mucci LA**, Graff RE. [Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31318977) Int J Cancer. 2020 May 15;146(10):2694-2702. PMCID: [PMC7905843](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7905843/).
294. Ugge H, Downer MK, Carlsson J, Bowden M, Davidsson S, **Mucci LA**, Fall K, Andersson SO, Andrén O. [Circulating inflammation markers and prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31212389) Prostate. 2019 Aug;79(11):1338-1346. doi: 10.1002/pros.23842. Epub 2019 Jun 18. PMID: 31212389.
295. Downer MK, Allard CB, Preston MA, Wilson KM, Kenfield SA, Chan JM, **Mucci LA**, Giovannucci E, Stampfer MJ. [Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study.](https://www.ncbi.nlm.nih.gov/pubmed/31017087) Eur Urol Oncol. 2019;2(2):126-134. Epub 2018 Jul 31. PMID: 31017087.
296. Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, **Mucci LA**, Chavarro JE, Loda M, Brown M. [High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.](https://www.ncbi.nlm.nih.gov/pubmed/31554818) Nat Commun. 2019 Sep 25;10(1):4358. PMCID: [PMC6761092](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6761092/).
297. González-Marrón A, Martín-Sánchez JC, Miró Q, Matilla-Santander N, Cartanyà-Hueso À, **Mucci L**, Martínez-Sánchez JM. [Relation between tobacco control policies and population at high risk of lung cancer in the European Union.](https://www.ncbi.nlm.nih.gov/pubmed/31541906) Environ Res. 2019 Jul 19;179(Pt A):108594. PMID: 31541906.
298. Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, **Mucci LA**, Fiorentino M, Ebot EM. [A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31533941) Cancer Epidemiol Biomarkers Prev. 2019;28:2047-2054. PMCID: [PMC6941930](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6941930/).
299. Harris JR, Hjelmborg J, Adami HO, Czene K, **Mucci L**, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) Collaboration. [The Nordic Twin Study on Cancer - NorTwinCan.](https://www.ncbi.nlm.nih.gov/pubmed/31512575) Twin Res Hum Genet. 2019 Sep 12:1-7. PMID: 31512575.
300. Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, **Mucci LA**, Lee GM, Nanjangud GJ, Kantoff PW. [Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression.](https://www.ncbi.nlm.nih.gov/pubmed/31796516) Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. PMCID: [PMC7416644](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7416644/).
301. Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, **Mucci LA**, Sun M, Trinh QD. [Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31784699) Prostate Cancer Prostatic Dis. 2020 Sep;23(3):410-418. PMID: 31784699.
302. Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, **Mucci LA**. [Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31754047) Clin Cancer Res. 2020 Mar 1;26(5):1086-1093. PMCID: [PMC7056554](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7056554/).
303. Wang Z, Du M, Yuan Q, Guo Y, Hutchinson JN, Su L, Zheng Y, Wang J, **Mucci LA**, Lin X, Hou L, Christiani DC.[Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers.](https://www.ncbi.nlm.nih.gov/pubmed/32062069) Neoplasia. 2020 Mar;22(3):154-161. PMCID: [PMC7021546](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7021546/).
304. Hollis B, Day FR, Busch AS, Thompson DJ, Soares ALG, Timmers PRHJ, Kwong A, Easton DF, Joshi PK, Timpson NJ; PRACTICAL Consortium; 23andMe Research Team, Ong KK, Perry JRB. [Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan.](https://www.ncbi.nlm.nih.gov/pubmed/32210231) Nat Commun. 2020; 11:1536. PMCID: [PMC7093467](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7093467/).
305. Khan S, Caldwell J, Wilson KM, Gonzalez-Feliciano AG, Peisch S, Pernar CH, Graff RE, Giovannucci EL, **Mucci LA**, Gerke TA, Markt SC. [Baldness and Risk of Prostate Cancer in the Health Professionals Follow-Up Study.](https://www.ncbi.nlm.nih.gov/pubmed/32277004) Cancer Epidemiol Biomarkers Prev. 2020 Jun;29(6):1229-1236. PMCID: [PMC7269836](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7269836/).
306. Dickerman BA, Ebot EM, Healy BC, Wilson KM, Eliassen AH, Ascherio A, Pernar CH, Zeleznik OA, Vander Heiden MG, Clish CB, Giovannucci E, **Mucci LA**. [A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study.](https://www.ncbi.nlm.nih.gov/pubmed/32164144) Metabolites. 2020 Mar 10;10(3). PMCID: [PMC7142752](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7142752/).
307. Stopsack KH, **Mucci LA**, Antonarakis ES, Nelson PS, Kantoff PW. [*TMPRSS2* and COVID-19: Serendipity or Opportunity for Intervention?](https://www.ncbi.nlm.nih.gov/pubmed/32276929) Cancer Discov. 2020 Jun;10(6):779-782. PMCID: [PMC7437472](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7437472/).
308. Fu BC, Song M, Li X, Han J, Adami HO, Giovannucci EL, **Mucci LA**. [Height as a mediator of sex differences in cancer risk.](https://www.ncbi.nlm.nih.gov/pubmed/32217057) Ann Oncol. 2020 May;31(5):634-640. Epub 2020 Mar 24. PMCID: PMC7384254.
309. Andrew T. Chan, David A. Drew, Long H. Nguyen, Amit Joshi, Wenjie Ma, Chuan-Guo Guo, Chun-Han Lo, Raaj S. Mehta, Sohee Kwon, Daniel R. Sikavi, Marina V. Magicheva-Gupta, Zahra S. Fatehi, Jacqueline J. Flynn, Brianna M. Leonardo, Christine M. Albert, Gabriella Andreotti, Laura E. Beane Freeman, Bijal A. Balasubramanian, John Brownstein, Fiona Bruinsma, Annie N. Cowan, Anusila Deka, Michael E. Ernst, Jane C. Figueiredo, Paul W. Franks, Christopher Gardner, Irene M. Ghobrial, Christopher A. Haiman, Janet E. Hall, Sandra L. Deming-Halverson, Brenda Kirpach, James V Lacey Jr, Loic Le Marchand, Catherine R. Marinac, Maria Elena Martinez, Roger L. Milne, Anne M Murray, Denis Nash, Julie R. Palmer, Alpa V. Patel, Lynn Rosenberg, Dale P. Sandler, Shreela V Sharma, Shepherd H. Schurman, Lynne R. Wilkens, Jorge E. Chavarro, A. Heather Eliassen, Jaime E. Hart, Jae Hee Kang, Karestan C. Koenen, Laura D. Kubzansky, **Lorelei A. Mucci**, Sebastien Ourselin, Janet W. Rich-Edwards, Mingyang Song, Meir J Stampfer, Claire J. Steves, Walter C. Willett, Jonathan Wolf, and Tim Spector. The COronovirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1283-1289. PMCID: [PMC7357669](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7357669/).
310. Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, Sudre CH, Cardoso MJ, Ourselin S, Wolf J, Spector TD, Chan AT; COPE Consortium. [Rapid implementation of mobile technology for real-time epidemiology of COVID-19.](https://www.ncbi.nlm.nih.gov/pubmed/32371477) Science. 2020 Jun 19;368(6497):1362-1367. PMCID: [PMC7200009](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7200009/).
311. Li J, Guasch-Ferré M, Chung W, Ruiz-Canela M, Toledo E, Corella D, Bhupathiraju SN, Tobias DK, Tabung FK, Hu J, Zhao T, Turman C, Feng YA, Clish CB, **Mucci L**, Eliassen AH, Costenbader KH, Karlson EW, Wolpin BM, Ascherio A, Rimm EB, Manson JE, Qi L, Martínez-González MÁ, Salas-Salvadó J, Hu FB, Liang L. [The Mediterranean diet, plasma metabolome, and cardiovascular disease risk.](https://www.ncbi.nlm.nih.gov/pubmed/32406924) Eur Heart J. 2020 Jul 21;41(28):2645-2656. PMCID: PMC7377580.
312. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, **Mucci LA**, Santillana M, Cai H. [Patients with Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study during the COVID-19 Outbreak.](https://www.ncbi.nlm.nih.gov/pubmed/32345594) Cancer Discov. 2020 Jun;10(6):783-791. PMCID: [PMC7309152](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7309152/).
313. Aboumrad M, Shiner B, **Mucci L**, Neupane N, Schroeck FR, Klaassen Z, Freedland SJ, Young-Xu Y. [Posttraumatic stress disorder and suicide among veterans with prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/33247977/) Psychooncology. 2020 Nov 28. PMID: 33247977.
314. [Hang D, Zeleznik OA, He X, Guasch-Ferre M, Jiang X, Li J, Liang L, Eliassen AH, Clish CB, Chan AT, Hu Z, Shen H, Wilson KM, **Mucci LA**, Sun Q, Hu FB, Willett WC, Giovannucci EL, Song M. Metabolomic Signatures of Long-term Coffee Consumption and Risk of Type 2 Diabetes in Women.](https://pubmed.ncbi.nlm.nih.gov/32788283/) Diabetes Care. 2020;43(10):2588-2596. PMCID: PMC7510042.
315. Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, Mucci L, Roberts T, Zanata SM, Zadra G, Loda M. [Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.](https://pubmed.ncbi.nlm.nih.gov/33166087/) J Pathol. 2021 Mar;253(3):292-303. PMCID: [PMC7898611](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7898611/).
316. Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, Batra J, Apcb BioResource, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, **Mucci LA**, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, The Impact Study Steering Committee And Collaborators, Kogevinas M, Wiklund F, Penney KL, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Ruyck K, Razack A, Newcomb LF, Canary Pass Investigators, Lessel D, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, The Profile Study Steering Committee, The Practical Consortium, Teixeira MR. [The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.](https://pubmed.ncbi.nlm.nih.gov/33158149/) Cancers (Basel). 2020 Nov 4;12(11):3254. PMCID: [PMC7694218](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7694218/).
317. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W, Mehta RS, Warner ET, Sikavi DR, Lo CH, Kwon S, Song M, **Mucci LA**, Stampfer MJ, Willett WC, Eliassen AH, Hart JE, Chavarro JE, Rich-Edwards JW, Davies R, Capdevila J, Lee KA, Lochlainn MN, Varsavsky T, Sudre CH, Cardoso MJ, Wolf J, Spector TD, Ourselin S, Steves CJ, Chan AT; COronavirus Pandemic Epidemiology Consortium. [Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study.](https://pubmed.ncbi.nlm.nih.gov/32745512/) Lancet Public Health. 2020 Sep;5(9):e475-e483. PMCID: [PMC7491202](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7491202/).
318. Iyer HS, James P, Valeri L, Hart JE, Pernar CH, **Mucci LA**, Holmes MD, Laden F, Rebbeck TR. [The association between neighborhood greenness and incidence of lethal prostate cancer: A prospective cohort study.](https://pubmed.ncbi.nlm.nih.gov/32656487/) Environ Epidemiol. 2020 Apr 9;4(2):e091. PMCID: [PMC7319229](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7319229/).
319. [Hurwitz LM, Agalliu I, Albanes D, Barry KH, Berndt SI, Cai Q, Chen C, Cheng I, Genkinger JM, Giles GG, Huang J, Joshu CE, Key TJ, Knutsen S, Koutros S, Langseth H, Li SX, MacInnis RJ, Markt SC, Penney KL, Perez-Cornago A, Rohan TE, Smith-Warner SA, Stampfer MJ, Stopsack KH, Tangen CM, Travis RC, Weinstein SJ, Wu L, Jacobs EJ, **Mucci LA**, Platz EA, Cook MB; Prostate Cancer Cohort Consortium (PC3) Working Group. Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.](https://pubmed.ncbi.nlm.nih.gov/33010161/) J Natl Cancer Inst. 2020 Oct 3:djaa154. PMID: 33010161.
320. Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, Fiorentino M, Ebot EM, **Mucci LA**. [Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/33500320/) Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33500320.
321. Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, **Mucci LA**, Loda M. [Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.](https://pubmed.ncbi.nlm.nih.gov/32913135/) Clin Cancer Res. 2020 Nov 15;26(22):5903-5913. PMCID: PMC7669556.
322. Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz M, Schmidt JA, **Mucci L**, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, Conti DV, Haiman CA. [Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/32853339/) J Natl Cancer Inst. 2020 Aug 27:djaa132. PMID: 32853339.
323. Feng X, Song M, Preston MA, Ma W, Hu Y, Pernar CH, Stopsack KH, Ebot EM, Fu BC, Zhang Y, Li N, Dai M, Liu L, Giovannucci EL, **Mucci LA**. [The association of diabetes with risk of prostate cancer defined by clinical and molecular features.](https://pubmed.ncbi.nlm.nih.gov/32467600/) Br J Cancer. 2020 Aug;123(4):657-665. PMCID: PMC7435261.
324. Wiggins EK, Oyekunle T, Howard LE, Markt SC, **Mucci LA**, Bliwise DL, Moreira DM, Andriole GL, Hopp ML, Freedland SJ, Allott EH. [Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.](https://pubmed.ncbi.nlm.nih.gov/32833249/) Prostate. 2020 Nov;80(15):1304-1313. PMCID: PMC7780858.
325. Brady L, Hayes B, Sheill G, Baird AM, Guinan E, Stanfill B, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, **Mucci L**, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell D, Sheils O, O'Leary J, Rudman S, McDermott R, Finn S. [Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.](https://pubmed.ncbi.nlm.nih.gov/33338056/) PLoS One. 2020 Dec 18;15(12):e0243928. PMCID: [PMC7748139](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7748139/).
326. Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, **Mucci LA**, Danila D, Kantoff PW. [Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.](https://pubmed.ncbi.nlm.nih.gov/33334906/) Clin Cancer Res. 2020 Dec 17. PMID: 33334906.
327. Cone EB, Marchese M, Paciotti M, Nguyen DD, Nabi J, Cole AP, Molina G, Molina RL, Minami CA, **Mucci LA**, Kibel AS, Trinh QD. [Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers.](https://pubmed.ncbi.nlm.nih.gov/33315115/) JAMA Netw Open. 2020 Dec 1;3(12):e2030072. PMCID: [PMC7737088](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7737088/).
328. Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, **Mucci LA**. [Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen.](https://pubmed.ncbi.nlm.nih.gov/32624279/) Eur Urol. 2020 Oct;78(4):637-639. PMID: 32624279.
329. Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, **Mucci LA**. [Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/32556091/) Carcinogenesis. 2020 Jul 14;41(7):904-908. PMCID: PMC7359768.
330. [Porta M, Pumarega J, Amaral AFS, Genkinger JM, Camargo J,**Mucci L**, Alguacil J, Gasull M, Zhang X, Morales E, Iglesias M, Ogino S, Engel LS; PANKRAS II Study Group. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.](https://pubmed.ncbi.nlm.nih.gov/32791343/) Environ Res. 2020 Nov;190:109781. PMCID: PMC7689512.
331. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokołorczyk D, Lubiński J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, **Mucci** **LA**, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Llorca J, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Holleczek B, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA. [Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.](https://pubmed.ncbi.nlm.nih.gov/33398198/) Nat Genet. 2021 Jan;53(1):65-75. PMID: 33398198.
332. Fu BC, Tabung FK, Pernar CH, Wang W, Gonzalez-Feliciano AG, Chowdhury-Paulino IM, Clinton SK, Folefac E, Song M, Kibel AS, Giovannucci EL, **Mucci LA**. [Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/33422354/) Eur Urol. 2021: 2021 Mar;79(3):405-412. PMCID: PMC7887049.
333. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, **Mucci L**, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. [Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.](https://pubmed.ncbi.nlm.nih.gov/32516092/) J Clin Oncol. 2020 Aug 20;38(24):2798-2811. PMCID: PMC7430215.
334. Rencsok EM, Bazzi LA, McKay RR, Huang FW, Friedant A, Vinson J, Peisch S, Zarif JC, Simmons S, Hawthorne K, Villanti P, Kantoff PW, Heath E, George DJ, **Mucci LA**. [Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.](https://pubmed.ncbi.nlm.nih.gov/32503813/) Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1374-1380. PMCID: [PMC7334076](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7334076/).
335. Grob S, **Mucci LA**. [COVID-19 and cancer in the United States.](https://pubmed.ncbi.nlm.nih.gov/33412790/) Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):26-27. PMID: 33412790.
336. Feng X, Zhou CK, Clish CB, Wilson KM, Pernar CH, Dickerman BA, Loda M, Finn SP, Penney KL, Schmidt DR, Vander Heiden MG, Giovannucci EL, Ebot EM, **Mucci LA.** [Association of pre-diagnostic blood metabolomics with prostate cancer defined by ERG or PTEN molecular subtypes.](https://pubmed.ncbi.nlm.nih.gov/33627383/) Cancer Epidemiol Biomarkers Prev. 2021 Feb 24;cebp.1363.2020. PMID: 33627383.
337. Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Nordestgaard BG, Wiklund F, Tangen CM, Giles GG, Wolk A, Albanes D, Travis RC, Blot WJ, Zheng W, Sanderson M, Stanford JL, **Mucci LA**, West CML, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Khaw KT, Park JY, Ingles SA, Maier C, Hamilton RJ, Thibodeau SN, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Penney KL, Huff C, Teixeira MR, Multigner L, Leach RJ, Cannon-Albright L, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Pandha H, Razack A, Newcomb LF, Fowke JH, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Bush WS, Roobol MJ, Parent MÉ, Hu JJ, Mills IG, Andreassen OA, Dale AM, Seibert TM; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium. [Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.](https://pubmed.ncbi.nlm.nih.gov/33623038/) Nat Commun. 2021 Feb 23;12(1):1236. PMID: 33623038.
338. Drouin-Chartier JP, Hernández-Alonso P, Guasch-Ferré M, Ruiz-Canela M, Li J, Wittenbecher C, Razquin C, Toledo E, Dennis C, Corella D, Estruch R, Fitó M, Eliassen AH, Tobias DK, Ascherio A, **Mucci LA**, Rexrode KM, Karlson EW, Costenbader KH, Fuchs CS, Liang L, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. [Dairy consumption, plasma metabolites, and risk of type 2 diabetes.](https://pubmed.ncbi.nlm.nih.gov/33742198/) Am J Clin Nutr. 2021 Mar 19 Online ahead of print.
339. Bazzi LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, Torfadottir J, Aspelund T, Czeisler CA, Lockley SW, Jonsson E, Launer L, Harris T, Gudnason V, **Mucci LA**, Markt SC. Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk. Prostate. 2021 Jun;81(8):487-496.
340. McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, Rencsok EM, Simmons S, Yates C, Vinson J, Kantoff PW, George DJ, **Mucci LA.** [Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.](https://pubmed.ncbi.nlm.nih.gov/33835826/)JCO Glob Oncol. 2021 Apr;7:495-505.
341. Plym A, Penney KL, Kalia S, Kraft P, Conti DV, Haiman C, **Mucci LA**, Kibel AS. [Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/33792693/) J Natl Cancer Inst. 2021 Apr Online ahead of print.
342. Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, Consortium P, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, **Mucci L**, Sweeney CJ. [A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/33956343/) Prostate.nh 2021; 81:683-693.
343. [Bazzi LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, Torfadottir J, Aspelund T, Czeisler CA, Lockley SW, Jonsson E, Launer L, Harris T, Gudnason V, **Mucci LA**, Markt SC. Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.](https://pubmed.ncbi.nlm.nih.gov/33860950/) Prostate. 2021; 81:487-496.
344. McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, Rencsok EM, Simmons S, Yates C, Vinson J, Kantoff PW, George DJ, **Mucci LA.** [Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.](https://pubmed.ncbi.nlm.nih.gov/33835826/) JCO Glob Oncol. 2021;7:495-505.
345. Imada EL, Sanchez DF, Dinalankara W, Vidotto T, Ebot EM, Tyekucheva S, Franco GR, **Mucci LA**, Loda M, Schaeffer EM, Lotan T, Marchionni L. [Transcriptional landscape of PTEN loss in primary prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/34311724/) BMC Cancer. 2021 Jul 26;21(1):856.
346. Fu BC, Chowdhury-Paulino IM, Giovannucci EL, **Mucci LA.** [Prenatal and perinatal factors and risk of cancer in middle and older adulthood among men.](https://pubmed.ncbi.nlm.nih.gov/34272265/) Cancer Epidemiol Biomarkers Prev. 2021 Jul 16. Online ahead of print.
347. Fu BC, Wang K, **Mucci LA**, Clinton SK, Giovannucci EL. [Aspirin use and prostate tumor angiogenesis.](https://pubmed.ncbi.nlm.nih.gov/34626297/) Cancer Causes Control. 2021 Oct 9. Online ahead of print.
348. Fang Z, Wu Y, Li Y, Zhang X, Willett WC, Eliassen AH, Rosner B, Song M, **Mucci LA**, Giovannucci EL. [Association of nut consumption with risk of total cancer and 5 specific cancers: evidence from 3 large prospective cohort studies.](https://pubmed.ncbi.nlm.nih.gov/34582546/) Am J Clin Nutr. 2021 Sep 28. Online ahead of print.
349. Hayes B, Brady L, Sheill G, Baird AM, Guinan E, Stanfill B, Dunne J, Holden D, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, **Mucci LA**, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell DM, Sheils O, O'Leary JJ, Rudman S, McDermott R, Finn S. [Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21).](https://pubmed.ncbi.nlm.nih.gov/34572916/) Cancers (Basel). 2021 Sep 18;13(18):4690.
350. Mazzu YZ, Liao Y, Nandakumar S, Sjöström M, Jehane LE, Ghale R, Govindarajan B, Gerke TA, Lee GM, Luo JH, Chinni SR, **Mucci LA**, Feng FY, Kantoff PW. [Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.](https://pubmed.ncbi.nlm.nih.gov/34792282/) Mol Oncol. 2021 Nov 18. Online ahead of print.
351. Stopsack KH, Salles DC, Vaselkiv JB, Grob ST, **Mucci LA\***, Lotan TL\*. [p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.](https://pubmed.ncbi.nlm.nih.gov/34969655/) Eur Urol Oncol. 2021 Dec 27:S2588-9311(21)00219-4. Online ahead of print. \*Shared last author
352. Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G\*, **Mucci LA\*.** [Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.](https://pubmed.ncbi.nlm.nih.gov/34939926/) Elife. 2021 Dec 23;10:e71265. doi: 10.7554/eLife.71265. \*Shared last author
353. Vaselkiv JB, Cheng I, Chowdhury-Paulino IM, Gonzalez-Feliciano AG, Wilkens LR, Hauksdottir AM, Eiriksdottir G, Le Marchand L, Haiman CA, Valdimarsdóttir U, **Mucci LA\***, Markt SC\*.[Urinary 6-sulfatoxymelatonin levels and prostate cancer risk among men in the Multiethnic Cohort.](https://pubmed.ncbi.nlm.nih.gov/34937795/) Cancer Epidemiol Biomarkers Prev. 2021 Dec 22. Online ahead of print. \*Shared last author
354. Loeb S, Fu BC, Bauer SR, Pernar CH, Chan JM, Van Blarigan EL, Giovannucci EL, Kenfield SA, **Mucci LA.** [Association of Plant-Based Diet Index with Prostate Cancer Risk.](https://pubmed.ncbi.nlm.nih.gov/34791008/) Am J Clin Nutr. 2021 Nov 13. Online ahead of print.
355. Stopsack KH, Nandakumar S, Arora K, Nguyen B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE, Slovin SF, Danila DC, Autio KA, Scher HI, **Mucci LA**, Solit DB, Gönen M, Chen Y, Berger MF, Schultz N, Abida W, Kantoff PW. [Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.](https://pubmed.ncbi.nlm.nih.gov/34667026/) Clin Cancer Res. 2022;28:318-326.
356. Chowdhury-Paulino IM, Ericsson C, Vince R Jr, Spratt DE, George DJ, **Mucci LA.** [Racial disparities in prostate cancer among black men: epidemiology and outcomes.](https://pubmed.ncbi.nlm.nih.gov/34475523/) Prostate Cancer Prostatic Dis. 2021: s41391-021-00451.
357. Swami N, Hwang WL, Guo JA, Hoffman H, Abramowitz MC, Elbakouny Z, Beltran H, Chipidza F, Choueiri T, Pra AD, Huang F, Kaochar S, Kantoff P, Kim DW, Kishan AU, Kobetz E, Marinac C, **Mucci LA**, Muralidhar V, Pollack A, Sanford NN, Schaeffer EM, Spratt DE, Zhao SG, Rebbeck TR, Nguyen PL, Feng FY, Mahal BA, Alshalalfa M. [Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).](https://pubmed.ncbi.nlm.nih.gov/34551377/) Cancer Genet. 2021;258-259:61-68.
358. Wang QL, Song M, Clinton SK, **Mucci LA**, Lagergren J, Giovannucci EL. [Longitudinal trajectories of lifetime body shape and prostate cancer angiogenesis.](https://pubmed.ncbi.nlm.nih.gov/35025021/) Eur J Epidemiol. 2022 Jan 13. Online ahead of print.
359. Ma C, Wang Y, Wilson KM, **Mucci LA**, Stampfer MJ, Pollak M, Penney KL. [Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/35047751/) JNCI Cancer Spectr. 2021; 6(1): eCollection 2022 Feb.
360. Geng JH, Plym A, Penney KL, Pomerantz M, **Mucci LA**, Kibel AS. [Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/35075214/) Prostate Cancer Prostatic Dis. 2022 Jan 24. Online ahead of print.
361. [Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, **Mucci LA**, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, Parent MÉ, Hu JJ, Zheng W; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium, Mills IG, Andreassen OA, Dale AM, Seibert TM. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.](https://pubmed.ncbi.nlm.nih.gov/35152271/) Prostate Cancer Prostatic Dis. 2022 Feb 12.
362. Wang F, Baden MY, Guasch-Ferré M, Wittenbecher C, Li J, Li Y, Wan Y, Bhupathiraju SN, Tobias DK, Clish CB, **Mucci LA**, Eliassen AH, Costenbader KH, Karlson EW, Ascherio A, Rimm EB, Manson JE, Liang L, Hu FB. [Plasma metabolite profiles related to plant-based diets and the risk of type 2 diabetes.](https://pubmed.ncbi.nlm.nih.gov/35391539/) Diabetologia. 2022 Apr 8. Online ahead of print.
363. [Morales Berstein F, McCartney DL, Lu AT, Tsilidis KK, Bouras E, Haycock P, Burrows K, Phipps AI, Buchanan DD, Cheng I; PRACTICAL consortium, Martin RM, Davey Smith G, Relton CL, Horvath S, Marioni RE, Richardson TG, Richmond RC. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study.](https://pubmed.ncbi.nlm.nih.gov/35346416/) Elife. 2022 Mar 29;11:e75374.
364. Pernar CH, Chomistek AK, Barnett JB, Ivey K, Al-Shaar L, Roberts SB, Rood J, Fielding RA, Block J, Li R, Willett WC, Parmigiani G, Giovannucci EL, **Mucci LA**, Rimm EB. [Validity and Relative Validity of Alternative Methods to Assess Physical Activity in Epidemiologic Studies: Findings from the Men's Lifestyle Validation Study.](https://pubmed.ncbi.nlm.nih.gov/35292800/) Am J Epidemiol. 2022 Online ahead of print.
365. Iyer HS, Hart JE, James P, Elliott EG, DeVille NV, Holmes MD, De Vivo I, **Mucci LA**, Laden F, Rebbeck TR. [Impact of neighborhood socioeconomic status, income segregation, and greenness on blood biomarkers of inflammation.](https://pubmed.ncbi.nlm.nih.gov/35255255/) Environ Int. 2022; Epub 2022 Mar 5.
366. Plym A, Dióssy M, Szallasi Z, Sartor O, Silberstein J, Powell IJ, Rebbeck TR, Penney KL, **Mucci LA**, Pomerantz MM, Kibel AS. [DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men.](https://pubmed.ncbi.nlm.nih.gov/35079693/) JNCI Cancer Spectr. 2021; eCollection 2022 Feb.
367. Vaselkiv JB, Ceraolo C, Wilson KM, Pernar CH, Rencsok EM, Stopsack KH, Grob ST, Plym A, Giovannucci EL, Olumi AF, Kibel AS, Preston MA, **Mucci LA.** [5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care.](https://pubmed.ncbi.nlm.nih.gov/35255119/) Cancer Epidemiol Biomarkers Prev. 2022 Mar 4.
368. Hansen M, Hamieh NM, Markt SC, Vaselkiv JB, Pernar CH, Gonzalez-Feliciano AG, Peisch S, Chowdhury-Paulino IM, Rencsok EM, Rebbeck TR, Platz EA, Giovannucci EL, Wilson KM, **Mucci LA.** [Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns.](https://pubmed.ncbi.nlm.nih.gov/35247879/) Cancer Epidemiol Biomarkers Prev. 2022 Mar 3:cebp.1064.2021.
369. Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita HB, Cohn BA, Deschasaux-Tanguy M, Dimou NL, Ferrucci L, Flicker L, Freedman ND, Giles GG, Giovannucci EL, Haiman CA, Hankey GJ, Holly JMP, Huang J, Huang WY, Hurwitz LM, Kaaks R, Kubo T, Le Marchand L, MacInnis RJ, Männistö S, Metter EJ, Mikami K, **Mucci LA**, Olsen AW, Ozasa K, Palli D, Penney KL, Platz EA, Pollak MN, Roobol MJ, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Tsai CJ, Touvier M, Van Den Eeden SK, Weiderpass E, Weinstein SJ, Wilkens LR, Yeap BB; PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS, Allen NE, Key TJ, Travis RC. [Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.](https://pubmed.ncbi.nlm.nih.gov/35726641/) Int J Epidemiol. 2022 Jun 21: Online ahead of print.
370. [Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, **Mucci LA**, Wibmer AG, Schultz N, Kantoff PW. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/35670774/) Clin Cancer Res. 2022 Jun 7: Online ahead of print.
371. [Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, **Mucci LA**, Wibmer AG, Schultz N, Kantoff PW. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/35670774/) Clin Cancer Res. 2022 Jun 7. Online ahead of print.
372. [Cheng E, Lee DH, Tamimi RM, Hankinson SE, Willett WC, Giovannucci EL, Eliassen AH, Stampfer MJ, **Mucci LA**, Fuchs CS, Spiegelman D. Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals.](https://pubmed.ncbi.nlm.nih.gov/35603853/) JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac021
373. [Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, Kenfield SA, Kibel AS, Giovannucci E, Penney KL, **Mucci LA.** A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/35637041/) Eur Urol. 2022 May 27:S0302-2838(22)02342-9. Online ahead of print.
374. Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita B, Chen C, Cohn BA, Dimou NL, Ferrucci L, Flicker L, Freedman ND, Giles GG, Giovannucci EL, Goodman GE, Haiman CA, Hankey GJ, Huang J, Huang WY, Hurwitz LM, Kaaks R, Knekt P, Kubo T, Langseth H, Laughlin G, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter JE, Mikami K, **Mucci LA**, Olsen AW, Ozasa K, Palli D, Penney KL, Platz EA, Rissanen H, Sawada N, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Tsai CJ, Tsugane S, Vatten L, Weiderpass E, Weinstein SJ, Wilkens LR, Yeap BB; PRACTICAL Consortium; CRUK; BPC3; CAPS; PEGASUS, Allen NE, Key TJ, Travis RC. [Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia.](https://pubmed.ncbi.nlm.nih.gov/35579976/) Int J Cancer. 2022 May 17. Online ahead of print.
375. [Zhang Y, Song M, **Mucci LA**, Giovannucci EL. Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.](https://pubmed.ncbi.nlm.nih.gov/35522215/) J Urol. 2022 May 6: Online ahead of print.
376. Heaphy CM, Joshu CE, Barber JR, Davis C, Lu J, Zarinshenas R, Giovannucci E, **Mucci LA**, Stampfer MJ, Han M, De Marzo AM, Lotan TL, Platz EA, Meeker AK.[The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy.](https://pubmed.ncbi.nlm.nih.gov/35836303/) J Pathol Clin Res. 2022 Sep;8(5):481-491. Epub 2022 Jul 14.
377. Graff RE, Langlais CS, Van Blarigan EL, Pernar CH, Stampfer MJ, Giovannucci EL, **Mucci LA**, Chan JM, Kenfield SA. [Post-diagnostic health behaviour scores in relation to fatal prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/36028533/) Br J Cancer. 2022 Aug 26. Online ahead of print.
378. Wang A, Xu Y, Yu Y, Nead KT, Kim T, Xu K, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Stopsack KH, **Mucci LA**, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, de Smith AJ, Conti DV, Huff C, Haiman CA, Darst BF. [Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.](https://pubmed.ncbi.nlm.nih.gov/36018819/) Hum Mol Genet. 2022 Aug 26:ddac214. Online ahead of print.
379. [Zhou CD, Pettersson A, Plym A, Tyekucheva S, Penney KL, Sesso HD, Kantoff PW, **Mucci LA**, Stopsack KH. Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?](https://pubmed.ncbi.nlm.nih.gov/36125434/) Cancer Prev Res (Phila). 2022 Sep 20:OF1-OF11. Online ahead of print.
380. Plym A, Zhang Y, Stopsack KH, Jee YH, Wiklund F, Kibel AS, Kraft P, Giovannucci E, Penney KL, **Mucci LA.** [Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.](https://pubmed.ncbi.nlm.nih.gov/36103261/) Clin Cancer Res. 2022 Sep 14:CCR-22-1723. Online ahead of print.
381. [Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, **Mucci LA.** Transcriptomes of prostate cancer with TMPRSS2:ERG and other ETS fusions.](https://pubmed.ncbi.nlm.nih.gov/36125519/) Mol Cancer Res. 2022 Sep 20:MCR-22-0446. Online ahead of print.
382. Zhang Y, Stopsack KH, Wu K, Song M, **Mucci LA**, Giovannucci E. [Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/36453265/) J Urol. 2022 Dec. Online ahead of print.
383. Zhang Y, Song M, **Mucci LA**, Giovannucci EL. [Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study.](https://pubmed.ncbi.nlm.nih.gov/36326979/) Eur J Epidemiol. 2022 Nov 3:1-10.
384. Yengo L, Vedantam S, Marouli E, Sidorenko J, Bartell E…**Mucci LA**… Willer CJ, Locke AE, Berndt SI, Lettre G, Frayling TM, Okada Y, Wood AR, Visscher PM, Hirschhorn JN. [A saturated map of common genetic variants associated with human height.](https://pubmed.ncbi.nlm.nih.gov/36224396/) Nature. 2022; 610(7933):704-712.
385. [**Mucci LA**, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ; IRONMAN Global Team.IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/36332173/) JCO Glob Oncol. 2022 Nov;8:e2200154.
386. Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, **Mucci LA**, Loda M, Tyekucheva S, Penney KL. [The prostate stromal transcriptome in aggressive and lethal prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/36511902/) Mol Cancer Res. 2022. Online ahead of print.
387. Ericsson CI, Pacheco LS, Romanos-Nanclares A, Ecsedy E, Giovannucci EL, Eliassen AH, **Mucci LA**, Fu BC. [Prospective Study of Avocado Consumption and Cancer Risk in US Men and Women.](https://pubmed.ncbi.nlm.nih.gov/36490225/) Cancer Prev Res (Phila). 2022 Dec 9. Online ahead of print.
388. Lindström S, Wang L, Feng H, Majumdar A, Huo S, Macdonald J, Harrison T, Turman C, Chen H, Mancuso N, Bammler T; Breast Cancer Association Consortium (BCAC); Gallinger S, Gruber SB, Gunter MJ, Le Marchand L, Moreno V, Offit K; Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family Registry Study (CCFR), Genetics And Epidemiology Of Colorectal Cancer Consortium (GECCO); de Vivo I, O'Mara TA, Spurdle AB, Tomlinson I; Endometrial Cancer Association Consortium (ECAC); Fitzgerald R, Gharahkhani P, Gockel I, Jankowski J, Macgregor S, Schumacher J, Barnholtz-Sloan J, Bondy ML, Houlston RS, Jenkins RB, Melin B, Wrensch M, Brennan P, Christiani D, Johansson M, Mckay J, Aldrich MC, Amos CI, Landi MT, Tardon A; International Lung Cancer Consortium (ILCCO); Bishop DT, Demenais F, Goldstein AM, Iles MM, Kanetsky PA, Law MH; Ovarian Cancer Association Consortium (OCAC); Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM; Pancreatic Cancer Cohort Consortium (Panscan); Klein A, Petersen G, Risch H; Pancreatic Cancer Case-Control Consortium (Panc4); PRACTICAL Consortium; Chanock SJ, Purdue MP, Scelo G, Pharoah P, Kar S, Hung RJ, Pasaniuc B, Kraft P. [Genome-Wide Analyses Characterize Shared Heritability Among Cancers and Identify Novel Cancer Susceptibility Regions.](https://pubmed.ncbi.nlm.nih.gov/36929942/) J Natl Cancer Inst. 2023 Mar 17.
389. Ma C, Ericsson C, Carlsson SV, Lilja H, Kibel A, Graff RE, Plym A, Giovannucci E, **Mucci LA**, Preston MA, Penney KL. [Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/36861107/) Eur Urol Open Sci. 2023 Feb 18;50:27-30.
390. [Stopsack KH, **Mucci LA**, Tworoger SS, Kang JH, Eliassen AH, Willett WC, Stampfer MJ. Promoting reproducibility and integrity in observational research: one approach of an epidemiology research community.](https://pubmed.ncbi.nlm.nih.gov/36719725/) Epidemiology. 2023 Jan 31. Online ahead of print.
391. Ma C, Ericsson C, Carlsson SV, Lilja H, Kibel A, Graff RE, Plym A, Giovannucci E, **Mucci LA**, Preston MA, Penney KL. [Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/36861107/) Eur Urol Open Sci. 2023 Feb 18;50:27-30.
392. [Lindström S, Wang L, Feng H, Majumdar A, Huo S, Macdonald J, Harrison T, Turman C, Chen H, Mancuso N, Bammler T; Breast Cancer Association Consortium (BCAC); Gallinger S, Gruber SB, Gunter MJ, Le Marchand L, Moreno V, Offit K; Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family Registry Study (CCFR), Genetics And Epidemiology Of Colorectal Cancer Consortium (GECCO); de Vivo I, O'Mara TA, Spurdle AB, Tomlinson I; Endometrial Cancer Association Consortium (ECAC); Fitzgerald R, Gharahkhani P, Gockel I, Jankowski J, Macgregor S, Schumacher J, Barnholtz-Sloan J, Bondy ML, Houlston RS, Jenkins RB, Melin B, Wrensch M, Brennan P, Christiani D, Johansson M, Mckay J, Aldrich MC, Amos CI, Landi MT, Tardon A; International Lung Cancer Consortium (ILCCO); Bishop DT, Demenais F, Goldstein AM, Iles MM, Kanetsky PA, Law MH; Ovarian Cancer Association Consortium (OCAC); Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM; Pancreatic Cancer Cohort Consortium (Panscan); Klein A, Petersen G, Risch H; Pancreatic Cancer Case-Control Consortium (Panc4); PRACTICAL Consortium; Chanock SJ, Purdue MP, Scelo G, Pharoah P, Kar S, Hung RJ, Pasaniuc B, Kraft P. Genome-Wide Analyses Characterize Shared Heritability Among Cancers and Identify Novel Cancer Susceptibility Regions.](https://pubmed.ncbi.nlm.nih.gov/36929942/)J Natl Cancer Inst. 2023 Mar 17:djad043
393. [Sheill G, Brady L, Hayes B, Baird AM, Guinan E, Vishwakarma R, Brophy C, Vlajnic T, Casey O, Murphy V, Greene J, Allott E, Hussey J, Cahill F, Van Hemelrijck M, Peat N, **Mucci L**, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell D, Sheils O, O'Leary J, Rudman S, McDermott R, Finn S. ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/37086362/) Support Care Cancer. 2023 Apr 22;31(5):292
394. Nolazco JI, **Mucci LA**, Sosnowski R, Przewoźniak K, Chang SL, De Nunzio C. [Relationship between cigarette use and prostate cancer risk: what do we know and what should we do?](https://pubmed.ncbi.nlm.nih.gov/37087528/) Prostate Cancer Prostatic Dis. 2023 Apr 22.
395. [Stopsack KH, Plym A, **Mucci LA.** The Imperative for Population-based Cancer Registration of All Metastatic Cancers.](https://pubmed.ncbi.nlm.nih.gov/37125486/) Cancer Epidemiol Biomarkers Prev. 2023 May 1;32(5):585-587.
396. Ha L, Tran A, Bui L, Giovannucci E, **Mucci L**, Song M, Le PD, Hoang M, Tran H, Kim G, Pham T. [Proportion and number of cancer cases and deaths attributable to behavioral risk factors in Vietnam.](https://pubmed.ncbi.nlm.nih.gov/37129148/) Int J Cancer. 2023 May 2.
397. Iyer HS, Vaselkiv JB, Stopsack KH, Roscoe CJ, DeVille NV, Zhang Y, Penney KL, Balk SP, Fiorentino M, Hart JE, James P, De Vivo I, **Mucci LA**, Laden F, Rebbeck TR. [Influence of neighborhood social and natural environment on prostate tumor histology in a cohort of male health professionals.](https://pubmed.ncbi.nlm.nih.gov/37139568/) Am J Epidemiol. 2023 May 3:kwad112.
398. [Yarmolinsky J, Bouras E, Constantinescu A, Burrows K, Bull CJ, Vincent EE, Martin RM, Dimopoulou O, Lewis SJ, Moreno V, Vujkovic M, Chang KM, Voight BF, Tsao PS, Gunter MJ, Hampe J, Pellatt AJ, Pharoah PDP, Schoen RE, Gallinger S, Jenkins MA, Pai RK; PRACTICAL consortium; VA Million Veteran Program; Gill D, Tsilidis KK. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.](https://pubmed.ncbi.nlm.nih.gov/37171501/) Diabetologia. 2023 May 12.
399. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, **Mucci L**, Morgan TM, Carlsson SV. [2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/37202314/) Eur Urol. 2023 May 16:S0302-2838(23)02786-0.
400. Iyer HS, Kensler KH, Vaselkiv JB, Stopsack KH, Roscoe C, Bandera EV, Qin B, Jang TL, Lotan TL, James P, Hart JE, **Mucci LA**, Laden F, Rebbeck TR.[Associations between etiologic or prognostic tumor tissue markers and neighborhood contextual factors in male health professionals diagnosed with prostate cancer.](https://pubmed.ncbi.nlm.nih.gov/37249585/) Cancer Epidemiol Biomarkers Prev. 2023 May 26:EPI-23-0217. Online ahead of print.
401. Yim K, Ma C, Carlsson S, Lilja H, **Mucci L**, Penney K, Kibel AS, Eggener S, Preston MA. [Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.](https://pubmed.ncbi.nlm.nih.gov/37384841/) J Urol. 2023 Jun 29 Online ahead of print.
402. Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S, **Mucci LA**, Hunter DJ, Penney KL, Tangen CM, Hamilton RJ, Parent MÉ, Stanford JL, Koutros S, Wolk A, Sørensen KD, Blot WJ, Yeboah ED, Mensah JE, Lu YJ, Schaid DJ, Thibodeau SN, West CM, Maier C, Kibel AS, Cancel-Tassin G, Menegaux F, John EM, Grindedal EM, Khaw KT, Ingles SA, Vega A, Rosenstein BS, Teixeira MR; NC-LA PCaP Investigators; Kogevinas M, Cannon-Albright L, Huff C, Multigner L, Kaneva R, Leach RJ, Brenner H, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Neuhausen SL, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, De Ruyck K, Xu J, Razack A, Teo SH; Canary PASS Investigators; Newcomb LF, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Castelao JE, Townsend PA, Crawford DC, Petrovics G, Casey G, Roobol MJ, Hu JF, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB. [Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.](https://pubmed.ncbi.nlm.nih.gov/37311464/) Am J Hum Genet. 2023 Jul 6;110(7):1200-1206. Epub 2023 Jun 12.
403. Rencsok EM, Slopen N, Autio K, Morgans A, McSwain L, Barata P, Cheng HH, Dreicer R, Heath E, McKay RR, Pomerantz M, Rathkopf D, Tagawa S, Whang YE, Ragin C, Odedina FT, George DJ, Kantoff PW, Vinson J, Villanti P, Haneuse S, **Mucci LA**; IRONMAN Registry. [Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.](https://pubmed.ncbi.nlm.nih.gov/37410340/) Qual Life Res. 2023 Jul 6.
404. Ma C, Wang X, Dai JY, Turman C, Kraft P, Stopsack KH, Loda M, Pettersson A, **Mucci LA**, Stanford JL, Penney KL. [Germline genetic variants associated with somatic TMPRSS2:ERG fusion status in prostate cancer: a genome-wide association study.](https://pubmed.ncbi.nlm.nih.gov/37555839/) Cancer Epidemiol Biomarkers Prev. 2023 Aug 9. Online ahead of print.
405. Song R, Riseberg E, Petimar J, Wang M, **Mucci LA**, Wu K, Zhang X, Willett WC, Giovannucci EL, Smith-Warner SA. [Different operationalizations of the 2018 WCRF/AICR cancer prevention recommendations and risk of cancer.](https://pubmed.ncbi.nlm.nih.gov/37500788/) Br J Cancer. 2023 Jul 27. Online ahead of print.
406. Chowdhury-Paulino IM, Hart JE, James P, Iyer HS, Wilt GE, Booker BD, Nethery RC, Laden F, **Mucci LA\*\***, Markt SC\*\*. [Association between outdoor light at night and prostate cancer in the Health Professionals Follow-Up Study.](https://pubmed.ncbi.nlm.nih.gov/37462694/) Cancer Epidemiol Biomarkers Prev. 2023 Jul 18. Online ahead of print.
407. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X; Biobank Japan Project; Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, **Mucci LA**, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M…[Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.](https://pubmed.ncbi.nlm.nih.gov/37945903/) Nat Genet. 2023 Dec;55(12):2065-2074.
408. Watts EL, Gonzales TI, Strain T, Saint-Maurice PF, Bishop DT, Chanock SJ, Johansson M, Keku TO, Le Marchand L, Moreno V, Newcomb PA, Newton CC, Pai RK, Purdue MP, Ulrich CM, Smith-Byrne K, Van Guelpen B; PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS; Day FR, Wijndaele K, Wareham NJ, Matthews CE, Moore SC, Brage S. [Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study.](https://pubmed.ncbi.nlm.nih.gov/38057395/) Br J Cancer. 2024 Jan;130(1):114-124.
409. Lee DJ, El-Khoury H, Tramontano AC, Alberge JB, Perry J, Davis MI, Horowitz E, Redd RA, Sakrikar D, Barnidge D, Perkins MC, Harding S, **Mucci L**, Rebbeck TR, Ghobrial IM, Marinac CR. [Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.](https://pubmed.ncbi.nlm.nih.gov/38212245/) Blood Adv. 2024 Jan 11:bloodadvances. Online ahead of print.
410. Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, **Mucci LA.** [Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer.](https://pubmed.ncbi.nlm.nih.gov/38189661/) Cancer Epidemiol Biomarkers Prev. 2024 Jan 8. Online ahead of print.
411. Rencsok EM, Slopen N, McManus HD, Autio KA, Morgans AK, McSwain L, Barata P, Cheng HH, Dreicer R, Gerke T, Green R, Heath EI, Howard LE, McKay RR, Nowak J, Pileggi S, Pomerantz MM, Rathkopf DE, Tagawa ST, Whang YE, Ragin C, Odedina FT, Kantoff PW, Vinson J, Villanti P, Haneuse S, **Mucci LA\*\***, George DJ\*\*; IRONMAN Registry. [Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.](https://pubmed.ncbi.nlm.nih.gov/38108490/) Cancer Res Commun. 2024 Jan 8;4(1):55-64.

**Other Peer Reviewed Publications**

1. Kuper HE, **Mucci LA** and Trichopoulos D. Coffee, pancreatic cancer and the question of causation. J Epidemiol Community Health 2000;54(9):650-1. PMCID: PMC1731751.
2. **Mucci LA**, Wedren S, Tamimi RM, Trichopoulos D and Adami HO. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 2001;249(6):477-93.
3. Tamimi R, Trichopoulos D, Lagiou A, **Mucci L**, Adami HO and Hsieh C. Authors' reply: Energy intake in pregnant women carrying boys or girls. BMJ 2003;327(7415):622. PMCID: PMC161555.
4. **Mucci L**, Dickman PW, Steineck G, Adami HO and Augustsson K. Reply: Dietary acrylamide and cancer risk: additional data on coffee. Br J Cancer 2003;89(4):775-6. PMCID: PMC2376922.
5. **Mucci L**, Rimm EB and Thompson KM. Re: Potential Regulatory Action Exempting from the Proposition 65 Warning Requirements, Exposures from Chemicals that form from natural Constituents in Food During Cooking or Heat Processing. Response to the Office of Environmental Health Hazard Assessment, State of California. 2005.
6. **Mucci LA** and Adami HO. The role of epidemiology in understanding the relationship between dietary acrylamide and cancer risk in humans. Adv Exp Med Biol 2005;561:39-47.
7. Wilson KM, Rimm EB, Thompson KM and **Mucci L**. Dietary acrylamide and cancer risk in humans: a review. J Verbrauch Lebensm 2006;1(1):19-27.
8. **Mucci LA** and Spiegelman D. Vitamin D and prostate cancer risk--a less sunny outlook? J Natl Cancer Inst 2008;100(11):759-61.
9. Stark JR, **Mucci L**, Rothman KJ and Adami HO. Screening for prostate cancer remains controversial. BMJ 2009;339:b3601.
10. **Mucci LA** and Adami HO. The plight of the potato: is dietary acrylamide a risk factor for human cancer? J Natl Cancer Inst 2009;101(9):618-21.
11. Szymanski KM, Wheeler DC and **Mucci LA**. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010;92(5):1223-33.
12. Martin NE, **Mucci LA**, Loda M and Depinho RA. Prognostic determinants in prostate cancer. Cancer J 2011;17(6):429-37. PMCID: PMC3240856.
13. Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E and **Mucci LA**. Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2012;21(7):1002-11. PMCID: PMC3392423.
14. Wilson KM, Giovannucci EL and **Mucci LA**. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012;14(3):365-74. PMCID: PMC3720164.
15. Gershman B, Shui IM, **Mucci LA**. Reply from Authors re: Andrea Salonia. Androgens and Prostate Cancer: We Are Still (Almost) Completely Ignorant. Eur Urol. 2013 Mar 19;65(1):690-691.
16. **Mucci LA**, Stampfer MJ. Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. J Clin Oncol 2014 Jan 1;32(1):1-2.
17. Freedland SJ, **Mucci LA**. Is active surveillance safe for obese patients? Nat Reviews Urology 2014; 2014;11:489-90.
18. Park H, Schoenfeld J, **Mucci L**. Reply to 'Meta-analysis procedure for the effect of statin on the recurrence of prostate cancer' by T. Kawada. Ann Oncol. 2014 Feb;25(2):543-4.
19. Torfadottir JE, Stampfer MJ, **Mucci LA**, Giovannucci EL. [RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial.](http://www.ncbi.nlm.nih.gov/pubmed/24685929) J Natl Cancer Inst. 2014 Apr;106(4):dju018.
20. **Mucci LA**, Siddiqui MM, Wilson KM, Giovannucci E. Vasectomy and prostate cancer response to Sokal, et al, J Clinical Oncology 2015 Feb 20;33(6):670-1.
21. **Mucci LA**, Hunter DJ, Williams M. [Dimitrios Trichopoulos: in memoriam (1938-2014).](http://www.ncbi.nlm.nih.gov/pubmed/25750250) Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):483.
22. Labbé D, Zadra G, Ebot E, **Mucci** **L**, Kantoff P, Loda M, Brown M. [Role of diet in prostate cancer: The epigenetic link](https://www.ncbi.nlm.nih.gov/pubmed/?term=Role+of+diet+in+prostate+cancer%3A+The+epigenetic+link). Oncogene 2015 Sep 3;34(36):4683-91. PMCID: PMC4476943.
23. Bourke L, Boorjian SA, Briganti A, Klotz L, **Mucci L**, Resnick MJ, Rosario DJ, Skolarus TA, Penson DF. Survivorship and Improving Quality of Life in Men with Prostate Cancer. Eur Urol. 2015 Sep;68(3):374-83. Review.
24. Rider JR, Wilson KM, Sinnott JA, Kelly RS, **Mucci LA**, Giovannucci EL. Reply to Herney Andrés García-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016 Dec;70(6):e156-e157.
25. Kelly RS, Vander Heiden MG, Giovannucci E, **Mucci LA**. [Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/27197278) Cancer Epidemiol Biomarkers Prev. 2016; 25(6):887-906. Review.
26. Pernar CH, Markt SC, McKay RR, **Mucci LA**. [CHALLENGE Trial 1 Year Feasibility Results-Letter.](http://www.ncbi.nlm.nih.gov/pubmed/27418272) Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1277.
27. Rider JR, Wilson KM, **Mucci LA**, Giovannucci EL. Reply to Cédric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2017 Jan;71(1):e18.
28. Stopsack KH, Greenberg AJ, **Mucci LA**. [Common medications and prostate cancer mortality: a review.](http://www.ncbi.nlm.nih.gov/pubmed/27492013) World J Urol. 2017 Jun;35(6):875-882.
29. Fankhauser CD, **Mucci LA**, Gerke TA. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017 Jun;71(6):907-912.
30. Markt SC, **Mucci LA**. [Authors' reply to Rishniw.](https://www.ncbi.nlm.nih.gov/pubmed/28623236) BMJ. 2017 Jun 16;357:j2910.
31. **Mucci LA**, Pernar CH, Peisch S, Gerke T, Wilson KM. [Prostate cancer incidence as an iceberg.](https://www.ncbi.nlm.nih.gov/pubmed/28560536) Eur J Epidemiol. 2017 Jun;32(6):477-479.
32. **Mucci LA**, Kantoff PW. [Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?](https://www.ncbi.nlm.nih.gov/pubmed/28817369) J Clin Oncol. 2017;35:3272-3274.
33. Graff RE, **Mucci LA**, Hjelmborg JB. Reply. Clin Gastroenterol Hepatol 2018; 298-9.
34. Dickerman B, **Mucci L**. [Metabolic Factors and Prostate Cancer Risk.](https://www.ncbi.nlm.nih.gov/pubmed/30459168) Clin Chem. 2018 Nov 20. [Epub ahead of print]
35. **Mucci LA**, Wilson KM, Preston MA, Giovannucci EL.[Is vasectomy a cause of prostate cancer?](https://www.ncbi.nlm.nih.gov/pubmed/31119274) J Natl Cancer Inst. 2019 May 23. [Epub ahead of print]
36. Dickerman BA, **Mucci LA**. [Obesity, height, and advanced prostate cancer: extending current evidence toward precision prevention.](https://www.ncbi.nlm.nih.gov/pubmed/31912798) Ann Oncol. 2020 Jan;31(1):7-8.
37. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, **Mucci L**, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. [Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.](https://www.ncbi.nlm.nih.gov/pubmed/31734020) Urol Oncol. 2019 Nov 13. [Epub ahead of print]
38. Dickerman BA, **Mucci LA**. [Obesity, height, and advanced prostate cancer: extending current evidence toward precision prevention.](https://www.ncbi.nlm.nih.gov/pubmed/31912798) Ann Oncol. 2020 Jan;31(1):7-8. doi: 10.1016/j.annonc.2019.10.011.
39. Khan AM, **Mucci LA.** Concerning trends in colorectal cancer in the wake of Chadwick Boseman’s death. J Cancer Policy 2020; volume 26.
40. Siddiqui MM, Giovannucci EL, **Mucci LA**. Can there be consensus on whether vasectomy is a prostate cancer risk factor? Prostate Cancer Prostatic Dis 2021 Jun 9. Online ahead of print.
41. Mahal BA, Gerke T, Awasthi S, Soule HR, Simons JW, Miyahira A, Halabi S, George D, Platz EA, **Mucci L**, Yamoah K. [Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.](https://pubmed.ncbi.nlm.nih.gov/34446369/) Eur Urol Oncol. 2022;5:18-29.
42. Stopsack KH, **Mucci LA**, Giovannucci EL [Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities.](https://pubmed.ncbi.nlm.nih.gov/37428996/) J Clin Oncol. 2023 Jul 10. Online ahead of print.

**Proceedings of Meetings**

1. **Mucci LA**, Adami HO. The Role of Epidemiology in Understanding the Relationship Between Dietary Acrylamide and Cancer Risk in Humans. In: Friedman M, Mottram DS. Chemistry and Safety of Acrylamide in Food; 2004; Anaheim, CA. New York: Springer; 2005. 39-48.
2. Kakizoe T, **Mucci LA**, Albertsen PC, Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urology Nephrology Suppl. 2008;(218):191-212.

**Book Chapters**

1. **Mucci L** and Adami HO. Oral and pharyngeal cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 1 ed. New York: Oxford University Press; 2002. p. 115-36.
2. Brennan P, **Mucci L** and Adami HO. Oral and pharyngeal cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 2 ed. New York: Oxford University Press; 2008. p. 155-74.
3. **Mucci L**, Signorello LB and Adami HO. Prostate Cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 2 ed. New York: Oxford University Press; 2008. p. 517-54.
4. **Mucci L** and Giovannucci E. The role of nutrition and diet in prostate cancer. In: A Bendich and RJ Deckelbaum, editors. Preventive Nutrition: The Comprehensive Guide for Health Professionals, 4 ed. Humana Press; 2009. p. 195-218.
5. Giovannucci E, Platz EA and **Mucci L**. Epidemiology of prostate cancer. In: PT Scardino, WM Linehan, MJ Zelefsky, NJ Vogelzang, BI Rini, BH Bochner and J Sheinfeld, editors. Comprehensive Textbook of Genitourinary Oncology, 4 ed. Baltimore, MD: Lippincott Williams & Filkins; 2011.
6. Wilson KM, **Mucci LA**. Epidemiology of prostate cancer. In: K Kelly, E Trabulsi, A Dicker, Editors. Current Multi-disciplinary Oncology: Prostate Cancer. New York, NY: Demos Medical Publishing; 2014.
7. Aronson W, Friedman M, Higano CS, Holden S, Keating NL, **Mucci L**, Simons JW, Tombal B. Survivorship Monograph: Maintaining Health on Androgen Deprivation Therapy. Smith MR, Editor. Prostate Cancer Foundation. Santa Monica CA 2015
8. **Mucci LA**, Wilson KM, Giovannucci EL. Epidemiology of Prostate Cancer. In: Loda M, Mucci, L, Mittlestadt M, Van Hemelricjck M, Cotter MB, Editors: Pathology and Epidemiology of Cancer. Switzerland. Springer Press International, 2017.
9. **Mucci LA**, Wilson KM, Rider JR.Cancer Screening. In: Loda M, Mucci, L, Mittlestadt M, Van Hemelricjck M, Cotter MB, Editors: Pathology and Epidemiology of Cancer. Switzerland. Springer Press International, 2017.
10. Mittlestadt ML, Giovannucci EL, **Mucci LA**, Loda M. The intersection of epidemiology and pathology. In In: Loda M, Mucci, L, Mittlestadt M, Van Hemelricjck M, Cotter MB, Editors: Pathology and Epidemiology of Cancer. Switzerland. Springer Press International, 2017.
11. Pernar CH, Ebot EM, Wilson KM, **Mucci LA**. The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine. 2018 Jan 8.
12. Boffetta P, **Mucci L**. Biomarkers in Cancer Epidemiology. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
13. Lagiou P, Trichopoulos D, **Mucci L**. Concepts in Cancer Epidemiology and Etiology. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
14. Bamia C, Stuver S, **Mucci L**. Cancer of the Liver and Biliary Tract. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
15. Benetou V, Ekbom A, **Mucci L**. Pancreatic cancer. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
16. Malhotra J, Boffetta P, **Mucci L**. Cancer of the Lung, Larynx, and Pleura. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
17. Wilson K, **Mucci L**. Prostate Cancer. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
18. Kogevinas M, Figueroa J, Garcia-Closas M, **Mucci L**. Urinary Bladder Cancer. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
19. Michaud D, Savitz D, **Mucci L**. Brain Cancer. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
20. Roman E, Smith A, **Mucci L**. Leukemias. In Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, Lorelei Mucci. (2018) Oxford University Press. New York, NY.
21. Wilson KM, **Mucci LA**. [Diet and Lifestyle in Prostate Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/31900902) Adv Exp Med Biol. 2019;1210:1-27.
22. Pernar C, Stopsack K, **Mucci L**. Molecular Epidemiology. In Modern Epidemiology, Fourth Edition, Editors: Timothy Lash, Tyler Vanderweele, Sebastien Haneuse, and Kenneth Rothman.

**Books as Editor**

1. [Editor] Textbook of Cancer Epidemiology, Editors: Hans-Olov Adami, David J Hunter, Pagona Lagiou, **Lorelei Mucci**. (2018) Oxford University Press. New York, NY.
2. [Editor] Pathology and Epidemiology of Cancer. Editors: Massimo Loda, **Lorelei Mucci,** Megan Mittlestadt, Mieke Van Hemelrijck, Maura Brid Cotter (2017). Switzerland. Springer Press International. \*\* Downloaded >86,000 times through September 2022

**Thesis**

1. **Mucci L**. The Epidemiology of Periodontal Disease: Evidence from the Swedish Twin Registry. Boston (MA): Harvard School of Public Health; 2002.

**Patents**

1. Dana-Farber Cancer Institute, et al. (2018). *Patent No. 17742021.3-1111 PCT/US2017014362. Compositions and methods for screening and identifying clinically aggressive prostate cancer.* European Patent Office; Munich, Germany